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THESIS ABSTRACT 
Background:  Polycystic ovary syndrome (PCOS) affects up to 10% of women, and is 
characterised by elevated testosterone (T) levels. Women with PCOS have higher scores 
than healthy women on a range of measures of psychological problems.  
Objective: To test the hypotheses that: 1/ The female fetus in a PCOS pregnancy 
experiences elevated T levels; 2/ T causes mood disturbance in women with PCOS. 3/ 
women with PCOS show more signs of mood disturbance typical of symptoms of reactive 
hypoglycaemia than healthy controls.  
Design: Mainly between-groups cross-sectional studies. Also two meta-analyses. 
Setting: The research took place mainly in two London gynaecology clinics, University 
College London Hospital (UCLH) and the Royal Free Hospital, Hampstead (RFH). Some of 
the research was conducted online, and at three other gynaecology and fertility clinics.  
Participants: Participants were recruited from hospital clinics, support groups for women 
with PCOS, or the internet. Most participants were women aged 18-40. 
Outcome Measures: Testosterone; psychometric measures of mood disturbance.  
Results: 1/ Elevated T was found in the umbilical cord blood of the female fetus in PCOS 
pregnancies; 2/ Mood problems in PCOS were not directly caused by T. 3/ Women with 
PCOS showed higher levels of mood problems typical of hypoglycaemia than controls. 
Conclusions: The findings suggest the female fetus in a PCOS pregnancy may be exposed 
to relatively high levels of T. Mood problems in adults with PCOS are possibly caused by 
the direct effects of low blood glucose and indirect effects of T (e.g. obesity) than direct 
effects of T. Further research using the gold-standard biochemical assessment methods is 
required for any replications of these findings.  
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KEY TO ABBREVIATIONS 
ACU  Assisted Conception Unit (Eastman Dental Hospital) 
ANOVA   Analysis of Variance 
ANCOVA   Analysis of Covariance 
BMI body mass body index  (metric weight divided by height squared).   
CAH  congenital adrenal hyperplasia 
CGM  continuous glucose monitor 
CV   coefficient of variation 
DHEAS dehydroepiandrosterone sulphate 
DHT dihydrotestosterone 
E2  estradiol, measured in nmol/l 
ECL  electrochemiluminescence assay 
EPQ Eysenck Personality Questionnaire, 
FAI  free androgen index calculated as (T*100)/SHBG. 
HADS   Hospital Anxiety and Depression Scale 
HSC-7  Hypoglycemia Symptom Checklist – 7 
ICC   intra-class correlation coefficients  
IR insulin resistance 
GI  glycaemic-index (as in ‘low GI diet’) 
MACL Mood Adjective Check List 
MS mass spectrometry 
NHS  National Health Service 
nmol/l nanomoles per litre 
OGTT Oral Glucose Tolerance Test 
Pco  polycystic ovaries (multiple ovarian cycsts) 
PCOS  polycystic ovary syndrome 
PCOSQ   PCOS Quality of Life Questionnaire  
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QoL  quality of life 
RH   Reactive hypoglycaemia 
RFH   Royal Free Hospital, London 
RH  Reactive (or ‘postprandial’) hypoglycemia 
RIA radioimmunoassay 
RLCQ Recent Life Changes Questionnaire 
SD  Standard Deviation 
SHBG  sex hormone binding globulin, measured in nmol/l 
SEC  Socio-economic classification 
STAXI State Trait Aggression Inventory 
T  testosterone (total i.e. bound + unbound to SHBG) measured in nmol/l 
UCLH   University College London Hospital. 
UVT umbilical venous T (testosterone from umbilical vein) 
UAT umbilical arterial T (testosterone from umbilical arteries) 
 13 
 
CHAPTER 1 
General introduction to the thesis   
1.1  Overview of this thesis  
1.2  The Impact of PCOS on Quality Of Life (QoL) 
1.3  Anxiety and Depression in PCOS 
1.4  Depression, Qol, and Obesity in PCOS 
1.5  Depression, Qol and Hirsutism in PCOS 
1.6  Depression, Qol and Infertility in PCOS 
1.7  Anxiety and Stress in PCOS in PCOS 
1.8  Neuroticism  
1.9  Anxiety, Stress, Depression and Fertility  
1.10  Social Avoidance 
1.11   T And Psychological Disturbance  
1.12  T and Aggression in PCOS and Healthy People 
1.13  PCOS, CAH and the masculinising effects of testosterone 
1.14  Biochemical aspects of testosterone 
1.15  The role of insulin in androgen production 
1.16  Types of PCOS 
1.17.1   Theoretical perspectives: the evolutionary perspective 
1.17.2  Theoretical perspectives: the genetic perspective 
1.17.3  Theoretical perspectives: the environmental perspective 
1.18  The fetal environment 
 14 
 
1.19  Evidence of PCOS in childhood 
1.20  Concluding comments for the introduction 
 
 
 
 
 
 
 
 15 
 
1.1 Overview of this thesis  
 
Polycystic ovary syndrome (PCOS) is a medical condition that affects 5-10% of 
women (Franks, 1995).  One of the characteristics of PCOS is elevated testosterone 
(T) levels. Research suggests that anxiety, depression, aggression, and various 
other psychological problems are greater in PCOS than in healthy women (Farrell 
and Antoni, 2010). However the cause of these problems has been a matter of 
debate.  
Three hypotheses regarding the cause of psychological problems in PCOS 
are explored in the present thesis. The first hypothesis is that exposure to elevated 
levels of T prenatally has organizational effects on neuroanatomical structures, and 
this has consequences for psychological functioning in adults with PCOS 
(Ingudomnukul et al, 2007). The second hypothesis is that psychological problems 
are caused by elevated T circulating in the bloodstream of adults (Weiner et al, 
2004). In general, the second hypothesis is that the effect of T is indirect; T causes 
distressing conditions such as obesity, infertility, and skin problems, and these 
symptoms of elevated T produce psychological problems. The third hypothesis is 
that low blood sugar, which is common in women with PCOS, is a direct cause of 
mood problems (Brand-Miller, Farid & Marsh, 2004). The three published papers 
in this thesis will explore key aspects of these three hypotheses.  
The flowchart in Figure 1 shows the pathway to psychological problems in 
PCOS suggested by the findings of the author’s PhD research programme. 
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Figure 1. A model of the main pathways to psychological problems in PCOS. The 
double headed shaded arrows indicate that comfort eating may feed back from 
mood to hypoglycaemia and obesity. The shaded arrow at bottom right of the 
figure indicates that anxiety may increase adrenal androgen production. 
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In this thesis, the basis for the first hypothesis is explored in Chapter 3 by testing 
the key issue of whether total T levels are higher in PCOS pregnancies than healthy 
pregnancies. Dumesic, Abbott & Padmanabhan (2007) review animal studies in 
several species where the pregnant mother is given large doses of T, resulting in 
developmental dysregulation of the hypothalamus & pituitary glands in the 
offspring. Prenatal exposure to T has also been found to masculinise brain structure 
in female sheep (Roselli et al, 2007). Therefore exposure to elevated T prenatally 
may be a risk for the development of PCOS in later life and could in theory lead to 
psychological problems. The aim of the study in Chapter 3 was to establish 
whether there was evidence that T was raised in the prenatal environment of 
daughters of women with PCOS compared to healthy pregnancies. The main 
outcome of interest was whether total T levels in the umbilical cord blood of 
newborns of mothers with PCOS was higher than healthy pregnancies. 
To provide some background to the first study, a meta-analysis and 
systematic review of research on umbilical cord total T levels in healthy 
pregnancies is presented in Chapter 3. This review is original in that it establishes 
that there is usually a sex difference in umbilical cord T, and offers the first 
evidence supporting the suggestion that T in the umbilical vein is of 
maternal/placental origin, an important point in identifying the etiology of PCOS. 
The meta-analysis also evaluates the quality of methods of measuring umbilical 
cord T.  
Chapter 5 tests the second hypothesis – suggested by the findings of 
Weiner et al (2004) - that circulating total T is related to anxiety, depression, and 
other mood problems in women with PCOS. Background material on this topic is 
presented in a meta-analysis and systematic review of research into self-reported 
anxiety and depression in PCOS (Chapter 2).  
The finding in Chapter 5 that mood was not related to total T in PCOS 
prompted a rejection of the second hypothesis and the search for plausible new 
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hypothesis. The third published study (Chapter 6) represents the result of this 
reappraisal, and tests the hypothesis that low blood glucose levels might be related 
to mood problems in PCOS. In this pilot study the outcome measures were 
psychological symptoms of low blood glucose. The third hypothesis links into the 
first hypothesis in that animal studies have found that fetal exposure to T in early 
gestation programmes for insulin resistance and type 2 diabetes in later life 
(Dumesic, Abbott & Padmanabhan, 2007), and chapter 6 suggests that it is this 
type of metabolic dysregulation that causes mood problems seen in adults with 
PCOS. 
The final chapter presents a discussion of the implications of the research 
presented in this thesis. An evaluation of theory, methodology, and clinical 
applications is also made. Conclusions and suggestions for future research are also 
presented. 
The following sections will firstly review the psychological dimensions 
associated with PCOS and the symptoms of PCOS, secondly explore the role of 
testosterone in PCOS, and finally look at hypotheses regarding the etiology of 
PCOS.  
1.2  The Impact of PCOS on Quality Of Life   
Health-related quality of life (HRQoL, or HRQL, or simply QoL) is defined as “a 
multidimensional concept that encompasses physical, emotional and social aspects 
associated with a specific disease or its treatment” (Jones et al 2008, p.15). Many 
of the studies in the following sections focus on various psychological aspects of 
PCOS, and although not all are QoL, it might be considered that QoL is implicitly 
measured in studies of anxiety and depression because there is some evidence that 
the three constructs are related. For example, Lipton et al (2006) found that QoL 
and Hospital Anxiety and Depression Scale (HADS) scores were highly correlated 
in women with PCOS, indicating that the poorer the QoL the more anxiety and 
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depression was experienced. Similarly, Barnard et al (2007) found that all PCOSQ 
(Polycystic Ovary Syndrome Questionnaire) domains were significantly correlated 
with depression ratings. 
Using the SF-36 (Short Form-36), a scale for measuring HRQoL for 
illnesses in general, Coffey et al (2006) found that women with PCOS scored 
similarly for physical problems to women with diabetes, epilepsy, back pain and 
asthma, but much lower (i.e. worse QoL) on the psychological dimension.  
 
1.3 Anxiety and Depression in PCOS 
In one of the earliest studies of the psychological aspects of PCOS Monzani et al. 
(1994) found that 23 PCOS patient had significantly higher levels of anxiety and 
depression on the Crown & Crisp Experiential Index than 20 age−matched healthy 
controls.  Research since then has very often found evidence for greater depression 
in women with PCOS than controls or normative populations. Although anxiety is 
less usually a focus of research, women with PCOS are sometimes significantly 
more anxious too.  
Some recent examples of studies in this area are Weiner et al (2004) who 
found depression was higher in women with PCOS than in healthy controls 
matched for BMI, age, ethnicity and educational level, and using as covariates 
body dissatisfaction, acne, hisutism, and stress. Using logistic regression 
Hollinrake et al (2007) found that 103 women with PCOS were significantly more 
at risk of clinical depression than 103 controls.  In a recent study of 49 women with 
PCOS and 49 age-matched controls, Mansson et al (2008) found higher rates of 
depressive episodes, social phobia, and antidepressant and anti-anxiety medication 
use in the PCOS group. They also found suicide attempts were 7 times more likely 
in the PCOS group. Manlove et al (2008) found that 34 women with PCOS 
reported less happiness than 27 controls, but this finding is undermined by the fact 
that happiness was measured using only one item. 
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Although it is clear that PCOS is a risk for depression, attempts to identify 
the specific cause of depression in PCOS have not provided a clear answer, 
probably because many variables could contribute (weight, acne, hirsutism, T etc) 
to depression in PCOS.  
 
1.4  Depression, QoL, and obesity in PCOS 
In their review of the QoL literature on PCOS Jones et al (2008) found that weight 
problems had the greatest negative impact on QoL. This problem starts in 
adolescence when the symptoms of PCOS manifest and continue into adulthood: 
using the CHQ-CF87 (Child Health Questionnaire) Trent et al (2005) found that 97 
adolescents with PCOS had worse HRQoL for weight issues than 186 healthy 
adolescent girls.  McCook (2005) found that weight was the main PCO SQ domain 
affecting adult women (mean age 30.4 + 5.5). McCook (2005) and Hahn et al 
(2005) found a significant correlation between QoL weight scores and BMI 
suggesting that a higher BMI causes worse quality of life regarding weight. 
Although Trent et al (2005) and McCook (2005) didn’t measure depression 
specifically – the PCOSQ measures the emotional impact of weight problems 
rather than BMI - most studies that have measured depression have found obesity 
related to depression, both in healthy women (Stunkard et al, 2003) and in PCOS 
(Rasgon et al, 2003). However not all studies have found this relationship, for 
example, McCook (2002) and Hahn et al (2005).  
It is common to use BMI as a covariate in studies of PCOS (see discussion 
below regarding the pitfalls in doing so) and when BMI is controlled group 
differences in depression scores are reduced (for example, Elsenbruch et al, 2003) 
suggesting that BMI is a contributor to depression. However women with PCOS 
often still have significantly higher depression than normative samples (Keegan et 
al, 2003) and age/weight-matched controls (Weiner et al, 2004).  Hollinrake et al 
(2007) found that a subgroup of obese women with PCOS (n=73) were 
 21 
 
significantly more at risk of clinical depression than obese controls.  It could be 
that the other symptoms of PCOS add to the depression risk, but it could also be 
that the type of obesity seen in PCOS is more distressing because android (or 
central) obesity has a less feminine appearance than gynoid obesity (weight gain on 
the hips) and is more resistant to ordinary dieting (Marsh and Brand-Miller, 2005). 
There is evidence that in general central obesity (‘apple shaped’ body 
rather than ‘pear shaped’) is considered unattractive in many cultures (Brown, 
1991). This body shape is caused by elevated androgens and is typical of PCOS. 
This cross-cultural evidence suggests that although it maybe be secondary in QoL 
terms to other issues, BMI is an issue for women with PCOS regardless of cultural 
background. 
Jones et al (2008) point out that BMI does not necessarily affect QoL 
domains other than weight (for example, McCook et al, 2005). Obesity contributes 
to higher androgen levels via the decrease in aromatase activity in adipose tissue 
(Wake et al, 2007) so we should expect that BMI has a global impact on features 
affected by T i.e. the other PCOSQ domains of acne, hirsutism, fertility, and (to 
some extent) emotions (see section on effects of T, below). However the fact that a 
direct correlation between BMI and other QoL variables does not always exist 
indicates the complexity of the interrelationships between the many variables 
involved in PCOS.  Psychological factors may ameliorate a relationship between 
BMI and QoL; for example, good general coping skills might reduces the QoL 
impact of BMI.  A measurement issue that might contribute to the lack of direct 
BMI/QoL correlation is the possibility that the waist:hip ratio (WHR) is a better 
measure of android or central obesity than BMI (Carranza-Lira et al, 2006) thus the 
WHR might be more sensitive to QoL issues than BMI. 
Overall the evidence suggests that obesity contributes to depression in 
PCOS, but one or more other factors are also contributors.  However the fact that 
there is at least some evidence that HRQoL is improved by weight loss in both 
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women with PCOS (Hahn et al, 2006) and in the general population (Kolotkin et al, 
2001b) underlines the importance of QoL. 
    
1.5  Depression, QoL and hirsutism in PCOS 
Hirsutism is associated with elevated androgen levels in general, and varies with 
ethnicity (Young & Sinclair, 1998). Kitzinger & Willmott (2002) interviewed 30 
women with PCOS, and it emerged that the condition is associated with feeling 
poorly adjusted to the feminine gender role. This is largely due to the affects of 
hyperandrogenism for example, hirsutism.  Using the HADS, Lipton et al (2006) 
found that 74% of 88 women who had problems with facial hair showed clinical 
levels of anxiety and 30% had clinical levels of depression.  However self-esteem 
(measured using the Rosenberg Self-Esteem Scales and WHOQoL-BREF) was not 
lower than normal in this group.  
Elsenbruch et al (2003) found that 50 women with PCOS felt particularly 
unattractive if hirsutism was a problem, and this caused them to experience sex as 
less satisfactory than 50 female controls. This was true even though the rates of 
sexual intercourse was similar in both groups, and when BMI was used as a 
covariate.  
Clayton et al (2005) found that laser treatment for facial hirsutism 
improved HRQoL and HADS anxiety and depression scores compared to a control 
group. In contrast Keegan et al (2003) did not find a significant correlation between 
distress and hirsutism in their study of 53 women with PCOS.  Also there is not a 
consistent relationship between objective measures of hirsutism and QoL for 
hirsutism; while McCook et al found the expected correlation, Trent et al (2002) 
and Guyatt et al (2004) did not. The sometimes inconsistent relationship between 
objective versus subjective measures is a recurring theme in QoL research. 
 
1.6  Depression, QoL and infertility in PCOS 
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Infertility is clinically defined as being unable to conceive within 12 months 
(Abma et al, 1997) and fertility problems are common in PCOS because elevated T 
and BMI disrupt the menstrual cycle. Although Trent (2003) found that adolescents 
with PCOS were 3.4 times more likely than healthy controls to have worries about 
future fertility, McCook (2002) and Himelein & Thatcher (2006a) found no 
significant difference between the depression ratings of fertile and infertile women 
with PCOS.   
McCook (2005) found that women with PCOS who had miscarried had 
lower PCOSQ scores than women with PCOS who had not ever succeeded in 
becoming pregnant.  van Wely et al (2004) randomized 168 women with PCOS 
into two fertility treatment conditions (laproscopic electrocautory Vs recombinant 
follicle stimulating hormone) and found that successful fertility treatment improved 
QoL Short Form 36 (SF-36) scores for emotional and mental health problems, 
though also increased role limitations (for example, feeling that they had 
accomplished less) due to normal physical restrictions of pregnancy.  
 
1.7  Anxiety and stress in PCOS 
In their review of PCOS and stress Eggers & Kirechenhast (2001) suggest that 
PCOS may be a cause of distress to the sufferer (due to symptoms) as well as be 
exacerbated by psychosocial stressors (for example, major life events).  As 
mentioned previously, stress activates the adrenal glands via the HPA (Reiche et 
al., 2004) and because women produce roughly 25% of their T from their adrenal 
glands (Burger, 2002) the level of stress a woman experiences in her daily life may 
exacerbate her PCOS symptoms. 
As with depression, obesity has been found to contribute to psychological 
distress in PCOS (Elsenbruch et al, 2006).  Several studies have found that women 
with PCOS experience raised anxiety levels (Mansson et al, 2008; Elsenbruch et al, 
2003; McCook, 2002; Greiner et al, 2005; and Keegan et al, 2003).  Barnard et al 
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(2007) found that almost one third of women with PCOS reported experiencing 
anxiety compared to under 10% of healthy controls. This represents a significant 
difference, but the validity, reliability, and even the items used in Barnard et al’s 
bespoke measure of anxiety are uncertain because this measure has not been 
published.  
There is evidence that women with PCOS show a stronger HPA 
(hypothalamic-pituitary adrenal axis) response to a stressor than healthy women. 
Mociali et al (1990) found that although a baseline measure of trait anxiety was 
similar between groups, after undertaking mental arithmetic problems state anxiety 
and various hormones were disrupted in 13 women with PCOS compared to 13 
controls. Using the Stroop task as a stressor, Gallinelli et al (2000) found that 
cortisol levels became higher in their PCOS group compared to controls. 
Benson et al (2009) compared 32 women with PCOS to 32 BMI- and age-
matched controls in their HPA responsivity to a stress-inducing public speaking 
task. They found that in the PCOS group, ACTH, cortisol, and heart rate were all 
significantly higher than controls.  Use of metformin did not have an impact on 
these differences.  
Greiner et al (2005) found that 18 women with PCOS scored significantly 
higher than 12 healthy controls for anxiety on Goldberg’s General Health 
Questionnaire (GHQ-30), and although depression was higher in the PCOS group 
on the Hamilton Depression Rating Scale the difference did not reach significance. 
Also, although the circadian cortisol pattern was not different between groups, a 
significantly lower percentage of the PCOS group secreted low levels of urinary 
cortisol and a significantly higher percentage of the PCOS group were unable to 
suppress cortisol below 1 ug/mL in response to an overnight 1 mg dexamethasone 
suppressor test; both of these results are indicators of increased sympathetic tone in 
the PCOS group. The authors conclude that the biochemical alterations caused the 
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anxiety, but how strong this relationship might be was not explored - the authors 
did not statistically correlate the psychological and biochemical outcomes. 
 
1.8  Neuroticism 
A character trait is a consistent pattern of thinking, feeling, and behaving (Perwin 
et al, 2004). Neuroticism is a character trait that combines features of anxiety, 
depression, and anger. Eysenck (1967) suggests that neuroticism is caused by 
lability of the ANS (autonomic nervous system) and predisposes a person to cope 
poorly with stressful events. Recent evidence has found a strong correlation 
between anxiety and neuroticism (Hettema et al, 2004). 
Although neuroticism has not been measured in a PCOS population before, 
it has been linked to three conditions that are associated with PCOS: hirsutism, 
cardiovascular disease (CVD), and fertility problems. Barth et al (1993) studied 69 
hirsute patients and found high EPQ Neuroticism scores. None were identified as 
having PCOS, and the authors did not compare the results to a control group. 
However the mean score of 14.6 + 4.0 is roughly 25% higher than the norm for 
women (Eysenck et al, 1985). It is also higher than the scores for obese women; in 
a study of 7889 English men and women aged 30 to 50 years old (Faith et al 
(2001). 
Neuroticism is associated with health outcomes too. In a 21 year 
prospective survey of 5424 adults in the general population of men and women, 
Shipley et al  (2007) found that after controlling for gender, age, social class, 
education, smoking, alcohol consumption, physical activity, and health, high 
neuroticism scores were significantly related to mortality from cardiovascular 
disease.  Verhaak et al (2005) studied 187 women who had recently failed to 
conceive after one treatment cycle with either IVF or ICSI. The causes of infertility 
were: 33% idiopathic (i.e. of spontaneous or unknown cause), 22% female causes, 
35 % male causes, and 10% a combination of male and female causes. The mean 
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age was 34.3 years, and the mean duration of fertility problems was 3.3 years. 
Measures included the EPQ, STAI (State Trait Anxiety Inventory) and BDI (Beck 
Depression Inventory). The infertile women scored slightly below the norm for 
neuroticism at baseline (before failing the first cycle) 4.7 (sd 3.0) Vs 5.72 (sd 2.91). 
However after the failed cycle there was a significant increase in anxiety and 
depression (p<.001 for both variables). The largest correlation between the change 
in the anxiety score from baseline to time 2 was for neuroticism (p<.001).  The 
change in depression was also correlated with neuroticism (p<.001). Multiple 
regression showed that baseline neuroticism scores were the best predictors of 
anxiety and depression after the failed cycle.   
The above studies demonstrate that neuroticism has known links with 
conditions that are associated with PCOS: hirsutism, CVD, and infertility. 
 
1.9  Anxiety, stress, depression and fertility 
Fertility problems are clearly distressing, but it is important to note that the 
causality may be reciprocal i.e. there is evidence that psychological stress can 
impair fertility (Boivin and Takefman, 1995). In his classic studies Selye (1950) 
found that exposure to stressors caused ovarian atrophy in rats. Psychological 
anxiety can activate the HPA axis, and because stress hormones interact with 
fertility hormones (for example, LH (luetinising hormone, and FSH (follicle 
stimulating hormone)) the HPG (hypothalamic-pituitry gonadal) axis is vulnerable 
to the affects of stress (Berga, 1996). Rivest and Rivier (1995) found that cortisol 
reduces levels of sex hormones by disrupting their synthesis. Anxiety and high 
cortisol levels, depression, avoidance and high expression of emotion also have 
been associated with lower pregnancy rates from fertility treatment (Demyttenaere 
et al, 1992; Smeenk et al, 2001, 2005). Smeenk et al (2001) found that anxiety and 
to a lesser extent depression were significantly negatively correlated with 
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pregnancy outcome in their study of 291 women who underwent fertility treatment 
with  IVF/ICSI (in vitro fertilization/intracytoplasmic sperm injection). Klonoff-
Cohen et al (2001) suggest that while the anxiety generated by fertility treatment 
procedures affects biological outcomes (for example, number of oocytes fertilized) 
baseline measures of acute and chronic stress are related to pregnancy outcomes 
such as birthweight. 
Cwikel et al (2004) suggest that chronic stress should be treated prior to 
fertility treatment, and although there has been very little research in this area there 
is evidence that psychological interventions improve fertility rates. For example 
Sarrel and DeCheney (1985) found that a psychotherapeutic interview yielded a 
pregnancy rate of 60% for 10 infertile couples compared to 10% for 10 controls. 
Hosaka et al (2002) found that 5 weekly 90-minute sessions of relaxation, guided 
imagery, and stress management reduced emotional distress and improved the 
pregnancy rate compared to controls (38% Vs 14%). Natural Killer (NK) cell 
activity was also lower in the treatment group (48% Vs 34%). NK cell activity is 
not usually measured in fertility studies but high NK cell activity has been 
observed in idiopathic infertile women and unexplained recurrent miscarriage 
(Matsubayashi et al, 2001). Levitas et al (2006) used a single session of hypnosis 
with 89 patients during the embryo transfer procedure and found a significantly 
higher pregnancy rate than 96 no-hypnosis controls (58% Vs 30%, p<.05).  The 
hypnosis group also had a higher implantation rate (28% Vs 14%, p<.001). Domar 
(2000) however found no significant effect of CBT + relaxation on pregnancy 
outcomes in a randomized controlled trial (RCT).   
As is seen with the QoL measures, self-reported anxiety is not always 
reflected in objective measures (for example, Gold et al, 2003). There is also the 
methodological issue of establishing the amount of variance in anxiety ratings that 
could be a cause (trait/chronic anxiety) or result (state anxiety) of fertility issues; 
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this is not an easy task because the relationship between infertility and 
psychological problems is reciprocal.  
 
1.10  Social avoidance 
There is evidence that from an early age women with PCOS may have 
interpersonal difficulties. Manlove et al (2008) found that compared to controls, 
women with PCOS reported that as children they felt less cared for by both their 
mother and father, and resented or disliked their brother more. This same group 
reported less sociability in adolescence, and reported more time spent reading and 
babysitting, and less time playing sports or dating boys.  
In a non-PCOS group Barth et al (1993) found that patients with hirsutism 
suffered from social and emotional stress, and it could be that the symptoms of 
PCOS are embarrassing and make socialising uncomfortable.  In support of this 
suggestion, Mansson et al (2008) found higher rates of social phobia in women 
with PCOS compared to age-matched controls. Elesenbruch et al (2003) found that 
women with PCOS scored significantly higher than controls on the SCL-90 
(Symptom Check List-90) Interpersonal Tender Mindedness scale. This difference 
remained even after Bonferroni correction and use of BMI as a covariate in 
ANCOVA, suggesting that BMI was not the cause of interpersonal sensitivity, 
though other PCOS symptoms may have been. 
The evidence is mixed regarding the degree to which PCOS symptoms 
cause social unease. Keegan et al (2003) did not find women with PCOS scored 
higher than normative levels on the Social Avoidance and Distress Scale. Using the 
SF-36, Hahn et al (2006) found that although obesity worsened physical QoL, 
social and emotional QoL were not related to obesity. Coffey et al (2006) found 
that 22 women with PCOS scored worse than 96 healthy controls on all PCOSQ 
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and SF-36  subscales, apart from physical and social functioning. Clayton et al 
(2005) found that laser treatment for facial hirsutism improved HRQoL and HADS 
anxiety and depression scores compared to controls, but no significant 
improvements in the QoL social or environmental domain were seen, nor self-
esteem. 
Overall, while there is some evidence of a negative impact of PCOS on 
social QoL, the evidence is not overwhelming. BMI does not appear to be the root 
cause. The direction of any causal relationship between social avoidance and 
factors such as anxiety or depression is open to speculation; Thatcher and Himelein 
(2006b) suggest depression causes social avoidance, but it could equally be 
suggested that the symptoms of PCOS cause anxiety, and this causes social 
avoidance. 
 
1.11  T and psychological disturbance 
The evidence relating T to psychological and emotional disturbance is not as 
clearcut as might be expected. Some studies of the general population have 
observed a raised free androgen index (FAI, a measure of bioavailable T) in women 
suffering from premenstrual syndrome (PMS, for example Eriksson et al, 1992), 
whereas other studies have found that androgen levels were not significantly 
different in women with PMS compared to women without PMS (for example, 
Rubinow et al, 1989). Indeed some research has found that T is associated with 
positive mood in both men and women. For example Dabbs et al (1997) found that 
men and women who were naturally higher in T than their same-sex peers reported 
having a restless energy to socialize with friends compared to low-T sex-matched 
controls, but they did not feel more anger or aggression.  Indeed assumptions that T 
causes rather than results from mental states may be erroneous. There is evidence 
from studies of humans (e.g. Booth et al, 1989) and non-human primates (e.g. 
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Bernstein et al 1983) that T increases as a result of winning in competitive 
encounters. Motivation before a competition is also associated with rising T 
(Salvador et al, 2003). 
In women with PCOS, three studies failed to find a link between T levels 
and depression (Hahn et al, 2005; McCook, 2002; Rasgon et al, 2003).  In a tightly 
controlled study, Weiner et al (2004) found that, contrary to expectations, the FAI 
was positively correlated with positive mood states in the PCOS group and 
negatively correlated for the control group; in other words free T seemed to have a 
calming affect on the PCOS group but not the controls.  Thus for example State 
Trait Anxiety Inventory (STAI) ratings were negatively related to the FAI for the 
PCOS group (r=-.39, n=27, p<.05) but positively correlated to the FAI in the 
control group (r= .55, n=27, p<.01).  Similar though less marked contrasts were 
seen for most of the State Trait Aggression Inventory (STAXI) and Aggression 
Questionnaire subscales. For example, for STAXI anger expression the correlation 
for the PCOS group was negative (r=-.37, n=27, p<.05) and for the controls was 
positive (r=.37, n=27, p<.05).  However Weiner et al’s conclusion that there is a 
cubic relationship between the FAI and mood states seems poorly founded given 
that this pattern of relationship was based on the combination of two different 
populations with significantly different FAI levels and with opposite patterns of 
correlations i.e. the pattern is bound to be nonlinear as the left side of the 
scatterplot is ascending (showing the positive relationship with FAI and disturbed 
mood for controls), and the right side descending (negative relationship with FAI 
and disturbed mood for PCOS).   
Barnard et al (2007) found that two thirds of women with PCOS rated 
themselves on the Zung depression scale (Zung, 1965) as experiencing mild 
depression or worse, compared to less than one third of healthy controls. The rates 
were similar regardless of whether the women were taking anti-androgen 
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medication or not (for example, contraceptive pill) in both the PCOS and control 
groups, suggesting that either the anti-androgens did not alter androgen levels, or 
that androgen levels do not affect depression levels. 
 
1.12  T and aggression in PCOS and healthy people 
Monzani et al. (1994) found that compared to 20 age−matched healthy controls, 23 
women with PCOS showed elevations (though non-significant) on Type A 
personality, a personality type associated with dominance, time urgency, hostility, 
competitiveness/leadership, and CHD. Although they did not measure T, the 
underlying assumption is that elevations in ratings related to dominance and 
aggression are caused by the elevated T often seen in PCOS.  
A methodological issue regarding this and other studies of PCOS is 
whether the source of anger in these studies is T, or the effects of T (i.e. troubling 
symptoms like hirsutism) or the other effects of having PCOS. It is easy to 
understand that having the troubling symptoms of PCOS might cause negative 
feelings, and Sills et al. (2001) found that 67% of 657 women with PCOS 
associated their diagnosis with “frustration”. Elesenbruch et al (2003) found that 
the significantly higher aggression scores of their PCOS group was negated when 
BMI was used as a covariate and Bonferroni corrections were made, though it 
could be argued that the group difference was legitimate but negated by statistical 
overcorrection.  
Assessing aggression in humans is a vast and complex area, and not central 
to the present thesis. Although males of a given species are generally perceived as 
being more aggressive than females, a review by Albert et al (1993) of the 
literature on aggression in humans concluded that there is little basis for the idea 
that testosterone causes aggression. Albert et al also cast doubt on the idea that 
 32 
 
women are inherently less aggressive than men, and cite evidence from domestic 
violence studies of women’s violence (against partners and children) that show 
rates of violence that are generally equal to those from men. This is supported by 
the meta-analysis by Archer (2000) finding that although in heterosexual 
partnerships women are more likely to be injured, women are also slightly more 
likely to use physical aggression and to do so more frequently.  
In a double-blind cross-over study of surgically menopausal women 
(oophorectomized i.e. had their ovaries removed), Sherwin and Gelfand (1985) 
found that administration of T or T and E2 combined caused increased hostility. As 
mentioned above, Weiner et al (2004) found that aggression was negatively 
correlated with FAI for 27 women with PCOS, but positively correlated for age- 
and weight-matched controls. Archer et al (2005) found that the correlation 
between T and aggression was stronger in women than in men.  
Bjorkquist & Niemela (1992) suggest that research on T and aggression 
has tended to look for overt forms of aggression (for example, physical rather than 
indirect or verbal aggression), and because men generally display the former type 
of aggression more than women, some researchers have erroneously concluded that 
men are more aggressive than women. 
Condry and Condry (1976) found that people are more inclined to label a 
baby’s crying in response to being startled as fear if they are led to believe it’s a 
girl, but interpret the response as anger if they think it’s a boy. Sometimes 
researchers in psychology appear to have viewed the world through a gendered 
schema when studying aggression. 
 
1.13  PCOS, CAH and the masculinising effects of testosterone  
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PCOS is the commonest cause of androgen excess in women and is estimated to 
affect about 10% of women (Ledger & Clark, 2003). It affects similar rates of 
women across the world (Azziz, 2006). Despite its high prevalence, most aspects 
of this condition (e.g. etiology) are only partially known, and reliably effective 
treatment remains elusive.  Polycystic ovaries (or pco – multiple small cysts on the 
ovaries) may be present in the full-blown syndrome (PCOS), but is not a necessary 
or sufficient condition according to the generally accepted definition, the 
Rotterdam Criteria (described in detail below).  
Broadly speaking, the effects of elevated T are known as 
hyperandrogenism. Elevated T is one of the characteristics of PCOS, and there is 
growing evidence that PCOS is associated with various physical and psychological 
conditions, largely thought to be caused by elevated T. It should be noted, 
however, that although it is normal and healthy for women to have some T in their 
bodies, levels over the norm can be problematic.   
Elevated T has been found to have various physical and psychological 
effects in a condition with some similarities to PCOS, classical congenital adrenal 
hyperplasia (CAH). CAH is a relatively rare condition (1 in 15 000 live births) 
caused by enzymatic deficiency in the glucocorticoid pathway and resulting in 
overproduction of adrenal androgens prenatally (Miller and Levine, 1987) and 
continuing until identified and treated, usually shortly after birth in females. The 
levels of androgens experienced by the fetus with CAH are difficult to estimate but 
probably much higher than seen in the fetus in a PCOS pregnancy. Forest et al 
(1981) found that T in the fetal environment of girls with CAH was in same range 
as that of normal male pregnancies at their highest point during the ‘testosterone 
surge’ of prenatal weeks 8-24 (Smail et al 1981). In CAH these levels are high 
enough to cause females to be born with ambiguous genitalia. PCOS has not been 
found to affect the external genitals of newborns, though can on rare occasions 
cause clitoromegaly (enlargement of the clitoris) in adulthood (Marshall, 2001).  
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The main findings from CAH research regarding psychology are that girls 
with CAH are more aggressive than their unaffected sisters (Pasterski et al, 2007), 
show increased male-typical play behaviour (e.g. Berenbaum and Hines, 1992), 
reduced heterosexual orientation (e.g. Hines et al, 2004), better targeting ability 
(Hines et al, 2003), and reduced interest in infants (Leveroni & Berenbaum, 1998; 
Mathews et al, 2008). The degree of influence on male-typical play behaviour has 
been found to relate to the severity of the CAH disorder (e.g. Nordenstrom et al, 
2002).  
Sample sizes in CAH research are small because the condition is rare. 
However the literature on CAH provides a reasonably sound analogue to the kinds 
of effects of T that might be seen in PCOS, and indeed there is some evidence for 
similar types of effects of T in PCOS as CAH. For example, Manlove et al (2008) 
found that women with PCOS reported less female-typical behaviour in childhood, 
though not at adolescence or adulthood. Agrawal et al (2004) found a significantly 
higher prevalence of PCOS and higher T levels in lesbians compared with 
heterosexual women, but this finding has not been replicated by Sutter et al (2008). 
Regarding aggression, Elsenbruch et al (2003) found that women with PCOS were 
significantly more aggressive than controls, but this difference became non-
significant when BMI was statistically controlled for. Ingudomnukul et al (2007) 
found that PCOS was more common in women with autistic spectrum disorder than 
healthy controls. However it should be noted that the difference was because PCOS 
was unusually low in the control group sample (2.7%), and normal rather than high 
in the ASD group (11.3%). Regarding cognition, women with PCOS have been 
found to perform less well than controls on verbal fluency, a cognitive task that 
usually favours women over men (Schattmann & Sherwin, 2007b), although other 
cognitive outcomes that often show sex differences (e.g. three dimensional mental 
rotation) showed no difference between PCOS and control women.   
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The majority of studies of boys with CAH show no difference between 
subjects and controls. There are two published exceptions: one study found reduced 
rough & tumble play (Hines & Kaufman, 1994), and another found reduced self-
reported male-typical behaviour in boys with CAH (Slijper, 1984), but these 
anomalies in the CAH literature may be caused by the boys’ frequent 
hospitalisation during their first two years of life (Hines, 2004). Similarly, Effects 
of PCOS in males seem minor compared to consequences for females, and are 
unreplicated. For example, early baldness has been suggested (Dusková & Stárka, 
2006) as have raised dehydroepiandrosterone sulfate (DHEAS), and a tendency to 
insulin resistance (IR) (Sam et al 2008), but as yet none of these suggestions have 
been substantiated. However amongst two relatively large samples of non-PCOS 
participants a significant relationship has been found between maternal T during 
pregnancy and gender-role behavior in the offspring. Hines et al (2002) found 
markers of high maternal androgen associated with masculinized gender-role 
behavior in female offspring, and Udry et al (1995)  found that gender-typical 
behavior was related to hormones from maternal serum only during the second 
trimester,  
 
1.14 Biochemical aspects of testosterone 
The principle gonadal hormones are T and estradiol (E2). T is an anabolic steroid 
and the prototypic hormone of the androgen family of sex hormones. Androgens 
affect masculine sexual development and function. T is considered a male sex 
hormone because the testes predominantly produce T, and T levels are normally 
about 10 times higher in men than women. Similarly E2 is considered a female 
hormone as the ovaries predominantly produce estrogens, and E2 levels are usually 
much higher in women than men. T is synthesised from androstendione and 
androstenediol, both of which come from DHEA. T can be synthesised into E2 or 
the androgen dihydrotestosterone (DHT) which is roughly three times more potent 
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than T. It is of note that DHEAS is a product of the adrenal glands and a precursor 
of T; thus not only is T produced by the gonads (testes and ovaries) but is also a 
byproduct of the adrenal glands. It is estimated that in healthy women roughly 25% 
of T is of adrenal origin (Burger, 2002), though the percentage is probably higher 
in PCOS because the adrenals are hyperresponsive to the stress hormone 
adrenocorticotropic hormone (ACTH) in PCOS (McKenna and Cunningham, 1995; 
Moran et al 2004).  
E2 is the principal estrogenic hormone. The other main estrogen is estrone 
(E1). Perhaps surprisingly, T is the biochemical precursor of E2. T is converted to 
E2 by the enzyme aromatase, and it is possible that a dysfunction in aromatase 
contributes to the higher T levels seen in PCOS (Xita et al, 2008).   
Sex hormone binding globulin (SHBG) is the main substance that attaches 
to sex hormones, and in binding to T and E2 renders them biologically inert. Its 
binding affinity is roughly twice as strong for T than E2 (Rosner, 1991). Thus 
higher levels of circulating SHBG will reduce androgenic activity more than 
estrogenic. Knowledge of binding by SHBG has led to the use of measurements of 
free androgens, for example, the free androgen index (FAI, sometimes known as 
the free testosterone index, or FTI) which calculates the amount of T that is 
biologically available in the blood once the amount of bound T has been taken into 
account. The FAI is often considered a better measure of the androgenic potential 
in serum than total T. However the FAI is not always used in because of the cost 
and inconvenience of the extra step of measuring SHBG is not always considered 
to outweigh the benefit of knowing the FAI as opposed to the total T level. 
T has a masculinising effect and can cause females to gain male-typical 
characteristics or lose female typical ones. The effects of T can be subdivided 
roughly into two types: 1/ organizational effects occur pre- or neonatally and are 
permanent, and 2/ activational effects occur after puberty and are reversible. 
Structural changes in the brain can result from either type of influence.  
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Three models describe the effects of sex hormones: the gradient model, the 
classic model, and the multidimensional model. The gradient model suggests that 
the effects of sex hormones are dose-dependant and the level of exposure to a 
hormone will affect the degree to which masculinisation or feminization occurs. 
The classic model suggests that T causes masculinisation and reduces feminization, 
and absence of T causes feminization and reduces masculinization, and there is a 
lot of evidence to support this model (Pfaff et al, 2002). For example, all 
mammalian fetuses will develop as phenotypic females unless the Y chromosome 
(called SRY) causes the gonads to differentiate as testes and produce T (Wilson et 
al, 1981). Prenatal exposure to T can alter brain structure, for example, creating a 
male-typical development of aromatase-expressing neurons in the sexually 
dimorphic nucleus of female sheep (Roselli et al, 2007). The multidimensional 
model (see below) allows for expansion beyond the gradient and classic models.  
Although estrogens are necessary for female-typical maturation and 
function in adulthood, they appear to have little or no role in promoting female 
development of the fetus. However active feminization of behaviour by estrogens 
occurs at other times, for example, Dunlap et al (1978) found that in rats near 
puberty, ovarian hormones fix some aspects of female typical sexual behaviour. 
There is also evidence that there are critical or sensitive periods for the 
influence of T on development in animals, though evidence in humans is limited 
(principally due to ethical constraints in research this area). For example, female 
mammals exposed to T during pre- or neonatal critical periods show increased 
sexual behaviour in adulthood toward females and reduced sexual responding 
to males; likewise depriving males of T during pre- or neonatal critical periods 
results in reduced male-typical and increased female-typical sexual behaviour 
in adulthood (Goy and McEwen, 1980; Beach 1975). 
There is evidence that masculinization and feminization are separate 
dimensions, and the simple idea of T causing male-typical development and the 
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absence of T causing female- typical development is an oversimplification; there 
are examples in rodents that demonstrate that in many cases T needs to be 
converted to E2 before acting on the E2 receptors to create male-typical neural and 
behavioural development  (McCarthy, 2008).  However it is likely that the type of 
pathway will differ by species and by type of behaviour, and Hines (2009) suggests 
this sexual differentiation is best understood by a multidimensional model that 
resolves apparent contradictions between earlier models. “This multidimensional 
conceptualization allows not only for differences in critical periods for hormones to 
act on specific behaviors, but also for different mechanisms… to be involved in 
differentiation of each characteristic. A multidimensional model is also consistent 
with evidence that individuals can vary in sex-related behavior from one dimension 
to another, being strongly sex-typical in some respects, but less so, or even sex-
atypical, in others” (Hines 2009, p.5).  
It can be difficult to differentiate between the effect of nature and the 
postnatal environment, especially when studying human behaviour. Traditionally, 
the literature on sex difference uses the term ‘gender’ to identify sex differences 
with cultural causes (for example the wearing of trousers rather than skirts) and the 
term ‘sex’ for difference due to biology (for example, having internal ovaries rather 
than external testes). However in many cases it is very difficult to establish whether 
a sex difference is mainly due to nature, nurture, or is some roughly equal 
combination of both. For this reason some authors (for example, Maccoby 1988) 
use the terms sex and gender interchangeably and with these caveats. 
 
1.15 The role of insulin in androgen production 
Insulin causes androgen production in the ovaries (Yen, 1991), and there is a 
positive correlation between T and insulin levels in women with PCOS (Buffington 
et al, 1991). Indeed insulin and T are in a cyclical relationship: insulin promotes T, 
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T promotes visceral fat and insulin resistance, and this elevates insulin levels 
(Stanley et al, 2008). 
Insulin resistance (IR) can be genetic or the result of a lifestyle 
characterised by a lack of exercise, high carbohydrate diet, and stress. IR is caused 
when the number of insulin receptors on cell walls is reduced, and in PCOS this 
reduction can be up to 75% (reduced from roughly 20 000 receptors to 5 000 
receptors). This means that the ability of serum glucose (blood sugar) to enter the 
cell to be converted to energy is reduced, and must instead remain in the 
bloodstream until converted by the liver into fat. The accumulation of fat leads to 
obesity, which in itself can contribute to PCOS. In women, carrying weight on the 
stomach rather than hips is known as central (or android) obesity, and is related to 
elevated androgen levels.  Although IR occurs in non-obese women (Dunaif et al, 
1989) non-diabetic women with central obesity typically have elevated androgens, 
IR, and hyperinsulinaemia (elevated blood insulin levels) (Kissebah et al, 1982). It 
seems likely then that insulin plays an important role in PCOS, though whether it is 
more important than T is open to debate (Azziz et al 2008) and may depend on the 
PCOS phenotype in question (see below) or the level at which etiology is being 
considered.  
Drug treatment of PCOS usually aims to reduce T levels, either indirectly 
by using the diabetic drug metformin or directly by using anti-androgens or 
contraceptives that have an anti-androgenic effect (for example, Dianette).  
Metformin is also used with the primary aim of reducing insulin resistance in 
PCOS, as insulin resistance is not uncommonly comorbid with PCOS (Dunaif et 
al., 1989). Hunter and Sterrett (2000) suggest that metformin reduces testosterone 
levels and restores normal menstrual cyclicity.  Pasquali et al. (2000) found that 
metformin decreased testosterone levels in women with PCOS, and that both 
women with PCOS and healthy controls treated with metformin experienced a 
reduction in their  body mass index  (BMI, calculated using metric units as weight 
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divided by height squared).  In a case study of a woman with untreated PCOS and 
major depression, Rasgon et al. (2002) found that treatment with metformin and the 
spironolactone (an anti-androgen also used for liver and heart complaints) resolved 
both the depression and PCOS.  Despite IR often being a feature of PCOS, the 
ovaries remain sensitive to insulin; there is as yet no explanation for this 
phenomenon (Diamanti-Kandarkis et al, 2008). 
 
1.16  Types of PCOS 
PCOS is today seen as a heterogeneous syndrome where a range of symptoms may 
be present or absent, and no distinct categories are very evident. For example, in 
their influential paper Hunter and Sterrett state that PCOS “is perhaps best viewed 
as a spectrum of symptoms, pathologic findings and laboratory abnormalities” 
(Hunter and Sterrett 2000, paragraph 10).    
Identifying types, or more specifically phenotypes (observable 
physiological characteristics created by the genes and environment) is a complex 
task because the most recent definition of PCOS, the Rotterdam criteria 
(Rotterdam ESHRE/ASRM (2003), explained in detail below) allows for a range 
of expression of the syndrome. Diamanti-Kandarakis et al (2006a) note that one of 
the problems of research in this area is that there is not simply one type of PCOS, 
and genes for one type (e.g. obese/ anovulatory) may not contribute to the 
development of another (e.g. lean/ ovulatory). In other words the fact that there are 
several overlapping phenotypes makes it difficult to identify the underlying 
genotype(s). 
There are important distinctions to be made in the types of problem 
experienced by women with PCOS e.g. insulin resistant Vs non-insulin resistant 
(Acien et al, 1999) but there is no consensus as to whether these basic dichotomies 
constitute types.  The most immediately obvious distinction that has some 
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agreement amongst clinicians is the distinction between the obese type that features 
insulin resistance (and possibly hyperandrogenism) and the lean type that is often 
hyperandrogenic. The lean type is far less common; in Spain the estimated rate of 
PCOS in lean women is 5.5% (Barclay & Murata, 2006).  
Although these two broad types are reasonably well established, there is a 
lot of speculation about the degree to which there are other distinct categories of 
PCOS, for example, types based on three differential responses to human 
corticotropin-releasing hormone suggested by Kondoh et al (1999). Differences in 
type can also be seen cross-culturally. For example, women from the Pacific 
Islands with PCOS are less inclined to acne and hirsutism than European women 
(Williamson et al, 2001). There is also the question of and the degree to which 
there is comorbidity between PCOS and the metabolic syndrome (‘syndrome x’), 
and how to categorise cases where overlapping occurs.   
Diamanti-Kandarakis et al (2008) describe two types of PCOS which they 
suggest are manifest from birth. The possibility of diagnosis at birth represents a 
significant advance, not least because early diagnosis offers the important 
possibility of early treatment. The first phenotype is expressed in low birth weight, 
but the weight is regained within 12 months.  Premature adrenarche occurs, and at 
adolescence hyperandrognesim and anovulation occur, but with normal ovarian 
morphology. They second type is overweight at birth, is obese in childhood, and 
experiences the complete ‘triad’ of problems of PCOS i.e. hyperandrogenism, 
anovulation and pco (see also section on PCOS in childhood, below).  
More longitudinal research in this area is necessary, and a good example of 
the insights that can be gained by taking a longitudinal approach is a recent study 
by Franceschi et al (2009).  They followed up 46 adolescent girls who had 
precocious puberty (with no identifiable pathological cause) and found that at age 
18 (+3 years) 32% of them had PCOS, mainly characterised by pco and elevated T 
(either by clinical signs e.g. hirsutism, or assay).  Obviously this cohort will be 
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tested again, but the evidence so far suggests that diagnosis of a specific type of 
PCOS (pco + hyperandrogenism) might be possible at a young age. The 
importance of this is that the earlier the type is identified, the earlier appropriate 
treatment can begin. In the case of this particular phenotype, it would seem likely 
that anti-androgens (e.g. spironolactone) would be more appropriate than insulin 
sensitizers (e.g. metformin). However without the knowledge of the type of PCOS 
that is likely to develop from precocious puberty, there would be no way of 
deciding whether treatment with either antiandrogens or insulin sensitizers would 
be more appropriate. From different combinations of these three criteria five 
different types can be made, and means that neither pco nor hyperandrogenism are 
necessary components for diagnosis. By contrast, the National Institutes for Health 
definition of PCOS (NIH, 1990) which was used prior to the Rotterdam revision, 
defined PCOS using criteria 1 and 2 above only. In other words, the Rotterdam 
criteria are more inclusive and suggest a greater prevalence of PCOS (up to 12% of 
women according to Azziz et al, 2004) than the NIH definition (up to 8%, Norman 
et al, 2007).  
The inclusion of pco in the Rotterdam definition not only makes sense at 
face value, but also biochemically because the cysts (immature ovarian 
follicles) prevent the conversion of T to E2. In the PCOS ovary an abnormal 
number of ovarian follicles develop, but don’t develop to maturity. Mature 
follicles contain granulosa cells that express aromatase, but in PCOS (and 
pco) this stage is of development is not reached (Gougeon, 1996). Note that 
insulin resistance does not figure in either definition despite the high rates of 
insulin resistance seen in PCOS and the fact that insulin leads to increased T levels 
in PCOS (Buffington et al, 1991). 
Not everyone accepts the Rotterdam criteria e.g. Azziz (2006).  Indeed in 
October 2008 a new Androgen Excess-PCOS Society Task Force which was set up 
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to define PCOS concluded that “PCOS should be defined by the presence of 
hyperandrogenism (clinical and/or biochemical), ovarian dysfunction (oligo-
anovulation and/or polycystic ovaries), and the exclusion of related disorders” 
(Azziz et al 2008, paragraph 1).  Predictably, not all members of the Task Force 
agreed; a minority thought it important that future research not rule out the 
possibility of non-hyperandrogenic PCOS.  
One problem facing the creation of a typology of PCOS is that many cases 
need to be seen in a single study before different categories become obvious, but 
research in PCOS has been hampered by small sample sizes (Escobar-Morreale et 
al, 2005). Although perhaps 10% of women have PCOS, because a smaller 
proportion have each type (for example, only perhaps 0.5% of women have lean-
type PCOS) the sample sizes required for an epidemiological study are quite large. 
All studies in the present thesis used the Rotterdam criteria to diagnose PCOS in all 
cases, and the limitations of this definition should be borne in mind. 
 
1.17.1  Theoretical perspectives: the evolutionary perspective 
Some authors have speculated that – paradoxically - there is adaptive value in 
being infertile, whether due to PCOS or other reasons. Eggers et al (2007) draw 
upon the kin selection hypothesis to explain how having PCOS offers a selective 
advantage. The kin selection hypothesis (Hamilton, 1963, 1964a,b) suggests that a 
person might help the offspring of a relative to survive, and because the helper 
shares genes with the relative’s offspring, at least some part of the helper’s genes 
survive into the next generation. Because raising human newborns is more 
demanding in time and energy than raising newborns in other species, it is 
especially useful to the survival of the human child to have a ‘helper at the nest’. 
Amongst primates, this helper is most likely to be nulliparous females, regardless 
of age (Hrdy, 1999). In humans, these females may be women who have not been 
reproductively successful in their own right, but they may show interest in caring 
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for the child of a sister, cousin, or niece. Indeed this provides an explanation for the 
adaptive value of old age in women too; ‘the grandmother hypothesis’ suggests that 
postmenopausal women have an important adaptive role (Hawkes et al, 1998). 
With help from non-reproductive female relatives, fertile women are more free to 
reproduce more frequently thus increasing the representation of the family’s genes 
– including the helper’s - in the gene pool. Having links to more children also 
benefits the helpers in increasing their chances of having someone to take care of 
them when they are ill or old.  
The metabolic abnormality often seen in PCOS that leads to weight gain 
can also confer an adaptive advantage, according to Shaw and Elton (2008). They 
suggest that the tendency to store fat confers a survival advantage on women 
during times when food is scarce. This advantage also applies to the fetus when 
such women are pregnant, consistent with the greater birth weight sometimes seen 
in newborns born to mothers with PCOS.  
1.17.2 Theoretical perspectives: the genetic perspective 
In the general population of healthy women, 40% of the variance in T levels is 
inherited (Harris et al, 1998), and more so in White people than Black (Hong et al, 
2001). The rate of inheritance is likely to be at least this high for PCOS, and Legro 
et al (1998) have found that 50% of sisters of women with PCOS have elevated 
free or total T. In their study of PCOS twins Jahanfar et al (2004) found that pco is 
less heritable than androgen and insulin levels. In a PCOS twin study (1332 
monozygotic and 1873 dizygotic twins) Vink et al (2006) found a concordance rate 
for PCOS symptoms of .71 for MZ compared to .38 for DZ twins and other sisters, 
indicating a contribution of heredity in PCOS. Dunaif and Thomas (2001) found 
that 50% of sisters of women with PCOS have pco and hyperandrogenemia. 
Kahsar-Miller et al (2001) found that 24-32% of first-degree relatives (mothers, 
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sisters, daughters) of women with PCOS also have PCOS.  The prevalence rate of 
PCOS also varies by ethnicity; Williamson et al (2001) found that PCOS is more 
prevalent in Indian women and less prevalent in Chinese women than European 
women. However the specific genetic factors associated with PCOS are complex 
and as yet poorly understood.  
Diamanti-Kandarakis et al (2006a) suggest five obstacles to understanding the 
contribution of genetics to PCOS.  Firstly there is the problem of overlapping 
phenotypes (outlined above). Secondly there is the obvious problem of finding 
evidence of heredity in a condition that works against having children. Thirdly, 
evidence for the phenotype can only be seen in women of reproductive age. 
Fourthly it is only possible to see the phenotype in females, not in males. Finally, 
inherited conditions can usually be modelled in mice - a very useful process known 
as ‘genetic mapping’. However PCOS is not known to occur spontaneously in any 
species other than humans, thus precluding the use of genetic mapping. 
As yet no gene has been identified that significantly contributes to the 
development of any one specific type of PCOS. Several sites have been proposed 
for PCOS genes including CYP11A, the insulin gene, the follistatin gene, and the 
insulin receptor, but to date the evidence implicating these areas is not particularly 
strong. The strongest case for linkage can be made for the region near (but not 
directly involving) the insulin receptor gene at chromosome 19p13.3 (Diamanti-
Kandarakis et al, 2006a). However the specific gene remains unidentified 
What has been established is that genes related to PCOS have defects that 
impact androgen biosynthesis, steroid genesis, insulin resistance, expression of the 
metabolic syndrome, and cancer. Recent research has found that women with 
PCOS have polymorphisms on the AKT2 gene, a gene which affects glucose 
metabolism, mitogenic signaling, and mediates cell survival in the ovary (Goodarzi 
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et al, 2008). AKT2 also interacts with another gene associated with PCOS, the 
glycogen synthase kinase 3beta (GSK3B) which Geraldes et al (2008) found is 
implicated in post-insulin receptor signalling and inhibition of apoptosis.  
 
1.17.3 Theoretical perspectives: the environmental perspective  
The first documented description of polycystic ovaries was made by Vallisieri in 
1721 (cited in Eggers et al, 2007). The observation was made in relation to 
infertility, and until very recently PCOS has been seen as solely a fertility problem 
(Hunter and Sterrett, 2000).  Fertility problems have existed for as long as mankind 
has existed, and the social importance of infertility is evidenced by the prevalence 
of fertility rituals and fertility goddesses from mankind’s earliest history (Gelis, 
1989; Schenker, 2000). The perceived importance of fertility exists cross-culturally 
too (Husain, 1998). Given that infertility is by its nature a condition that acts 
against being inherited, its historical prevalence suggests that its cause is not 
primarily genetic, and may therefore have environmental causes.  
PCOS is not simply an inherited condition; it appears to follow the diathesis-stress 
model i.e. it is a genetic syndrome most likely to become manifest under certain 
environmental conditions.  One of the principal stressors is diet. In their review of 
the genetic and molecular basis of PCOS, Escobar-Morreale et al (2005) conclude 
that the phenotype is modified by ethnicity, diet, and lifestyle factors. The modern 
Western diet (plentiful, and high in calories, saturated fats, sugars and 
carbohydrates) is well established as a risk factor for PCOS.  A lack of exercise 
compounds the problem caused by diet. Unsurprisingly then, interventions that 
improve diet and exercise tend to have good outcomes for women with PCOS 
although long-term outcomes need more research (Moran et al, 2006).  
Other environmental factors that have been suggested to trigger PCOS are 
medication, viruses, and stress.  
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Valproic acid is a medication used to treat epilepsy, bipolar disorder and 
migranes, and there is some evidence that long-term use can cause PCOS, and that 
discontinuation will reduce the PCOS symptoms (Isojarvi, 1998). However this 
view has been contested on the grounds that the evidence is retrospective and relies 
on small samples (Genton et al, 2001).  
There is evidence that the adenovirus-36 (Ad-36) causes obesity in rhesus 
and marmoset monkeys (Dhurandhar, 2002) and is related to obesity in humans 
(Dhurandhar, 1997). Although there is no evidence that Ad-36 is associated with 
the development of PCOS, its potential as a contributor and deserves research.   
Eggers & Kirchenghast (2001) suggest that psychological stress may 
contribute to the development of PCOS. This is possible via a number of 
psychological and behavioural pathways e.g. if an adolescent girl engages in 
comfort eating due to stress this may cause obesity (Keski-Rahkonen et al, 2007) a 
known risk for PCOS. Stress is a sufficient cause for the development of functional 
hypothalamic secondary amenorrhea (FHSA), a condition characterised by 
elevated adrenal androgens (Gallinelli et al, 2000). Similarly, psychological 
distress may activate the adrenal glands releasing DHEAS, which will raise T 
levels, especially in PCOS patients whose adrenal glands are hyperresponsive to 
the stress hormone ACTH (Moran et al, 2004). However although stress is 
potentially a risk factor for PCOS, the contribution of ovarian androgens alone is 
unlikely to be sufficient to cause the range and severity of metabolic and 
endocrinological problems that constitute any PCOS phenotype. 
 
1.18 The fetal environment  
A special case of possible environmental causes of PCOS is the fetal environment. 
Barker (2004) proposed that some diseases of adulthood may have their origin in 
conditions in the fetal environment, and women with PCOS have been found to 
have much higher levels of T than controls during the first trimester (Hu et al, 
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2007). Although placental aromatase is traditionally thought to protect the fetus 
from raised maternal T (Abbott et al, 2002), the results of animal research suggest 
otherwise. For example, Resko et al (1984; 1987) gave doses of T (10 to 15 mg) to 
pregnant rhesus monkeys. The doses were high for a female fetus but normal for a 
male, and the resulting female offspring were twice as likely to develop PCOS than 
a control group of untreated females. Based on this and similar evidence, Dumesic 
& Abbott (2007) hypothesise that PCOS develops as a result of exposure to 
abnormally high levels of T prenatally.   
Insulin resistance in PCOS offers another possible pathway for prenatal 
androgenisation, because aromatase activity is inhibited by insulin (Nestler, 1990). 
Aromatase normally converts T into E2, and interference with this process could 
create an androgen-rich fetal environment.  However it remains unclear how much 
maternal T contributes to fetal levels in human pregnancies, or whether it is 
possible to control maternal T levels. Vanky et al (2006) found that taking 
metformin – an insulin sensitizer – reduced pregnancy complications (e.g. 
premature birth) in women with PCOS without reducing T levels. Similarly, 
Glueck et al (2004) did not find that metformin significantly reduced T during 
PCOS pregnancies, though they found that T levels were remained fairly stable 
over the three trimesters (56.5, 54.3, and 63.8 ng/dl) on metformin.  
 
1.19 Evidence of PCOS in childhood 
If PCOS has its origins in prenatal development, then it stands to reason that there 
could be signs of PCOS evident in childhood. Diamanti-Kandarakis et al (2008) 
review the literature on the early expression of PCOS. They suggest that signs can 
be seen at birth (high birth weight, or low birth weight with postnatal catch-up 
within a year) and the classic symptoms of PCOS begin to show in adolescence. 
However a criticism of Diamanti-Kandarakis et al’s description of postnatal weight 
catch-up as an early sign of PCOS is that the evidence for this is almost entirely 
 49 
 
based on animal studies e.g. sheep, experiencing supraphysiological doses of T 
(Manikkam et al, 2003) thus not necessarily applicable to humans with only 
moderately elevated T. However there is research evidence in humans that 
postnatal catch-up in early childhood is associated with many problems at three 
years of age, including obesity and insulin resistance (Inuguez et al, 2006).  
Precocious puberty (early onset) is also seen as a sign of the potential 
development of PCOS (e.g. Franceschi et al, 2009).  However diagnosing PCOS at 
puberty can lead to Type 1 errors. Diamanti-Kandarakis et al (2008) suggest that 
because some of the signs of a normal puberty are similar to those of PCOS (acne, 
irregular menstrual cycles) caution in diagnosis of PCOS at puberty is warranted. 
This is especially true as in puberty it is not unusual to see multiple cysts on at least 
one ovary in 10% of normally menstruating adolescents. Also, because of the 
increase in growth hormone in adolescence, insulin resistance is not uncommon. 
For these reasons the presence of four of five criteria (menstrual irregularity, acne 
or hirsutism, elevated T, insulin resistance, pco) are recommended to diagnose 
PCOS in adolescence (Sultan and Paris, 2006).  
Franks (2008) suggests that the rise in childhood obesity is responsible for 
triggering symptoms of PCOS, and of exacerbating insulin-related problems at 
adolescence. Franks also suggests that elevated serum androgens should be 
considered the hallmark of PCOS in adolescents. However Diamanti-Kandarakis et 
al (2008) caution against biochemical measures of T in diagnosis because of the 
perceived low reliability of some types of T assays.   
 
1.20 Concluding comments for the introduction 
As can be seen, PCOS is a complex condition and completing our knowledge of 
even the most basic aspects of it – the causes and the most reliable treatments - still 
requires a great deal of research.  There is a long way to go before we know 
whether PCOS is caused by prenatal exposure to T, the cause of any such exposure, 
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and whether such exposure has orgnanizational effects on development. It also 
remains to be seen whether psychological factors in PCOS are directly caused by T 
(due to prenatal organization, or activation by circulating T), or other factors such 
glucose fluctuations, or are simply caused by the stress of having PCOS symptoms. 
This thesis describes studies that attempt to address these issues.  
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Abstract 
BACKGROUND:  
Our aim was to assess differences in anxiety and depression between women with and 
without (controls) PCOS. 
METHODS: Systematic review and meta-analysis of published literature comparing women 
with PCOS to control groups on anxiety and depression. Electronic databases were searched 
up to December 17th 2010. The inverse variance method based, as appropriate, on a random- 
or fixed-effects model in Review Manager, Version 5 was used to analyse the data.   
RESULTS: Twelve comparative studies were included; all studies assessed depression (910 
women with PCOS and 1347 controls) and six also assessed anxiety (208 women with 
PCOS and 169 controls). Analysis revealed higher depression (Z = 17.92, p<.00001; 
Hedges’ g = 0.82; 95% CI 0.73 to 0.92) and anxiety (Z = 5.03, p<.00001; Hedges’ g = 0.54; 
95% CI 0.33 to 0.75) scores in the participants with, than without, PCOS. Studies controlling 
for BMI showed a smaller difference between women with PCOS and controls on anxiety 
and depression scores than studies not controlling for BMI. 
CONCLUSIONS: Women with PCOS on average tend to experience mildly elevated 
anxiety and depression, significantly more than women without PCOS. Women with lower 
BMI tended to have slightly lower anxiety and depression scores, suggesting that having a 
lower BMI reduces anxiety and depression.  Future studies might consider (i) controlling for 
BMI, (ii) stratifying by medication use in order to control for any anti-androgenic effects of 
medication, and (iii) excluding women with polycystic ovaries from control groups.  
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Introduction 
Polycystic ovary syndrome (PCOS) is one of the most common hormone disorders affecting 
women, with a prevalence of 5-10% in women of reproductive age (Franks, 1995).  It is the 
most common cause of androgen excess in women and the most common cause of ovulatory 
failure. Clinically, the androgen excess presents as hirsutism and acne, whereas anovulation 
presents as subfertility and menstrual irregularity.  In addition, PCOS is associated with 
obesity.  It is therefore perhaps not surprising that women with PCOS experience mood 
dysfunction and psychiatric problems to a greater degree than women without PCOS (Farrell 
and Antoni, 2010). Many studies, for example, Hollinrake et al. (2007) have found that 
anxiety and depression are higher in PCOS than healthy women. Most studies have focused 
on depression but others, such as Månsson et al. (2008), have found that anxiety in PCOS is 
also an important issue.  
It has been suggested that mood problems in PCOS are caused by the distress 
associated with the symptoms often seen in PCOS (obesity, hirsutism etc; Eggers and 
Kirchengast, 2001). In general, studies find that obesity is related to depression, both in 
healthy women (Stunkard et al., 2003) and in PCOS (Rasgon et al., 2003). In their review of 
the quality of life (QoL) literature on PCOS Jones et al. (2008) found that weight problems 
had the greatest negative impact on QoL. However not all studies of obesity in PCOS have 
found this (Hahn et al., 2005) and some studies, such as Weiner et al. (2004), find that 
depression is higher in women with PCOS even after controlling for BMI. 
Women vary in how much their mood is affected by the various PCOS symptoms. 
For example, Farrell and Antoni (2010) suggest that PCOS symptoms that affect appearance 
are more likely to cause distress in younger women than older women. Because PCOS 
involves so many potentially distressing symptoms, it is difficult to identify the main cause 
of distress or the relative contribution of causal factors. The physical symptoms of PCOS are 
largely the result of elevated testosterone; for example, hirsutism is caused by elevated 
androgen levels (Young and Sinclair, 1998). Hirsutism is also associated with distress in 
women with PCOS (Kitzinger and Willmott, 2002).  Thus it is tempting to view distress in 
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PCOS as mainly an indirect effect of testosterone and the cure for distress, therefore, to 
lower testosterone levels.  
Two drugs widely used to treat the symptoms of PCOS, metformin and the oral 
contraceptive co-cyprindiol (commonly marketed under the brand name ‘Dianette’), differ in 
their action; metformin acts primarily to increase insulin sensitivity, whereas co-cyprindiol 
is composed of oestrogen and anti-androgen. Some authors use the umbrella term ‘anti-
androgens’ to describe these and other medications of this kind used to treat PCOS (Barnard 
et al., 2007). In 52 women with PCOS, Harborne et al. (2003) found that co-cyprindiol was 
more effective than metformin in treating acne, whereas hirsutism responded better to 
metformin than co-cyprindiol.  
Some authors suggest that the drugs commonly used to reduce symptoms of PCOS 
may also reduce the distress associated with these symptoms (Bruce-Jones et al., 1993; 
Farrell and Antoni, 2010). In support of this suggestion, Rasgon et al. (2003) found that 
women with PCOS taking oral contraceptives were significantly less depressed than those 
with PCOS not taking oral contraceptives. In contrast, Barnard et al. (2007) found that rates 
of depression were slightly higher in women with PCOS taking anti-androgens (71%) than 
women with PCOS not taking anti-androgens (67%). Depression rates were lower in 
controls and showed the opposite pattern; 30% taking anti-androgens and 37% not taking 
anti-androgens showed some sign of depression. Thus there is, at present, uncertainty 
regarding the benefits of medications on mood in PCOS. 
The primary objective of the present paper is to assess the degree to which women 
with PCOS score differently to women without PCOS on measures of anxiety and 
depression. The secondary objective is to determine whether there is an impact of BMI and 
PCOS medication use (AUTHOR: you do not seem to present results – some discussion only 
- on use of medication. Please would you check and delete this mention of medication here?) 
on anxiety and depression scores. All between-groups designs were considered. 
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Materials and Methods 
Literature search  
All studies that measured anxiety and depression in women with PCOS listed in Pubmed and 
Medline published up to Dec 17th 2010, and EMBASE from 1980 to Dec 17th 2010, were 
identified. The Cochrane Reviews database was also searched up to Dec 17th 2010. The 
keyword search terms ‘polycystic ovary syndrome’ and ‘anxiety’ or ‘polycystic ovary 
syndrome’ and ‘depression’, were entered simultaneously. From a search of Pubmed from 
1968 to 2010, 98 articles emerged related to depression and 32 related to anxiety. A Medline 
search from 1950 produced 95 depression and 31 anxiety papers but none in addition to 
those cited in Pubmed. An EMBASE search from 1980 produced 79 depression and 36 
anxiety papers, two of which were not found in other searches and met the inclusion criteria 
(see below) for the present meta-analysis. The ‘related article’ function was used to widen 
the results. Additionally two Medical Subject Heading (MeSH) searches were performed 
using firstly the terms ‘polycystic ovary syndrome’ AND ‘depression’ and ‘polycystic ovary 
syndrome’ AND ‘anxiety’. This retrieved 27 and 15 publications, respectively, all of which 
were previously found using the Pubmed keyword search. The Cochrane Reviews database 
did not produce any published reviews of PCOS and anxiety or depression. A hand search of 
relevant articles referenced in these publications was performed, which produced two 
publications not previously found, neither of which met the inclusion criteria. Also included 
was a paper by the present authors (Barry et al., 2011). Each article was assessed by the first 
author and articles that fitted the main criteria (measuring anxiety and/or depression in 
PCOS) were accessed. Methodological quality was assessed by the first author based on the 
criteria of the Newcastle-Ottowa Quality Assessment Scale (NOS) for case-control studies 
(Wells et al., 2000) adapted for cross-sectional studies.  This adaptation meant changing the 
‘ascertainment of exposure’ criterion to ‘ascertainment of diagnosis’. The Cochrane Non-
Randomized Studies Methods Working Group consider the NOS one of the best tools 
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available for assessment of non-randomized studies (Reeves et al., 2008). A protocol for the 
present review has not been registered. 
 
Inclusion and exclusion criteria 
Studies that compared women with PCOS to controls were eligible for inclusion 
provided that: 
a. The studies reported a quantitative outcome on a standardized measure of depression 
or anxiety 
b. Comparison groups did not have a severe illness (for example, cancer) which would 
undermine the equivalence of the groups. 
c. The studies reported outcomes as mean and SD.  
d. The studies reported other relevant data e.g. n values in each group 
Papers with titles or abstracts that indicated that they were not relevant (for example, 
reviews, single case studies etc) were excluded. A table of excluded studies (Supplementary 
Table 1) is available online on the Human Reproduction website [appendix in thesis].  
 
Statistical analysis 
Statistical analyses were performed using Review Manager, Version 5 (RevMan 5). Anxiety 
and depression scores were meta-analysed using the fixed effect or random effects model, as 
appropriate. The inverse variance method was used. Heterogeneity was assessed using I² and 
Chi Square statistics.  I² values of 30% or above were considered likely to represent 
moderate heterogeneity, and Chi Square p values <.10 were considered to represent 
significant heterogeneity, thus studies showing I² values < 30% and Chi Square p values 
>.10 were analysed using fixed effects models. The effect size was measured as the standard 
mean difference, calculated using Hedges’ g.  Like Cohen’s d, a Hedges’ g of 0.2 can be 
considered a small difference, 0.5 a moderate difference, and 0.8 or more a large difference 
between groups. It should be noted that these values indicate statistical differences measured 
in terms of effect size; clinical differences must be assessed by reference to scores on 
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clinical measures of anxiety and depression (see Supplementary Table 2 and Supplementary 
Table 3 on the Human Reproduction website [in appendix in thesis]).  
 
Results  
Studies of anxiety and/or depression in PCOS (n=138) were retrieved, mostly from the 
electronic databases (Fig. 1). Of these, 126 studies were excluded, thus 12 studies including 
2257 participants (910 women with PCOS and 1347 controls), qualified for review 
according to the inclusion criteria. For all of these studies, those that measured depression 
also measured anxiety. There were no separate studies that examined only anxiety.  
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Figure I  Literature search and study selection for systematic review of studies of anxiety and depression in women with polycystic ovary syndrome (PCOS) 
compared to controls.  
Database searched Articles identified 
Pubmed 130
Medline 126 
EMBASE 115 
MeSH 42 
Cochrane Reviews 0 
From bibliography 2 
Other 1 
 
 
Excluded = 92  
Laboratory biological study 
No PCOS group  
Anxiety or depression not 
measured 
Single case study 
Animal study 
Qualitative 
Mixed PCOS/non-PCOS group 
Review paper 
  
 
Total citations 
n = 416 
Duplicate = 278   
Abstracts & titles  
reviewed = 138 
Excluded = 34 
Mean or SD not given; no 
comparison group; 
comparison group sample 
size not given; control 
group inappropriate (e.g. 
cancer); mixed PCOS and 
controls; same data used as 
another included study; 
poor methodological quality 
 
Full text analysis = 
46
Included studies = 12, 
using 2257 participants  
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Two of the included studies (Rocco et al., 1991; Weiner et al., 2004) used the State-
Trait Anxiety Inventory (STAI; Spielberger, Gorsuch & Lushene 1970) and reported scores 
for both state and trait anxiety and depression. The results were similar on state and trait 
measures in both studies. Because the most frequently used measure of depression in the 
included studies was a measure of state depression ,the Beck Depression Inventory (BDI; 
Beck, Ward, Mendelson, Mock & Erbaugh, 1961), for the sake of consistency only state 
anxiety and depression scores were included in the meta-analysis.  
Himelein and Thatcher (2006) had two control groups, one infertility group and one 
community control.  Because women with PCOS may experience problems with fertility, in 
the interests of maximising between-group comparability only, the infertility control group 
was included in the present analysis.   
Table 1 shows the characteristics of the included studies and Table II shows the 
methodological quality of the included studies. 
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Table I Characteristics of the twelve included studies of anxiety and depression in polycystic ovary syndrome (PCOS) compared to controls.  
Study Age (years) BMI(kg/m
2
) 
Control 
group 
features 
Controls: 
ovarian 
cysts 
excluded? 
Psychiatric 
cases 
excluded 
Diagnosis 
PCOS 
Medication status Duration 
on 
medication 
Variables 
controlled
a, b 
Outcome 
measure PCOS Control PCOS Control 
Metformin 
OCP 
Rocco et al 
(1991) 
20.2 
(2.75) 
21.7 
(2.21) 
22.7 
(1.81) 
21.01 
(0.95) 
Healthy 
medical 
students 
Yes No 3 
symptoms 
Not stated Not 
stated 
Not stated Age, culture MMPI, 
STAI 
Weiner et 
al (2004) 
28.19 
(4.84) 
30.07 
(6.48) 
37.7 
(3.46) 
36.89 
(7.24) 
Advert. 
Normal 
menstruation 
& 
Testosterone 
No Yes 3 
symptoms; 
some self 
report 
none 
none off 
minimum 2 
months 
Age, BMI, 
ethnicity, 
education 
DACL, 
STAI 
Himelein 
& Thatcher 
(2006) 
32.1 
(5.5) 
(all participants). 
33.8 
(8.5) 
23.4 
(3.6) 
2 groups; 
infertile & 
healthy. 98% 
all 
Participants 
White 
Unclear No Rotterdam-
likef 78% PCOS report 
receiving 
“some type of treatment 
for PCOS” 
Not stated Fertility. Also 
age, 
demographics 
BDI-SF 
Hollinrake 
et al 
(2007) 
29.8 
(6.2) 
30.7 
(8.5) 
34.9 
(8.5) 
24.5 
(4.7) Healthy 
No No Rotterdam 
Not stated 
Same rate 
in both 
groups 
Not stated Age, 
demographics 
BDI-II 
Barnard et 
al (2007a) 
No AA g 
31 
(6.5) 
31 
(7.9) 
31 
(10.23) 
25 
(5.12) Internet 
No No Rotterdam 
(self-report) none 
none Not stated AA Zung 
Barnard et 
al (2007a) 
AA g 
29 
(5.6) 
26 
(5.11) 
32 
(9.4) 
23 
(4.3) Internet 
No No Rotterdam 
(self-report) AA 
AA Not stated AA Zung 
Soyupek et 
al (2008) 
24.1 
(6.1) 
26.1 
(5.7) 
24.5 
(6.5) 
22.5 
(2.6) Healthy 
No No Rotterdam No PCOS on meds for 
PCOS. Not stated 
controls. 
Not stated Age d BDI 
Adali et al  
(2008) 
23.54 
(3.13) 
24.45 
(2.47) 
28.42 
(4.3) 
24.11 
(4.14) 
No PCOS 
features 
Yes Yes Rotterdam 
All Ps clear for minimum 6 months 
Age, 
demographics 
BDI 
Benson et 
al (2008) 
28.9 
(0.7) 
29.9 
(1.2) 
29.6 
(1.0) 
23.6 
(0.7) 
Advert. 
No No Rotterdam 
Not stated 
Not 
stated 
Not stated Age BDI 
Ozenli et 
al (2008) 
27.58 
(7.66) 
26.54 
(5.16) 
25.43 
(5.58) 
24.76 
(5.37) 
Friends & 
family of staff 
No Yes Rotterdam 
None 
Not 
stated 
PCOS off for 
min. 3 
months
BMI, age, 
demographics 
BDI, 
STAI 
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Benson et 
al  (2009) 
30.1 
(0.9) 
31.5 
(1.1) 
29.8 
(1.6) 
28.7 
(1.5) Advert; 
healthy 
No Yes Rotterdam 
44% PCOS; 
controls? 
0% 
controls; 
PCOS? 
Not stated BMI, age, 
demographics, 
psych. 
problems 
BDI, 
STAI 
Laggari et 
al (2009) 
16.95 
(2.0) 
 
17.04 
(2.16) 
24.63 
(6.42) 
 
20.7 
(2.97) 
Schools, 
colleges 
No No Rotterdam 
Not stated 
none Never Age BDI, 
STAI 
Barry et al 
(2011) 
28.8 
(4.81) 
35.12 
(4.37) 
27.87 
(7.36) 
24.69 
(7.08) 
Subfertility 
No Severe 
psychiatric 
cases 
excluded 
Rotterdam 76% PCOS & 11% 
controls on AA. Status of 
33% of total sample 
unknown. 
Not stated Infertilityc HADS 
a Variables controlled prior to statistical manipulation.  
b Demographics here indicates that one or more of the following were controlled or were not significantly different in each group: race, education, income. Other demographics factors may be 
included in some studies e.g. religion, city or rural dwelling.  
c  Barry et al (2011) has also performed a subgroup analysis controlling for age and BMI but because medians were presented for depression, data from the total group analysis is presented here. 
d  Groups were matched for age. Although age was significantly different in both groups, the difference was not of clinical significance. 
e  “Infertile women with PCOS were not included in the study because infertility imputes depressive characters for these patients” (Ozenli et al 2008, p. 191). 
f  Rotterdam-like indicates that PCOS diagnosis was based on 2 of 3 PCOS symptoms, but not as defined by the Rotterdam criteria (2004).  
g Barnard et al (2007a) has two rows, one for participants taking anti-androgen (AA) medication and one for those not taking AA.   
AA = anti-androgen medication; OCPs, metformin, or other medication capable of reducing testosterone levels; OCP = oral contraceptive pill, or other anti-androgen; Metf. = metformin, or 
other insulin sensitiser;  
MMPI = Minnesota Multiphasic Personality Inventory 
STAI = State-Trait Anxiety Inventory 
DACL = Depression Adjective Check Lists 
BDI = Beck Depression Inventory; BDI-II = Beck Depression Inventory-II 
BDI-SF = Beck Depression Inventory Short Form 
Zung = Zung Self-Rating Depression Rating  
HADS = Hospital Anxiety and Depression Scale
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Table II  Evaluation of the methodological quality of the studies using the Newcastle-Ottowa Quality Assessment Scale (NOS). 
Study Case 
definition 
adequate 
Representativeness 
of cases 
Selection of 
Controls 
Definition 
of Controls 
Comparability 
of both 
groups 
Ascertainment 
of diagnosis 
Same 
ascertainment 
method for 
both groups 
Non-
Response 
rate 
NOS Score 
Rocco et al 
(1991) 
* x * * a * * x x 5 
Monzani et 
al (1994) b 
* x x xa * x x x 2 
Weiner et al 
(2004) 
x * * * ** x x x 5 
Himelein & 
Thatcher 
(2006) 
* * * * a * * x * 7 
Hollinrake et 
al (2007) 
* * x * * * x * 6 
Barnard et al 
(2007a) 
x x * x ** x * x 4 
Soyupek et al 
(2008) 
* * x * ** * x x 6 
Adali et al  
(2008) 
* * x * a ** * * x 7 
Benson et al 
(2008) 
* x * * * * * x 6 
Ozenli et al 
(2008) 
* x * * ** * x x 6 
Benson et al  
(2009) 
* x * * ** * x x 6 
Laggari et al 
(2009) 
* * * * * * x x 6 
Barry et al 
(2011)  
* x * * * * x * 6 
a Controls screened for presence of polycystic ovaries; b Excluded from meta-analysis because of low NOS score; * NOS quality assessment star 
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The funnel plots in Supplementary Figure I (see online supplement [appendix in thesis]) 
suggest that publication bias was probably not a significant problem for this meta-analysis. 
The plot on the right shows that all of the anxiety studies are (a) closely grouped, (b) 
reasonably symmetrical, and (c) the larger studies (near the top of the graph) tend towards 
the mean more than the smaller studies. The plot on the left is less symmetrical than the plot 
on the right, indicating that the studies reporting on only depression (rather than anxiety and 
depression) may show signs of possible publication bias. Only two of the 12 studies included 
fewer than 50 participants, making the possibility of small study effects unlikely. 
 
 
Main outcomes 
Table III shows the results of the meta-analyses. Figures II and III show forest plots and test 
statistics for the main outcomes, depression and anxiety, respectively, and subgroup analyses 
are shown in Supplementary Figures -II to VII (online supplement [appendix in thesis]). 
Most analyses used fixed effects models, except the three subgroups that used random 
effects models due to showing levels of heterogeneity outside the accepted limits for the use 
of fixed effects models (Supplementary Figures II, V and VI). The findings were fairly 
similar regardless of whether fixed or random effects models were applied.   
82 
 
Table III.  Results of meta-analyses for all included studies and the subgroups for women 
with PCOS compared to controls.  
Analysis Number of 
studies 
Hedges’ g 
[95% CI]
a 
Z  
(p) 
Chi²  
(p) 
I² 
Depression  
 
12 0.82  
[0.73, 0.92] 
 
Z = 17.92  
(P < 0.00001) 
 
14.76  
(P = 0.19) 
 
25% 
Depression 
b
 13 0.82  
[0.61, 1.03] 
 
Z = 7.65  
(P < 0.00001) 
 
40.14 
(P = 0.0001) 
70% 
Anxiety 
 
6 
 
0.54  
[0.33, 0.75] 
 
Z = 5.03  
(P < 0.00001) 
 
5.45  
(P = 0.36) 
8% 
Anxiety 
b
 7 0.76  
[0.35, 1.17] 
 
Z = 3.64  
(P = 0.0003) 
 
23.03 
(P = 0.0008) 
 
74% 
Depression  
on AA 
c d 
 
5 
0.84 
[0.64, 1.04] 
8.20  
(P < 0.00001) 
7.55 
(P = 0.11) 
47% 
Depression  
no AA 
c 
 
5 
0.74  
[0.61, 0.88] 
10.76  
(P < 0.00001) 
2.36  
(P = 0.67) 
0% 
 
Depression  
matched BMI 
3 0.65  
[0.37, 0.94] 
 
4.48  
(P < 0.00001) 
0.54 
(P = 0.76) 
0% 
 
Depression  
BMI unmatched
 d
 
9 0.77  
[0.62, 0.93] 
 
9.64  
(P < 0.00001) 
 
12.61 
(P = 0.13) 
37% 
Anxiety 
matched BMI
d 
3 0.48  
[0.08, 0.87] 
 
2.38  
(P = 0.02) 
3.60 
(P = 0.17) 
44% 
Anxiety 
BMI unmatched 
3 0.63  
[0.33, 0.93] 
 
4.11  
(P < 0.0001) 
 
1.28 
(P = 0.53) 
 
0% 
 
a 95% CI = 95% confidence intervals 
b These results show the effect on heterogeneity of including data from Monzani et al (1994); 
I2 is increased above 30% and the Chi2 p value becomes significant, thus the random effects 
model has been used. This study also had a low score for methodological quality and was 
excluded from the meta-analysis based on the criteria described by Xiong et al. (2010)c AA = 
anti-androgen medication, i.e. medication commonly used to treat PCOS, mostly metformin 
or oral contraceptives. 
d The random effects model was used, as I2 was >30% and the Chi2 p value was almost 0.10 
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Figure II  Forest plot of all included studies of depression in women with PCOS compared to controls.  
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Figure III Forest plot of all included studies of anxiety in women with PCOS compared to controls.    
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The most commonly used outcome measure for assessing depression was the BDI, which 
was used in eight of the 12 studies (see Supplementary Table II). Six of these studies used 
comparable versions of the BDI, with mild depression being indicated when scores reach 11. 
For these six studies the mean BDI score for women with PCOS was 11.47, and for controls 
it was 7.31. This difference is statistically significant (Z = 5.94, p<.00001; Hedges’ g = 0.60; 
95% CI 0.40 to 0.80) with 0% heterogeneity (I2 =0%). In clinical terms this represents the 
difference between, on average, mild depression in the PCOS groups and no depression in 
the control groups. For anxiety, the most commonly used outcome measure was the STAI-S 
(state anxiety measure), and was used in 5 of the 6 studies. In these five studies the women 
with PCOS indicated statistically significantly higher anxiety scores (Z = 3.47, p<.0005; 
Hedges’ g = 0.46; 95% CI 0.20 to 0.73) with little heterogeneity (I2 =14%). The control 
groups scored a mean of 34.6 on the STAI-S, which is slightly below the norm of 36.2 for 
women of this age group (Spielberger, 1983), and the mean score for women with PCOS 
was 40.7, which is mildly elevated.   
Table III shows a slightly larger difference in depression scores between women 
with PCOS and controls for women with PCOS were taking anti-androgen medication 
(Hedges’ g = 0.84; 95% CI 0.64 to 1.04) than for women with PCOS were not taking anti-
androgen medication (Hedges’ g = 0.74; 95% CI 0.61 to 0.88). 
  
Discussion 
Analysis of the 12 studies and subgroups revealed differences in the scores for anxiety and 
depression, which were significantly higher in the PCOS groups compared to controls. 
These findings support those of the previous research reviewed by Farrell and Antoni 
(2010). The confidence intervals for the included studies were generally narrow and showed 
effect sizes which may be clinically relevant. Of the 18 results (12 depression and 6 anxiety), 
four confidence intervals encompassed a zero value, which suggests that overall (14 of the 
18 studies) the results were representative of those likely to be seen in the general population 
of women with PCOS and healthy women.  
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This meta-analysis helps to quantify the impact of BMI on anxiety and depression, and 
suggests that BMI has a small effect on anxiety and depression in PCOS. The three studies 
that controlled for BMI (Weiner et al., 2004; Özenli et al., 2008; Benson et al., 2009) found 
on average a smaller difference in depression between women with PCOS and controls 
(Hedges’ g = 0.65) than the eight studies that did not control for BMI (Hedges’ g = 0.77), a 
small difference in effect size (g = 0.12). This finding lends modest support to previous 
research suggesting an impact of obesity on depression (Rasgon et al, 2003) and perhaps 
also QoL (Jones et al., 2008). For anxiety, the three studies that controlled for BMI also 
found on average a smaller difference between women with PCOS and controls (Hedges’ g 
= 0.48) than the three studies that did not control for BMI (Hedges’ g = 0.63). The difference 
in anxiety when controlling for BMI represents a small effect size (g = 0.15), similar to the 
impact of BMI on depression.  
The differences between women with PCOS and controls for anxiety and depression 
were statistically significant, but what is the clinical significance of these findings? The most 
commonly used outcome measure for assessing depression, the BDI, found that women with 
PCOS scored statistically significantly higher than women without PCOS. In clinical terms 
this represents the difference between, on average, mild depression in the PCOS group and 
no depression in the control group. This appears to suggest that the difference between the 
groups is, on average, only of limited clinical significance. However the SDs in 
Supplementary Table II indicate that some proportion of the women in these studies had 
depression scores of greater clinical interest, especially in the PCOS groups. For example, 
Benson et al (2008) found a mean PCOS BDI scores of 10.1 with an SD of 7.55; given that 
these scores passed tests of normality of distribution, and given the properties of the normal 
distribution, we can infer that roughly 15% of women with PCOS in this study had 
depression scores of 18 or more, which places them in the range of moderate to severe 
depression. However it should be noted that although the cut offs for BDI scores offer 
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guidance on depression severity, interpretation of scores should be based on clinical 
judgement (Beck, Steer & Garbin, 1988). 
 For anxiety, the most commonly used outcome measure was the STAI-S (state 
anxiety measure), used in 5 of the 6 studies. The control groups scored slightly below the 
norm, and the PCOS groups’ score wasmildly elevated.  Although this is perhaps only a 
modest clinical difference in anxiety scores, any increase in anxiety might be clinically 
significant in PCOS because of the potential impact of anxiety on testosterone  levels; given 
that stress activates the adrenal glands via the hypothalamic-pituitary adrenal axis (HPA) 
(Reiche et al., 2004) and that women produce roughly 25% of the testosterone from their 
adrenal glands (Burger, 2002) the level of stress that a woman experiences in her daily life 
may potentially increase her testosterone levels, thus exacerbating the symptoms of PCOS. 
Furthermore, there is evidence that women with PCOS show a stronger HPA response to a 
stressor than healthy women (Benson et al., 2009; Gallinelli et al., 2000) which suggests that 
the elevations in anxiety ratings seen in the studies reviewed in the present meta-analysis are 
of special relevance. The potential impact of anxiety and stress on testosterone levels in 
PCOS is clearly of importance and could be explored in future research. 
It should be noted that the control group participants from the included studies were 
drawn from a variety of sources, for example, the Internet, friends and family of the 
researchers, and medical students (Table 1). Although the NOS criteria specify that 
community controls are preferable to hospital controls, the wide variety of control groups in 
the present review implies a heterogenous selection process, which introduces uncertainty in 
interpretation of the findings because of the unknown influence of possible selection bias. 
Variation in the selection of participants is an issue often seen when reviewing comparative 
observational studies and the possible effects of this should be borne in mind when 
considering the findings of the present review. The NOS quality ratings ranged from four to 
seven, out of a maximum of nine. Eleven of the 12 studies scored five or more, which 
indicates reasonably good methodological quality overall. The NOS criteria specify that 
community controls are preferable to hospital controls but it could be argued that in studies 
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where women with PCOS were recruited from hospitals and clinics, a hospital or clinic 
control group may be the most appropriate comparison provided that the controls had 
medical conditions of comparable impact to PCOS. Nonetheless, in the interests of 
adherence to the NOS criteria, studies that used hospital control groups (Adali et al., 2008; 
Hollinrake et al., 2007; Barry et al., 2011) lost an NOS quality assessment star. Where a 
study presented more than one control group, the one best matched to the PCOS group was 
used in the presented analysis. Thus Himelein and Thatcher's (2006) infertility control group 
was used, which had the effect of reducing the size of the difference in depression between 
women with PCOS and controls. The Barry et al.(2011) matched group was not used 
because the median rather than mean was given for the depression outcome. 
Only three studies (Adali et al., 2008; Himelein and Thatcher, 2006; Rocco et al., 
1991) tested for polycystic ovaries in control groups. Although the findings from the present 
study suggest that screening controls for polycystic ovaries is not essential (see below), this 
raises the question of whether a woman with polycystic ovaries can be classified as a control 
in a study of PCOS. Controls can be defined by excluding menstrual problems and 
hyperandrogenism (Rotterdam criteria i and ii; Rotterdam ESHRE/ASRM, 2004) without 
reference to polycystic ovaries, but this leaves open the possibility that women in the control 
groups had one of the diagnostic conditions (polycystic ovaries) for membership of the 
PCOS group. Polycystic ovary morphology (as seen on ultrasound)  has been found in 
around 23% of regularly menstruating women (Koivunen et al., 1999; Polson et al., 1988), 
and although this may represent one end of the spectrum of symptom severity in genetically 
predisposed individuals, this single symptom in asymptomatic women is not generally 
considered to be of clinical importance. Theoretically therefore the failure to screen controls 
for polycystic ovaries could reduce group differences on outcomes related to PCOS, but in 
the present meta-analysis the three studies that excluded polycystic ovaries in their control 
groups had a slightly lower mean Hedge’s g for depression than the other nine studies (g = 
0.74 versus 0.83, respectively): the smaller difference in depression score in these studies is 
not explained by other factors (study quality, BDI scores etc), thus it could be concluded that 
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screening for polycystic ovaries in control groups does not seem to be a confounding 
variable in studies of depression in PCOS. Only one of the three studies measured anxiety, 
so an assessment of the effect of screening for polycystic ovaries on anxiety scores cannot be 
made. 
The finding that women with PCOS on medication for PCOS were slightly more 
depressed compared to controls than women with PCOS not on medication  appears to 
suggest there is a small benefit in terms of depression of not taking PCOS medication, 
contradicting the finding by Rasgon et al., (2003) and supporting the finding of Barnard et 
al., (2007). However, because different outcome measures were used in the various studies 
(none of the on-medication PCOS groups used exactly the same scale), it is difficult to 
compare scores for the women with PCOS on medication to the women with PCOS not 
taking medication. Also the apparent benefit – relative to controls - of women with PCOS 
not taking anti-androgen medication is possibly caused in part by high depression scores in 
two of the control groups relative to their respective PCOS groups (Laggari et al., 2009; 
Özenli et al., 2008). Furthermore, medication use was not clearly defined in the studies (see 
below). For these reasons the small apparent affect of medication use  (Hedge’s g = 0.1) 
should be interpreted with caution. Regarding the effect of medication for PCOS on anxiety 
scores, there were too few studies of anxiety that differentiated groups by medication status 
to assess any effect. 
A weakness of the present meta-analysis is that medication use was not clearly 
defined in the included studies. Whether oral contraceptives or other anti-androgenic  
medications were used by the control group is unclear in seven of the twelve control groups, 
perhaps because these researchers did not hypothesise that healthy women would be affected 
by anti-androgen medication use. In the five studies classified as ‘on medication’, the 
numbers of women with PCOS taking medication ranged from 100% to 44% (see Table 1). 
The study that most clearly stratified by medication use (100% on medication in Barnard et 
al., 2007) relied on self-report, and as always self-report introduces uncertainty as to the 
exact numbers. The type of medication was not stratified in any of the studies making it 
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impossible to assess, for example, whether insulin sensitisers affect women differently than 
anti-androgens, as found by Harborne et al., (2003). Four of the 12 studies stated the length 
of time that participants with PCOS had not been taking medication (minimum two months), 
and none stated the duration that the controls were on medication. Because the most 
common PCOS medications will have had their major effects within six months (Harborne 
et al., 2003), it would be useful to know at least whether they had been taking medication for 
a longer or shorter period than six months. Future studies would be improved by stratifying 
findings by medication type, duration of medication, and dose.  
Some studies controlled for age. All studies were of adult women of childbearing 
age, and apart from the Laggari et al. (2009) sample who were in their mid to late teens, all 
studies were of women aged on average in their mid twenties to early thirties. The Hedges’s 
g for the Laggari et al. (2009) sample was smaller than the mean Hedges’s g for the other 
studies for depression (g =0.33 versus 0.84) but was the same for anxiety (g = 0.54 versus 
0.54) suggesting that younger women with PCOS may be similarly anxious but less 
depressed than women with PCOS in their 20s and 30s. This finding undermines to some 
degree the suggestion that PCOS causes more distress to younger women because of the 
impact of PCOS on physical appearance (Farrell and Antoni 2010) and fertility (Trent et al., 
2003). However more studies with young women with PCOS are needed to help clarify this 
issue.  
Five of the 12 studies screened for psychiatric illness, and these studies showed 
slightly smaller differences between depression scores in women with PCOS and controls 
(Hedge’s g = 0.76) compared to those with no screening (Hedge’s g = 0.84). This suggests 
that screening for psychiatric illness in studies of anxiety and depression in PCOS does not 
have a major impact on results. However other factors that might affect mood in women 
with PCOS should also be accounted for in future research e.g. the presence of 
hypoglycaemia (Kasim-Karakas et al., 2007) or proinflammatory cytokines (González et al., 
2010). 
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Because of the possibility that state anxiety might be raised simply by being in a 
hospital context, future studies might also consider stating the context in which the 
questionnaires were completed. Although none of the included studies published data on this 
issue, the present authors know that 59% of the Barry et al (2011) sample opted to fill in the 
questionnaire online, the remainder doing so at the clinic. However, context appeared to 
have little effect on Hospital Anxiety and Depression (HADS; Zigmond & Snaith, 1983) 
anxiety scores as there was no significant difference between those completing the survey at 
the clinic for the PCOS group, controls or both groups combined. 
 
Conclusion  
PCOS is generally seen as a reproductive endocrine disorder, with symptoms of modest 
importance compared to other conditions with more obvious effects on wellbeing but the 
results of this systematic review highlight the psychological distress experienced by the 5-
10% of women affected by this condition.  General practitioners, gynaecologists, 
endocrinologists and clinical psychologists should be more aware that levels of anxiety and 
depression are higher in women with PCOS than controls. The fact that differences in 
anxiety and depression scores  between women with PCOS and controls are slightly lower 
when both groups have a similar BMI would suggest that  mood in PCOS might be 
improved to some degree through weight control, and a recent study  found that the low GI 
diet has some advantages for women with PCOS (Marsh et al., 2010). Future studies in this 
field should also be directed at assessing the potential to alleviate psychological distress 
using antiandrogens and insulin sensitisers, currently used to treat physical symptoms of 
PCOS, as well as conventional antidepressant and anxiolytic therapy. A ‘talking treatment’, 
such as cognitive behavioural therapy or counselling, should be considered too. 
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APPENDIX 
 
Supplementary Table I  Excluded studies (N=126). ‘Y’ indicates that the full paper 
was reviewed, ‘N’ indicates that only the title &/or abstract were reviewed. 
 Study and reason for exclusion  Full 
article 
reviewed? 
1 Herbert et al (2010) no data on depression or anxiety Y 
2 Krysztof & Blazej (2010) no means/SDs N 
3 Loughlane (2010) non-research article Y 
4 Peraita-Adrados et al (2010) focus is sleep; one patient with 
PCOS 
N 
5 Rassi et al (2010) no means/SDs Y 
6 Teede et al (2010) review N 
7 Farrell K, Antoni MH (2010)  review N 
8 Benson S, et al (2010) no comparison group Y 
9 Deeks et al (2010) no comparison group Y 
10 Peacock et al (2010) Review menstrual problems  N 
11 Harrison  et al (2010) non-research: hirsute. problems  Y 
12 Rathnayake, Sinclair et al (2010) non-research  N 
13 Cinar et al (2010) no means/SDs. N 
14 Cheang et al (2010) no means/SDs. N 
15 Danciulescu Miulescu et al (2010) no means/SDs N 
16 Sayyah Melli M., Kazemi-shishvan M. (2010) no comparison N  
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group 
17 Moreira et al (2010) psychosocial approach to PCOS N 
18 Jedel et al (2010) median & range Y 
19 Wheatley & Ahmed (2010) single case N 
20 Onno et al (2010) conference abstract (duplicates Benson et al, 
2009) 
N 
21 Bhattacharya  & Jha (2009) no means /SDs Y 
22 Vrbikova & Hainer (2009) not anxiety or depression N 
23 Thomson & Buckley (2010) no control group Y 
24 Mallappa & Hanji (2010) Review (medical info for women with 
PCOS) 
N 
25 Flanagan & Jensen (2009) Hidradenitis suppurativa patients N 
26 Benson et al (2009) normative groups & N of norm groups not 
stated. 
Y 
27 Moran et al (2009) no means /SDs Y 
28 Eyvazzadeh et al (2009) review N 
29 Bishop et al (2009) review N 
30 Manlove (2008) not anxiety or depression Y 
31 Marangell (2008) review of bipolar N 
32 Mansson et al (2008) no means /SDs Y 
33 Aylwin & Al-Zaman (2010) Review of surgery for BMI N 
34 Kapoor (2009) comment Y 
35 Battaglia et al (2009) no means /SDs Y 
36 Rofey et al (2009) no cont or norm  Y 
37 Kerchner (2009) no comparison group  Y 
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38 Morgan (2008) mixed PCOS & hirsute group; no comparison 
group 
Y 
39 Castillo-Quan (2008) comment N 
40 Tan et al (2008) no comparison group Y 
41 Aylwin & Al-Zaman (2008) review of obesity N 
42 Janssen et al (2008) review N 
43 Szalat & Raz (2007)  review diabetes N 
44 Barnard et al (2007b) women from 2007a sample (right handed 
only) 
Y 
45 Magnotti & Futterweit (2007) review BMI & PCOS N 
46 Blume-Peytavi et al (2007) review hirsutism N 
47 Barron (2007) review menstrual (biological) N 
48 Setji & Brown (2007) review PCOS care N 
49 Galletly et al (2007) low carb., no control group Y 
50 Peritogiannis et al (2007) single case N 
51 Pecori Giraldi et al (2007) Cushing’s N 
52 Anger et al (2007) no control group  Y 
53 Elsenbruch (2006) no means /SDs; norm comparison.  Y 
54 Vgontzas et al (2006) sleep & BMI review N 
55 Himelein & Thatcher (2006)  review N 
56 Lipton et al (2006) “suspected” PCOS & no controls Y 
57 Legato et al (2006) review diabetes N 
58 Lipton  et al (2006) hirsutism survey (not specifically PCOS) N 
59 Biton (2006) review BMI N 
60 Daniels (2006) review BMI children N 
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61 Sobjanek et al (2006) acne N 
62 Rasgon & Kenna (2005) Alzheimers etc N 
63 Dawber (2005) review hirsutism N 
64 McCook et al (2005) QoL only (uses data from McCook 02) Y 
65 Clayton et al (2005) RCT (PCOS in all groups) Y 
66 Penovich et al (2004) epilepsy review N 
67 Swann (2004) bipolar N  
68 Brown (2004) review depression & IR in PCOS N 
69 van Wely et al (2004) RCT (PCOS in all groups) Y 
70 Ozanne et al (2004) review of Barker hypothesis N 
71 Coffey & Mason (2004) review of HRQoL in PCOS N 
72 Boro & Haut (2003) epilepsy review N 
73 Hernandez-Escalante (2003) binge eating N  
74 Keegan et al (2003) norm group of cancer patients.  Y 
75 Elsenbruch (2003) no means /SDs & compared to norms  Y 
76 Rasgon (2003) no control group and no means/SDs given Y 
77 Joffe (2003) review N 
78 McIntyre (2003) bipolar N 
79 Childres et al (2003) not about anxiety & depression specifically  Y 
80 Ledger (2003) review N  
81 McCook (2002) unpublished thesis N 
82 Rasgon (2002) single case study  N 
83 Resch & Szendei (2002) review eating disorders  N 
84 O'Brien & Dixon (2002) obesity review N 
85 Rohr (2002) review T & depression N 
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86 Merke et al (2002) review CAH N 
87 Martin-Du Pan (2002) review (effects of aging) N 
88 Ernst (2002) bipolar N 
89 Kitzinger & Willmott (2002) no means/SDs Y 
90 Henmi et al (2001) rats N 
91 Sills (2001) no means/SDs N 
92 Eggers & Kirchengast (2001) review/theoretical paper Y 
93 Simon-Vermot & Keller (2000) review obesity N 
94 Graña-Barcia et al (1998) GnRH depression N 
95 Björntorp (1998) review obesity N 
96 Bragagni  et al (1995) not PCOS  N 
97 Monzani et al. (1994) Poor methodological quality NOS rating Y 
98 Cavagnini & Invitti (1994) Cushing’s Syndrome N 
99 Matsunaga & Sarai M (1993) all psych patients, no PCOS N 
100 Matsunaga Taniguchi et al (1993) bipolar N 
101 Sonino et al (1993) PCOS group mixed with non-PCOS  N 
102 Bruce-Jones (1993) no means/SDs Y 
103 Levin et al (1992) case study (psychiatric patient) N 
104 Matsunaga et al (1992) psychiatric, non-PCOS N 
105 Mason et al (1990) cell function N 
106 Macleod et al (1990) biological study, no controls N 
107 Johnson & Pearce (1990) miscarriage (no psychological 
measures) 
N 
108 Fleming et al (1990)  biological study, no controls N 
109 Ghaziuddin (1989) case study, bipolar N 
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110 Schlaff (1989) biological / non-psychological study N 
111 Orenstein et al (1989) Unstandardized outcome measure & 
PCOS diagnosis unclear 
N 
112 Fleming (1985) biological study, no controls N 
113 Mori (1985) biological study, no controls N 
114 Cumming et al (1984) biological study, no controls N 
115 Orenstein & Raskind (1983)  two cases, no controls  N 
116 Suginami et al (1982) biological study, no controls N 
117 Duignan (1976) review PCOS biological studies N 
118 Netter (1976) ovarian dystrophy, non-psychological N 
119 Beck et al (1976)  biological study, no controls N 
120 Mendelsohn et al (1970) biological study N 
121 Lopez et al (1969) biological study N 
122 Wiese et al (1969) biological study N 
123 Rhodes (1968) biological study N 
124 Bardin et al (1968) biological study N 
125 Serment & Piana (1968) biological study N 
126 Hart et al (1968) biological study N 
SDs, Standard Deviations. 
Norm, Normative 
RCT, randomized controlled trial 
HRQoL, health-related quality of life 
CAH, Congenital adrenal hyperplasia 
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Supplementary Table II  Mean and standard deviation (SD) depression scores in 
the PCOS and control groups of the included studies and Monzani et al (1994).a 
 
 PCOS Control 
Study Outcome Mean SD N Mean SD N 
Rocco et al (1991) MMPI 73.0 18.33 21 47.1 7.59 10 
Monzani et al (1994) CCEI 8.25 2.04 23 2.69 1.14 20 
Weiner et al (2004) DACL 11.3 6.49 27 6.81 4.87 27 
Himelein & Thatcher (2006) BDI-SF 7.5 7.0 40 4.56 5.03 40 
Hollinrake et al (2007) BDI-II 11.9 11.1 103 4.5 5.9 103 
Barnard et al (2007) Zung 56.0 12.28 419 45.5 11.0 930 
Adali et al (2008) BDI 11.69 9.49 42 5.8 4.58 42 
Soyupek et al (2008) BDI 9.78 8.05 41 6.42 5.03 35 
Benson et al (2008) BDI 10.1 7.55 57 5.9 7.41 28 
Ozenli et al (2008) BDI 14.71 7.67 35 10.5 5.26 35 
Laggari et al (2009) BDI 12.82 7.86 22 10.32 7.19 22 
Benson et al (2009) BDI 9.7 7.92 32 4.9 5.09 32 
Barry et al (2011) HADS 5.42 1.98 71 3.73 2.04 43 
MMPI = Minnesota Multiphasic Personality Inventory 
CCEI = Crown-Crisp Experiential IndexDACL = Depression Adjective Check 
ListsBDI-SF = Beck Depression Inventory Short Form (scores of 5-7 = mild to moderate 
depression) 
BDI-II = Beck Depression Inventory-II (scores of 14-19 = mild to moderate 
depression)BDI = Beck Depression Inventory (scores of 11-18 = mild to moderate 
depression) 
Zung = Zung Self-Rating Depression Rating 
HADS = Hospital Anxiety and Depression Scalea The Monzani et al (1994) data was 
excluded due to its affect on heterogeneity and the study’s relatively low score on 
methodological quality. 
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Supplementary Table III  Mean and standard deviation (SD) anxiety scores in the 
PCOS and control groups of the included studies and Monzani et al (1994).a 
 PCOS Control 
Study Outcome Mean SD N Mean SD N 
Rocco et al (1991) STAI 46.3 13.75 21 33.7 3.48 10 
Monzani et al (1994) CCEI 9.95 3.11 23 4.08 1.64 20 
Weiner et al (2004) STAI 37.67 12.42 27 32.56 7.61 27 
Ozenli et al (2008) STAI 47.8 8.13 35 42.5 5.47 35 
Laggari et al (2009) STAI 36.55 10.44 22 31.5 8.24 22 
Benson et al (2009) STAI 35.0 9.05 32 34.0 9.62 32 
Barry et al (2011) HADS 10.12 4.54 71 7.56 4.2 43 
 
STAI = State-Trait Anxiety Inventory 
CCEI = Crown-Crisp Experiential Index 
HADS = Hospital Anxiety and Depression Scale 
a The Monzani et al (1994) data was excluded due to its affect on heterogeneity and the 
study’s relatively low score on methodological quality. 
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Supplementary Figure I Funnel plots for assessment of publication bias. Effect size is on the X axis and study size is on the Y 
axis.
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Supplementary Figure II. Forest plot of the difference in depression levels in studies of women with PCOS taking medication for PCOS, and controls.   
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Supplementary Figure III Forest plot of the difference in depression levels in studies of women with PCOS not taking medication for PCOS, and controls.    
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Supplementary Figure IV Forest plot of studies of depression in women with polycystic ovary syndrome (PCOS) compared to controls, where BMI was 
matched 
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Supplementary Figure V Forest plot of studies of depression in women with polycystic ovary syndrome (PCOS) compared to controls, where BMI was not 
matched 
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Supplementary Figure VI Forest plot of studies of anxiety in women with polycystic ovary syndrome (PCOS) compared to controls, where BMI was 
matched 
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Supplementary Figure VII Forest plot of studies of anxiety in women with polycystic ovary syndrome (PCOS) compared to controls, where BMI was not 
matched 
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Summary   
This meta-analysis reviewed published literature comparing human male and female 
umbilical cord total testosterone (T) levels. Eighteen studies using 1229 samples 
from 602 male and 627 female newborns were analyzed using the RevMan 5 
statistical package. Analysis using the inverse variance method based on a random-
effects model revealed significantly higher cord T in boys than girls at a moderate 
effect size (Hedges’ g = 0.57). There was significant heterogeneity between the 18 
studies, though the five studies using direct assays showed no heterogeneity. For 
studies using extraction and chromatography, those that combined T from arterial 
and venous cord blood found a larger sex difference than those using only cord 
venous samples (Hedges’ g = 0.94 versus 0.32); this suggests umbilical cord venous 
T is of maternal/placental origin and arterial T is of fetal origin. The wide range of T 
values between studies suggests high cross-reactivity in the assay methods reviewed.  
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Introduction 
Barker (2004) proposed that some diseases of adulthood may have their 
origin in conditions in the fetal environment, and that low birth weight is associated 
with insulin resistance, type 2 diabetes, hypertension, and coronary heart diseases in 
adults. This hypothesis is supported by research showing that elevated maternal 
testosterone (T) is related to low birth weight in sheep (Manikkam et al., 2006) and 
humans (Carlsen et al., 2006).  Elevated maternal T in rhesus monkeys in late 
pregnancy causes hyperinsulinemia, and in early pregnancy additionally causes type 
II diabetes (Abbott et al., 2009). Elevated maternal T in either early or late gestation 
doubles the risk of the female offspring of rhesus monkeys suffering from 
anovulation and polycystic ovaries in adulthood (Resko et al., 1987).  Animal 
research suggests that females may be more sensitive to the effects of T on brain 
development than males (Roselli et al., 2007) so it is especially important to assess 
potential risks to the female fetus of exposure to T. However at present there is no 
definitive consensus as to whether T is normally lower at birth in the umbilical cord 
of healthy human females pregnancies than in male, so it has been difficult to make 
clinical judgements regarding prenatal risk of T exposure based on levels of 
umbilical cord T. It is hoped that the identification of normative sex differences in T 
levels in the present meta-analysis will contribute to our scientific and clinical 
understanding of this issue. 
Polycystic ovary syndrome (PCOS) affects 5-10% of women (Franks, 1995) 
and is hypothesised to develop as a result of exposure to elevated T prenatally 
(Dumesic et al., 2006).  Some recent research suggests that umbilical vein T is 
elevated in female newborns of mothers with PCOS (Barry et al., 2010).  Placental 
aromatase is traditionally thought to protect the fetus from raised maternal T, but 
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animal research contradicts this hypothesis (Resko et al., 1987; Manikkam et al., 
2006; Abbott et al., 2009). 
To date, studies have produced mixed evidence regarding a sex difference in 
umbilical vein T. Some studies have found that compared to female newborns, male 
newborns have more umbilical vein T (Herruzo et al., 1993), less (Pardo et al., 1993), 
or virtually identical levels (van de Beek et al., 2004). Establishing a norm for 
umbilical cord T is difficult because the commonly used ‘direct’ assay methods 
(described in discussion section, below) lack the sensitivity to accurately detect T at 
levels below 10 nmol/l (Rosner et al., 2007); although umbilical vein T tends to be 
higher than circulating T in women of reproductive age (Baik et al., 2004) it is 
usually below the 10 nmol/l detection threshold suggested for direct assays (see 
Table II).  
 
 Fetal T can be measured from various sites. Although amniotic fluid is the 
best candidate to investigate the effects of early fetal androgen exposure (van de 
Beek et al., 2004), it is not comparable to cord T at the end of gestation because 
amniotic T is sampled around weeks 11 to 21 when a sex difference in T is likely to 
largest because of the testosterone surge in male fetuses (Smail et al., 1981).  Most 
studies of fetal T sample from the umbilical vein at birth; fewer studies sample 
mixed (arteries + vein) cord blood, and very few sample directly from umbilical 
arteries. Almost all studies measure total T rather than free (unbound) T. 
Some papers on this topic (Mathur et al., 1980; Bolton et al., 1989; Pardo et 
al., 1993; Troisi et al., 2003; Anderson et al., 2010) speculate or infer that umbilical 
arterial T is of fetal origin and umbilical vein T is of maternal/placental origin. This 
hypothesis has not been proved, but if male fetuses produce more T than females, 
and if the umbilical arteries carry hormones of fetal origin, then the umbilical arteries 
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of males should contain more T than the arteries of females (i.e. a sex difference in 
arterial T). By extension, because mixed cord T contains arterial T, mixed cord T 
should show a larger sex difference than the sex difference for venous T.  
The objective of the present paper was to discover whether there is a sex 
difference in umbilical vein T across comparable studies..  
 
Materials and Methods 
Literature search 
All studies that measured testosterone in umbilical cord listed in Pubmed and 
Medline published up to March 1st 2010, and EMBASE from 1980 to March 31st 
2010, were identified. The Cochrane Reviews database was also searched. The 
keyword search terms, ‘umbilical’ ‘cord’ and ‘testosterone’, were entered 
simultaneously. This produced 115 articles from Pubmed from 1965 to 2010, and 73 
from Medline. Medline produced no new papers in addition to those cited in 
Pubmed. EMBASE produced four additional studies, but these did not meet the 
inclusion criteria for the present meta-analysis. The “related article” function was 
used to widen the results. Additionally three Mesh searches were performed using 
firstly the terms “testosterone” AND “umbilical cord”, “testosterone” AND 
“umbilical veins”, and “testosterone” AND “umbilical arteries”. This retrieved 52, 
26, and 16 publications respectively, all of which were previously found using the 
Pubmed keyword search. The Cochrane Reviews database produced six publications, 
but these were not relevant. A hand search of relevant articles referenced in these 
publications were obtained, which produced nine publications not previously found. 
Each article was assessed by JAB and MT, and articles that fitted the main criteria 
(assaying T in umbilical cord vein in healthy pregnancies) were accessed. 
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Methodological quality was assessed based on the criteria of the Scottish 
Intercollegiate Guidelines Network (2010). 
 
Inclusion and exclusion criteria 
Human studies that compared male and female umbilical cord total T at birth 
were eligible for inclusion provided that: 
a. The pregnancies were healthy  
b. The deliveries were spontaneous, or else planned caesarean sections 
c. The assay methods were IA, CLIA/ECL, a method using extraction, or mass 
spectrometry. 
Papers with titles or abstracts that indicated that they were not relevant (for various 
reasons e.g. reviews, single case studies etc) were excluded. A literature search flow 
chart (S1), an additional Forest plot (S2), table of excluded studies (S3), conversion 
table for T to nmol from other units (S4), and tables of methodological quality (S5a, 
b, and c) are available as supplemental digital content on the JOG website [appendix 
in thesis].  
Table 1 shows the characteristics of the included studies. 
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Table 1.  Characteristics of the included studies.          
Study Assay Original T units Mother Delivery Newborn T source 
Simmer et al (1972) C-X-IA 
“ng %” 
(ng/100ml) 
Not stated Vaginal, term 
Normal, 
primiparous 
Vein 
Forest et al (1973) C-X-IA ng/100ml Not stated Normal, vaginal Normal Mixed 
Forest et al (1974) C-X-IA ng/100ml Healthy Normal, vaginal Normal Mixed 
Abramovich et al (1974) IA ng/100ml Not stated Mix of C-S and vaginal Not stated “mainly venous” 
Dawood & Saxena 
(1977) 
X-IA pg/ml 
Not stated, (some had 
amnio.) 
Spontaneous vaginal Not stated vein 
Maccoby et al (1979) C-X-IA ng/ml Not stated Term, no C-S Normal 
“Predominantly 
venous” 
Penny et al (1979) C-X-IA ng/100 ml Healthy Vaginal Not stated Mixed 
Miyamoto (1981) IA ng/ml Not stated normal pregnancy & delivery Term Vein 
Furuhashi et al (1982) C-X-IA ng/ml Not stated Normal, vaginal Normal Vein 
Shinkawa et al (1983) IA ng/dl Not stated Not stated Term vein 
Bolton et al (1989) C-X-IA nmol/l Not stated Not stated Term vein 
Herruzo et al (1993) IA ng/ml Not stated Uneventful Term vein 
Simmons et al (1994) X-IA nmol/l Healthy Normal Not stated vein 
Maffeis et al (1999) CLIA nmol/l Uncomplicated Uncomplicated Term vein 
Troisi et al (2003) C-X-IA ng/dl healthy Normal: SVD or C-S Not stated mixed 
Van de Beek et al (2004) C-X-IA nmol/l Healthy SVD Term Vein 
Gol et al (2004) IA ng/ml Healthy Uncomplicated, C-S only Term Not stated (mixed?) 
Anderson et al (2010) LCMS ng/dl Healthy 
74% SVD; 26% C-S; 
uncomplicated 
>35weeks gestation mixed 
IA = Direct immunoassay  
CLIA = Direct CLIA 
X-IA = IA, after extraction 
C-X-IA = IA, after extraction and chromatography (TLC and/or column) 
LCMS = Liquid Chromatography-Mass Spectrometry. 
C-S = Caesarian section 
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Of the included studies, six used direct methods (five IA and one 
CLIA/ECL), eleven used extraction methods (9 with thin layer chromatography and 
two with di-ethyl ether extraction alone), and one used LCMS. There were no mixed 
cord X-IA studies, and only one direct assay mixed cord study. Two studies 
(Dawood & Saxena, 1977; Bolton et al., 1989) measured T in umbilical arteries and 
vein separately. The venous samples for these two studies were included in the 
venous subgroup, and the means of their arterial and venous samples combined were 
included in the mixed cord subgroup. Only the venous samples for these two studies 
were included in the ‘all groups’ analysis. Two studies used ‘predominantly’ 
(Abramovich, 1974) or ‘mainly’ (Maccoby et al., 1979) venous blood, so were 
classified as venous. One study did not state whether they differentiated between 
arteries and vein (Gol et al., 2004) and was classified as ‘mixed’. Thirteen of the 
studies were classified as being of moderate quality, four were classified as poor 
(Forest et al., 1973; Abramovich, 1974; Dawood & Saxena, 1977; Shinkawa et al., 
1983) and one classified as good (Troisi et al., 2003). 
 
Statistical analysis 
Statistical analyses were performed using Review Manager, Version 5 
(RevMan 5). Heterogeneity tests suggested that a random effects model was 
appropriate to assess the sex difference in umbilical vein T levels in seven of the 
eight subgroups and the studies as a whole. The I² value in the direct assay subgroup 
was zero thus suggesting no problem with heterogeneity, but in the interests of not 
risking an underestimation of the heterogeneity between studies the more 
conservative random effects model was used rather than fixed effects. The inverse 
variance method was used. The effect size was measured as the standard mean 
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difference, calculated using Hedges’ g.  By convention, like Cohen’s d the thresholds 
for small, moderate and large Hedges’ g effect sizes are 0.2, 0.5, and 0.8 
respectively. All T values are presented in nmol/l, and were converted from other 
units for most studies.  
 
Results 
Seventy studies of umbilical cord T were retrieved from the electronic 
databases. Eighteen studies using 1229 samples (602 male and 627 female) qualified 
for review according to the inclusion criteria. 834 samples were venous (410 male 
and 424 female), 395 were mixed (192 male and 203 female), and 41 were arterial 
(Bolton et al., 1989), (Dawood & Saxena, 1977) (21 male and 20 female). Fifty-two 
trials were excluded. 
Table II shows cord T levels (nmol/l) for the included studies.  It can be seen 
that most studies (16 of 18) found higher cord T in boys than girls, and that overall 
this difference was of a moderate effect size (Hedges’ g = .57).  
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Table 2. Testosterone levels (nmol/l) for all of the included studies, in chronological order. ‘g’ 
indicates Hedges’ g, the standard mean difference between male and female umbilical cord T. Levels 
for 41arterial samples (Dawood & Saxena, 1977;  Bolton et al., 1989) are not shown. 
Study          Male          Female Difference 
  Mean  SD  n   Mean  SD  n    Hedges’ g [95% CI] 
Simmer et al (1972) 0.69 0.45 16 0.80 0.52 24 
-0.22 
[-0.85, 0.42] 
Forest et al (1973) 1.17 0 .33 35 0.92 0.26 46 
0.85 
[0.39, 1.31] 
Forest et al (1974) 1.24 0.36 51 0.93 0.28 53 
0.96 
[0.55, 1.36] 
Abramovich et al (1974) 2.92 0.59 20 2.63 1.25 20 
0.29 
[-0.33, 0.91] 
Dawood & Saxena (1977) 0.79 0.47 11 0.31 0.15 18 
1.51 
[0.65, 2.36] 
Maccoby et al (1979) 0.97 0.24 58 0.74 0.15 58 
1.14 
[0.75, 1.54] 
Penny et al (1979) 1.35 0.30 21 0.90 0.25 22 
1.60 
[0.91, 2.30] 
Miyamoto (1981) 16.69 3.78 55 14.44 3.23 57 
0.64 
[0.26, 1.02] 
Furuhashi et al (1982) 682.93 
43.6
5 
37 659.99 
162.
2 
35 
0.19 
[-0.27, 0.66] 
Shinkawa et al (1983) 7.67 4.23 45 6.80 2.01 44 
0.26 
[-0.16, 0.68] 
Bolton et al (1989) 0.34 0.10 12 0.28 0.37 12 
0.21 
[-0.59, 1.02] 
Herruzo et al (1993) 22.17 
11.4
5 
27 14.23 5.62 25 
0.86 
[0.29, 1.43] 
Simmons et al (1994) 2.10 0.3 62 1.80 0.60 63 
0.63 
[0.27, 0.99] 
Maffeis et al (1999) 10.40 5.54 48 8.50 4.24 50 
0.38 
[-0.02, 0.78] 
Troisi et al (2003) 1.01 0.83 49 0.76 0.59 37 
0.34 
[-0.09, 0.77] 
Van de Beek et al (2004) 4.01 2.50 19 3.72 3.30 18 
0.10 
[-0.55, 0.74] 
Gol et al (2004) 875.13 
121.
2 
29 809.2 
100.
2 
31 
0.59 
[0.07, 1.11] 
Anderson et al (2010) 0.49 0.35 7 0.66 1.01 14 
-0.19 
[-1.10, 0.72] 
Subtotal  
(95% CI) 
  602   627 
0.57 
[0.37, 0.77] 
 
 
 
 
Table III shows the results of meta-analyses. Although there was a lot of 
heterogeneity in the findings (evidenced by the large I² values) the various groups 
based on assay types and sources of serum all indicate significantly higher T in male 
umbilical cord than female.  
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Table 3.  Results of meta-analysis for all studies and the subgroups  
Group Number of 
studies 
Hedges’ g 
[95% CI] 
Z (p) Chi² (p) I² 
All 18 0.57 
[0.37, 0.77] 
5.66 
(P < 
0.00001) 
45.96 
(P = 0.0002) 
63% 
All venous 12 0.50 
[0.26, 0.73] 
4.17 
(P < 0.0001) 
28.48 
(P = 0.003) 
61% 
All mixed 
a
 8 0.81 
[0.48, 1.15] 
4.77 
(P < 
0.00001) 
17.38 
(P = 0.02) 
60% 
All extraction 11 0.66 
[0.36, 0.95] 
4.31 
(P < 0.0001) 
36.79 
(P < 0.0001) 
73% 
Venous extraction 7 0.51 
[0.09, 0.92] 
2.40 
(P = 0.02) 
24.06 
(P = 0.0005) 
75% 
All C-X-IA 9 0.59 
[0.24, 0.94] 
3.31 
(P = 0.0009) 
33.03 
(P < 0.0001) 
76% 
Venous  
C-X-IA 
5 0.32 
[-0.23, 0.86] 
1.15 
(P = 0.25) 
18.76 
(P = 0.0009) 
79% 
Mixed  
C-X-IA 
b
 
5 0.94 
[0.53, 1.34] 
4.51 
(P < 
0.00001) 
11.31 
(P = 0.02) 
65% 
Venous direct 
c
 5 0.48 
[0.27, 0.68] 
4.62 
(P < 
0.00001) 
3.98 
(P = 0.41) 
0% 
95% CI = 95% confidence intervals 
C-X-IA = IA after extraction and chromatography (TLC and/or column) 
a
  Includes the mean of umbilical arterial T and umbilical vein T combined, for two studies , (Dawood 
& Saxena, 1977;  Bolton et al., 1989). 
b Includes the mean of umbilical arterial T and umbilical vein T combined for one study (Bolton et al., 
1989) 
c Using the fixed variance method improved results slightly (Z = 4.79, P < 0.00001; g = 0.52 [0.31, 
0.73]; Chi² = 3.78, (P = 0.44); I² = 0%). 
 
 
 
Figure 1 shows the Forest plot of sex difference in umbilical vein T for all 
included studies. The findings of the studies tend towards the right hand side of the 
vertical zero point, indicating the tendency of the studies to find higher T in the 
umbilical cord of boys.   
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Figure 1. Forest plot of sex difference in umbilical vein T for all included studies.   
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Figure 2 compares the magnitude of sex differences in venous compared to mixed 
cord blood in studies using chromatography with extraction. The findings in the lower Forest 
plot (mixed cord blood) are further to the right of the zero point than those in the upper Forest 
plot (venous cord blood); this indicates that T values for boys in the lower plot showed a 
greater sex difference than T values for boys in the higher plot. 
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Figure 2. Comparison of the magnitude of the sex differences in venous compared to mixed cord blood in studies using chromatography 
with extraction. 
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Discussion 
Analysis of all eighteen studies combined, and all subgroups, revealed 
significantly higher umbilical cord T in boys than girls. There was significant 
heterogeneity between the 18 studies and in all subgroups except for the direct assay 
venous subgroup. The confidence intervals for the subgroups were generally narrow 
and showed effect sizes of clinical interest. With the exception of the venous 
chromatographic extraction subgroup the confidence intervals did not encompass a 
zero value, which suggests that overall the sex differences were representative of 
those likely to be seen in the general population of newborns. Four of the 18 studies 
were rated as poor, largely due to these papers lacking information regarding 
methodological quality rather than explicitly being of poor quality. The four ‘poor’ 
ratings were on the borderline for scores for moderate quality and excluding them 
from the overall analysis made almost no difference to the results, thus their 
inclusion is appropriate.  
The most widely available assay methods, in descending order of accuracy, 
use mass spectrometry, thin layer chromatography (TLC), extraction with ethyl 
ether, and direct measurement (Rosner et al., 2007). A therefore unexpected finding 
of this meta-analysis is that, judging by heterogeneity measures, the direct method 
may be a more reliable indicator than extraction methods of the sex difference in 
cord T. However it is likely that the direct method assay detected more substances 
than T alone, and the interference of other steroids and substances may have simply 
masked the heterogeneity evidenced in the extraction group. The cross-reacting 
substances are most likely to have been androgens such as 11-keto-testosterone, 11-
beta-OH-testosterone, and dihydrotestosterone (Roche Diagnostics, 2000); for this 
reason the direct assay might be viewed as an omnibus measure of androgens rather 
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than simply a measure of T. This interpretation remains to be confirmed by a 
superior assay method, though it is of interest that Legro et al (2010) recently found 
good correlations between T levels measured using a direct assay and using liquid 
chromatography mass spectrometry in women with PCOS. Only one study to date 
(Anderson et al., 2010) has measured T levels in umbilical cord samples using liquid 
chromatography mass spectrometry. Anderson et al found that 14 healthy girls had 
nonsignificantly higher mixed cord T than seven healthy boys (0.66+1.01 vs 
0.49+0.35 nmol/l). Sixty-six percent of these samples (10 of the 14 female and four 
of the seven male) had T levels lower than the detection limit of 0.24 nmol/l.  These 
samples were assigned a value of 0.24 nmol/l. The fact that the actual T level is 
unknown for 66% of these samples indicates that more sensitive mass spectrometry 
assays are needed.  
Two of the 18 studies (11% of the studies) found that girls had higher cord T 
than boys, and across studies the large amount of variation in the observed T levels 
gives cause for concern. Rosner et al. (2007) found that some of their direct assays of 
T in healthy women were roughly 10 times higher than others; the present authors 
found that two studies (Gol et al., 2004), (Furuhashi, 1982) reported T values over 
100 times higher than some other studies using comparable assays and sample sites. 
These studies were of moderate methodological quality, and the disparity is not 
explained by other features of the studies. Although the Hedges g values of the two 
studies are in keeping with the other sixteen studies, their relatively high observed T 
values are suggestive of the unreliability of these assay types. With the exception of 
one study (Furuhashi, 1982), the extraction methods showed generally lower mean T 
values with a smaller range than the direct assay studies. Because the studies 
included in this meta-analysis are similar in most relevant characteristics, it might be 
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concluded that although the direct assays give reliable findings in terms of the size of 
the sex difference, no method appears to yield reliable findings in terms of the 
absolute T levels, especially the direct immunoassay due to its poor specificity, cross 
reactivity with other steroids and matrix effects1 (Rosner et al., 2007).   
A finding of potential clinical importance is that, using comparable assays, a 
larger sex difference was seen in mixed cord samples (g = .94, a large effect size) 
than venous samples (g = .32, a small effect size).  This in turn would suggest that 
the higher level in males is due at least part to fetal production.   This has 
implications for understanding the etiology of conditions such as PCOS in which 
prenatal T exposure is theorised to be a causal factor.  Future studies might compare 
T levels in the umbilical arteries and veins in newborns of women with PCOS, and 
compare these to healthy pregnancies; relatively high T in the umbilical arteries 
compared to the vein in PCOS, and higher umbilical arterial T in PCOS compared to 
healthy pregnancies, would suggest fetal T production  in this condition. A recent 
study of PCOS and metformin - a medication that lowers T – had the potential to 
address this issue, but interpretation of the findings is difficult because the results 
were not presented for girls whose mothers had PCOS and were not taking 
metformin (Carlsen & Vanky, 2010)  
The conclusion of this meta-analysis is that although there appears to be a 
reliable sex difference in umbilical vein T of a moderate effect size, the direct and 
extraction assay methods lack ecological validity; differences in steroid milieu 
outside that usually used for in vitro diagnostic purposes produce wide differences in 
results where such assays are employed to measure specific steroids in real-world 
samples. Current direct assays are known to be poorly discriminative of testosterone 
                                                 
1 If there is interference that is not known to be caused by other factors (such as cross‐reactivity), 
this interference is termed a ‘matrix effect’ until such time as its cause is identified.  
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at low values (Rosner et al., 2007).  This being the case, our knowledge of gross T 
levels in cord blood remains limited, and norms for umbilical cord T at birth remain 
to be established through further research using more specific methods, such as 
tandem mass spectrometry. Nevertheless the findings of the present meta-analysis 
suggest that serum in the male umbilical cord at birth might contain a higher level of 
androgen than seen in the female cord at birth, and this might provide clinicians a 
rough index (i.e. relative to values seen in the opposite sex) as to whether a female 
newborn has experienced elevated androgen prenatally, or whether a male newborn 
has experienced reduced androgen prenatally.  Future research might also compare 
sex hormones in both umbilical veins and arteries (not mixed) from male and female 
progeny as way of identifying the source (maternal/placental, or fetal) of hormones.  
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Appendix 1. Literature search graph 
 
Database searched Articles identified 
Pubmed 115
Medline 73 
EMBASE 39 
Cochrane Reviews 6 
From bibliography 9 
 
 
Excluded = 63 
Non-human  
One sex only  
Study of T function (e.g. binding) 
Single case study 
T exogenous 
Pregnancy termination 
No T; study of placental function 
or of other hormones 
Review paper 
T not assayed 
Double isotope derivative assay 
Hysterotomy 
 
 
Total citations 
n = 242 
Duplicate = 109 
Abstracts & Titles  
reviewed = 133 
Excluded = 52 
Blood not presented by sex; 
unhealthy pregnancies; 
Emergency C-S or induced 
deliveries; Mean or SD not 
given; Assay methodology 
unclear; Same data used as 
another study; Same paper 
in different language; Free 
T or T derivative (e.g. 
sulphate), not Total T, 
presented; T not sampled at 
birth. 
Full text analysis = 
70 
Included studies = 18, 
using 1229 cord samples 
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Appendix 2. Forest plot of sex differences in umbilical cord venous T for direct assay methods only (n=5). 
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Appendix 3. Exclusion criteria and excluded studies (N=115) presented in order of 
frequency and chronologically.   
Studies of T (or aromatase 
etc) function (also usually 
not presented by sex) 
(N=24) 
Cairrão et al (2008)  
Jin et al (2007)  
Perusquía et al (2007)  
Jin et al (2005)  
Zapata et al (2005)  
Yildiz et al (2005)  
Ijiri et al (2003)  
Zhang et al (2002)  
Nie et al (2001)   
Du et al (2001)  
Cid et al (1994) 
Loganath et al (1992) 
Gunasegaram (1991) (EMBASE) 
Higano et al (1989) 
Milewich et al (1987) 
Lewis et al (1986) 
Sybulski et al (1975) 
Ahluwalia et al (1974) (cocaine users) 
Swartz et al (1974) 
Stárka et al (1974) 
Simmer et al (1972) 
Rosenfield (1971)      
Heyns & De Moor (1971) 
Kobayashi et al (1969) 
Animal studies (n=17) Huang et al (2010) 
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Hayashi et al (1997) 
Okamoto et al (1996) 
Heyns et al (1993) 
Mitchell et al (1986) 
Vreeburg et al (1986) 
Ford et al (1980)    
Ellinwood et al (1980) 
Resko (1977)    
Tseng et al (1975) 
Mongkonpunya et al (1975)  
Challis et al (1974) 
Resko (1974) 
Resko (1973)   
Milgrom et al (1973) 
Goy & Phoenix (1972) 
Dang and Meusy-Dessolle (1970) (EMBASE) 
One sex only, or T not 
presented separately for 
each sex (N=17) 
Hickey et al (2010) 
Whitehouse  et al (2010) 
Whitehouse et al (2010) 
Hickey et al (2009) 
Rohrmann et al (2009) 
Troisi et al (2008) 
Nagata et al (2007) (also arteries only) 
Nagata et al (2006) (also arteries only) 
Baik et al (2006)  
Baik et al (2005)   
Schubring et al (1998) 
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Sakai et al (1991) (same sex twins) 
Milewich et al (1990) 
Bradshaw et al (1986) 
Tapanainen et al (1984) (EMBASE)  
Tapanainen (1983) 
Mathur et al (1980)  
Total T not measured or not 
reported (N=12) 
Toth et al (2009) 
Clifton et al (2007) 
Tan & Tan (2001) (unclear if total or free T) 
Fausett et al (1999) 
Maffei et al (1998) 
Gemer et al (1997) (maternal T only) 
Adeyemo & Jeyakumar (1993)  (Free T only) 
Ikegawa (1986) (Free T only) 
Tojo (1981) 
Plotti et al (1975) 
Nunez et al (1974) 
Ermini et al (1974) (T sulphate)  
Same data from another 
study (N=12) 
Faupel-Badger  et al (2009) [Troisi et al’s 2006a  data] 
Savage (2009) (Cohrane cited twice) 
Troisi et al (2006) (b) [Troisi et al’s 2006a data] 
Troisi et al (2006) (c) [Troisi et al’s 2006a data] 
Zupan et al (2004) (Cohrane cited twice) 
Jacklin et al (1988) (same Maccoby et al (1979)) 
Marcus et al (1985) (same Maccoby et al (1979)) 
Jacklin et al (1984) (same Maccoby et al (1979)) 
Jacklin et al (1983) (same Maccoby et al (1979)) 
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Abramovich & Rowe (1973) (almost identical to Abramovich 
et al (1974). (hand search) 
Gandy (1971) (same Gandy (1968)) (hand search) 
Mizuno et al (1968) (Japanese version of (1969) paper) 
double isotope derivative 
assay (N=5) 
Saez & Bertrand (1969) (hand search) 
Mizuno et al (1969) 
Rivarola et al (1968) 
Gandy (1968) (hand search)  
Bertrand & Saez (1968) (hand search) 
Data from unhealthy women 
and/or children &/or 
pregnancy complications or 
healthy women and/or 
children not presented 
separately from other cases 
(N=6) 
Carlsen & Vanky (2010) 
Jin et al (2009)  
Pardo et al (2004) (EMBASE) 
Su et al (1996) 
Simmons (1995) 
Forest et al (1980) 
Single case study (N=4) Bertalan et al (2007) 
da Silva et al (2007) 
Holt et al (2005)  
Hensleigh et al (1975) 
Aborteses  (N=3) Stern et al (1975) 
Reyes et al (1974) (hand search) 
Reyes et al (1973) (hand search) 
Amniotic (N=3) Ahluwalia et al (1992) (also arteries) 
Nagamani et al (1979) (hand search) 
Caputo et al (1974) 
Mean &/or SD not given Adkins et al (2007)   
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(indicating a non-normal 
distribution of values) 
(N=5) 
Yuguang et al (2007) (geometric mean, no SD; hand search) 
Tan et al (1998) 
Bammann et al (1980) (hand search) 
August et al (1969) 
Sampled mid gestation 
(N=2) 
Abramovich  (1974)  
Ling et al (1974) 
Other (N=7) Savage (2009) (ENT, Cochrane review)  
Owens (2008) (vocal cords, Cochrane review) 
Zupan et al (2004) (cord hygiene, Cochrane review) 
Hofmeyr (1997) (cord complications, Cochrane review) 
Ghione et al (1993) (Review; not about cord T) 
Wei et al (1990) (assay methodology) 
Mitchell (1970) (Review) 
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Appendix 4. Table for conversion of testosterone to nmol/l from other units. 
Units  Conversion factor 
 pg/mL  multiply by 0.00347  
 ng/dL  multiply by 0.0347 
 ng/100ml  multiply by 0.0347  
 ng %  multiply by 0.0347  
ng/100ml multiply by 0.0347 
 mμg/100 ml  multiply by 0.0347 
 μg/dl  multiply by .347  
 ng/mL  multiply by 3.47  
 μg/L  multiply by 3.47 
 pmol/L  multiply by .001 
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Appendix 5a. Methodological qualities of prospective studies included (Adapted from the Scottish Intercollegiate Guidelines Network).   
1= yes; 0=no.  Maximum score = 20.     Scores of: 0-6 = poor methodology; 7-13 = fair; 14-20 =good. 
 
Quality variables  Simmer et al 
(1972) 
Forest et al 
(1973) 
Forest et al 
(1974) 
Abramovich 
et al (1974) 
Dawood & 
Saxena 
(1977) 
Maccoby 
et al 
(1979) 
Inclusion Criteria  0 0 0 0 1 1 
Exclusion Criteria  0 0 1 0 0 1 
Demographics comparable 0 0 0 0 0 0 
Can the number of participating centers be determined  0 0 1 0 0 1 
Has the source of cord T been identified (e.g. vein) 1 1 1 1 1 1 
Are the mother’s baseline characteristics comparable in the two 
groups 
0 0 1 0 0 0 
Are the children’s baseline characteristics comparable in the two 
groups 
1 1 1 0 0 1 
Can the number of hospital staff taking cord samples be determined  0 0 0 0 0 0 
Can the reader determine how expert the sampler was 0 0 0 0 0 0 
Can the reader determine how expert the lab technician (assayer) 
was  
1 0 0 1 0 0 
Is the cord sampling technique adequately described  1 0 1 1 1 1 
Is the assay technique adequately described 1 1 1 1 1 1 
Is there any way that they have tried to standardize the cord 
sampling technique  
1 0 1 0 1 1 
Is there any way that they have tried to standardize the assay 
technique 
1 1 1 1 1 1 
Is the delivery type identified 1 1 1 0 0 1 
Is the delivery type comparable in the two groups 1 1 1 0 0 1 
Do authors address whether there is any missing data  0 0 0 0 0 0 
Was the study period stated  0 0 0 0 0 1 
Is it clear whether all the patients asked to enter the study took part  0 0 0 0 0 1 
Analysis by intention to treat  0 0 0 0 0 0 
Score  9 6 11 5 6 13 
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Appendix 5b. Methodological qualities of prospective studies included (Adapted from the Scottish Intercollegiate Guidelines Network).   
1= yes; 0=no.  Maximum score = 20.     Scores of: 0-6 = poor methodology; 7-13 = fair; 14-20 =good. 
 
Quality variables  Penny et al 
(1979)
 
Miyamoto 
(1981)
 
Furuhashi 
et al (1982)
 
Shinkawa et 
al (1983)
 
Bolton et al 
(1989)
 
Herruzo 
et al 
(1993) 
Inclusion Criteria  0 0 0 0 0 1 
Exclusion Criteria  1 1 0 0 0 0 
Demographics comparable 0 1 0 0 0 0 
Can the number of participating centers be determined  0 0 0 0 0 1 
Has the source of cord T been identified (e.g. vein) 1 1 1 1 1 1 
Are the mother’s baseline characteristics comparable in the two 
groups 
1 0 0 0 0 0 
Are the children’s baseline characteristics comparable in the two 
groups 
0 1 1 1 1 1 
Can the number of hospital staff taking cord samples be determined  0 0 0 0 0 0 
Can the reader determine how expert the sampler was 0 0 0 0 0 0 
Can the reader determine how expert the lab technician (assayer) 
was  
0 1 0 1 0 1 
Is the cord sampling technique adequately described  1 0 1 0 1 1 
Is the assay technique adequately described 1 1 1 1 1 1 
Is there any way that they have tried to standardize the cord 
sampling technique  
0 0 1 0 1 0 
Is there any way that they have tried to standardize the assay 
technique 
1 1 1 1 1 1 
Is the delivery type identified 1 1 1 1 1 1 
Is the delivery type comparable in the two groups 1 1 1 0 0 1 
Do authors address whether there is any missing data  0 0 0 0 0 0 
Was the study period stated  0 0 0 0 0 1 
Is it clear whether all the patients asked to enter the study took part  0 0 0 0 0 0 
Analysis by intention to treat  0 0 0 0 0 0 
Score  8 9 8 6 7 11 
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Appendix 5c. Methodological qualities of prospective studies included (Adapted from the Scottish Intercollegiate Guidelines Network).   
1= yes; 0=no.  Maximum score = 20.     Scores of: 0-6 = poor methodology; 7-13 = fair; 14-20 =good. 
 
Quality variables  Simmons et al 
(1994)
 
Maffeis et al 
(1999)
 
Troisi et al 
(2003) 
Van de Beek 
et al (2004)
 
Gol et al 
(2004) 
Anderson 
et al 
(2010) 
Inclusion Criteria  1 0 1 1 1 1 
Exclusion Criteria  1 0 1 1 0 1 
Demographics comparable 1 0 0 0 1 1 
Can the number of participating centers be determined  0 0 1 1 0 0 
Has the source of cord T been identified (e.g. vein) 1 1 1 1 0 1 
Are the mother’s baseline characteristics comparable in the two 
groups 
1 1 1 1 1 1 
Are the children’s baseline characteristics comparable in the two 
groups 
0 1 0 1 1 0 
Can the number of hospital staff taking cord samples be determined  0 0 0 0 0 0 
Can the reader determine how expert the sampler was 0 0 0 0 0 0 
Can the reader determine how expert the lab technician (assayer) 
was  
0 1 0 0 1 0 
Is the cord sampling technique adequately described  1 1 1 0 0 1 
Is the assay technique adequately described 1 1 1 1 1 1 
Is there any way that they have tried to standardize the cord 
sampling technique  
1 1 1 0 0 1 
Is there any way that they have tried to standardize the assay 
technique 
1 1 1 1 1 1 
Is the delivery type identified 1 1 1 1 1 1 
Is the delivery type comparable in the two groups 1 1 1 1 1 1 
Do authors address whether there is any missing data  1 0 1 1 0 1 
Was the study period stated  0 0 1 1 0 0 
Is it clear whether all the patients asked to enter the study took part  0 0 1 0 0 0 
Analysis by intention to treat  0 0 0 0 0 0 
Score  12 10 14 12 9 12 
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Summary 
 
The aetiology of Polycystic Ovary Syndrome (PCOS) is poorly understood, but an 
intrauterine hyperandrogenic environment has been implicated. This study was designed to 
assess whether the female offspring of mothers with PCOS are exposed to raised levels of 
testosterone (T) in utero.  In this case-control study, three groups of pregnant women were 
recruited from Labour Ward: PCOS women with a female baby (n=10, PCOS girls); control 
women with a female baby (n=20, Control girls) and control women with a male baby 
(n=10, Control boys). Maternal and Umbilical Vein (UV) blood was assayed for T levels.  
UV T in PCOS girls was significantly raised, compared to control girls (p<0.012). The 
difference in UV T between PCOS girls and control boys was not significant (p<0.254).  
This is the first demonstration of a hyperandrogenic in utero environment in PCOS 
pregnancies; UV T in female infants is raised to male levels. 
 
 
Keywords: Polycystic ovary syndrome, Testosterone, Fetal programming, Umbilical vein 
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Introduction 
 
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy of women of 
reproductive age, with a prevalence of 5-10% (Franks, 1995). The features of the syndrome 
are those associated with anovulation (amenorrhoea, irregular cycles) and with 
hyperandrogenism (hirsuitism, acne). Frequently presenting in adolescence, PCOS is 
associated with the development in later life of insulin resistance (Dunaif et al., 1989), type 
2 diabetes (Dahlgren et al., 1992) and hypertension (Talbott et al., 1995).  
 
The aetiology of PCOS remains poorly understood. A genetic basis is supported by family 
studies showing first degree relatives of women with PCOS to have increased rates of 
hyperandrogenism (Goodarzi et al., 2007) and metabolic disease (Billargeon et al., 2007; 
Franks et al., 2008). However, no genes have been conclusively implicated in the 
inheritance of PCOS (Nam and Strauss, 2007). 
 
Familial clustering of the PCOS phenotype could also result from fetal programming in 
response to an abnormal intrauterine environment. Animal studies have shown that prenatal 
exposure to excess androgen results in the biochemical and morphological features of PCOS 
(Abbott et al., 2005).  A similar process in the human could result in vertical transmission of 
PCOS since hyperandrogenaemia persists during pregnancy in women with this syndrome 
(Sir-Petermann et al., 2002).   
 
Excess prenatal androgen exposure may also have important consequences for health in 
adult life.  There is evidence of a sex difference in prenatal androgen levels; T levels in 
umbilical cord blood are higher in healthy male infants than in healthy female infants 
(Maccoby et al., 1979).  Studies in experimental animals show that administration of 
androgens during pregnancy leads to insulin resistance and hypertension in the offspring 
(King et al., 2007).  There is evidence of a similar effect in the human; daughters of women 
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with PCOS have metabolic derangement (Sir-Petermann et al., 2009).  
 
Although there are a few studies of maternal androgen levels in pregnant women with 
PCOS, we are not aware of any study which has compared levels in the fetal circulation in 
such pregnancies with healthy controls. This study was designed to study the levels of total 
testosterone (T) in the umbilical vein (UV) of babies born to mothers with PCOS and in 
healthy controls (both male and female babies).  
 
Methods 
 
Design 
 
In this case-control study, pregnant women were recruited from the Labour Wards of 
University College Hospital and the Royal Free Hospital, in London. Women were recruited 
either in early labour, or prior to an elective caesarean section and gave written informed 
consent.1 
 
Three groups of women were recruited: women with PCOS, defined by Rotterdam criteria 
(ESHRE/ASRM 2003) who delivered a female baby (n=10, PCOS girls); control women 
without PCOS, who delivered a female baby (n=20, Control girls) and control women 
without PCOS, who delivered a male baby (n=10, Control boys). 
 
Exclusion criteria were: multiple pregnancy, age under 18 years, hypertensive disorders, 
gestation under 38 weeks at delivery, fetal abnormality and endocrine disorders other than 
PCOS. The study was approved by the Royal Free Hospital and Medical School Research 
Ethics Committee and the Joint UCL/UCLH Committees on the Ethics of Human Research. 
                                                 
1 All women who met the inclusion / exclusion criteria were approached. Their PCOS status – 
according to the Rotterdam criteria - was ascertained from their medical records subsequent to 
recruitment.  
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On admission to Labour Ward, anthropometric data, medical history, and obstetric history 
were obtained from the case-notes. A venous blood sample was obtained from the mother 
upon admission. Samples were centrifuged and serum stored at -80oC . 
 
Following delivery of the placenta, the umbilical cord was clamped and a 2 ml sample of 
umbilical cord venous blood was obtained. Samples were again centrifuged and stored at -
80oC, as above.  
 
Gestational age, infant weight, duration of labour and mode of delivery were recorded.  
 
 
Assays 
 
T concentrations were measured using the Roche Elecsys system 1010/2010 Modular E170, 
using a direct electrochemiluminescence methodology.2  
 
 
Statistics 
 
The results are expressed as the mean +/- SD.  p values of <0.05 were considered significant. 
Comparisons were made using Student’s t-tests for parametric distributions, and Mann-
Whitney tests for non-parametric distributions. Relationships between variables were 
assessed using Pearson’s correlations for parametric distributions, and Spearman’s 
                                                 
2 For this assay: the intra-assay coefficients of variation were all less than 4.6%; reference intervals 
for women between 18 and 40 are 0.22–2.9 nmol/L; the dynamic range is 0.069 to 52.00 nmol/L. For 
this assay the cross-reacting substances are most likely to have been androgens such as 11-keto-
testosterone, 11-beta-OH-testosterone, and dihydrotestosterone (Roche Diagnostics, 2000) thus this 
assay might be viewed as an omnibus measure of androgens rather than simply a measure of T. 
Because research such as that described in this thesis is interested in androgenic effects rather than T 
per se, whether what is measured is T or another androgen is not of primary importance.  
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correlations for nonparametric distributions. One-way between-groups ANOVA was used 
when comparing multiple groups. Statistical analyses were performed using SPSS version 
15 (SPSS Inc., Chicago IL).3 
 
 
Results 
 
Patient characteristics (Table I) 
None of the three groups differed significantly from any other in ethnicity, maternal age or 
BMI, or in gestational age at delivery or birthweight.  
 
                                                 
3 Maccoby et al. (1979) found a sex difference for cord T with a Cohen’s d effect size of 
1.14; an a priori sample size estimate based on this suggests 11 per group would be required 
to show a group difference with power at 0.80 and alpha at .05. In the present study, with 
groups sizes of n=10 and n=20, power is exactly at 0.80 with alpha at .05, and the effect size 
for the main outcome of interest (PCOS girls compared to control girls) was 1.03. 
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Table I – Patient characteristics 
 n mean SD ANOVA 
Age 
  
PCOS girls 10 30.5 4.28  
ns Control girls 20 30.5 6.30 
Control boys 10 33.0 5.87 
BMI 
(kg/m
2
) 
  
PCOS girls 10 23.8 4.67  
ns Control girls 20 24.0 3.00 
Control boys 10 24.0 5.31 
Gestational age at 
delivery (days) 
PCOS girls 10 277.0 8.10  
ns Control girls 20 274.2 5.27 
Control boys 10 276.5 8.25 
Birthweight (g) PCOS girls 10 3318 492  
ns Control girls 20 3172 543 
Control boys 10 3406 678 
ns – not significant 
 
There were 5 vaginal deliveries and 5 Caesarean sections (of which 4 were elective) in the 
PCOS girls group, 6 vaginal deliveries and 4 Caesarean sections (of which 3 were elective) 
in the control boys group and 9 vaginal deliveries and 11 Caesarean sections (of which 3 
were elective) in the control girls group. Neither mode of delivery, nor whether the patient 
laboured, related significantly to levels of either maternal or UV T (t=-0.666, df=37, 
p<0.510, 2-tailed, and t= 0.977, df=39, p<0.334, 2-tailed). 
 
 
Testosterone (Table II) 
Although T was somewhat elevated in women with PCOS, there was no significant 
difference in maternal T between the three groups (p<0.737). 
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ANOVA showed a significant difference between the groups for UV T (p<0.037). UV T was 
significantly higher in the PCOS girls than the control girls (p<0.012, post-hoc analysis). 
The difference between PCOS girls and control boys was not significant (p<0.254, post-hoc 
analysis). The mean UV T in control boys was higher than in control girls but this did not 
reach statistical significance (p<0.091) 
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Table II – Maternal and UV testosterone in PCOS girls, control boys and control girls.  
 n mean SD ANOVA 
Maternal T 
(nmol/L) 
  
PCOS girls 9 4.76 2.75  
ns Control girls 19 4.02 2.15 
Control boys 10 4.00 2.96 
UV T (nmol/L) 
  
PCOS girls 10 7.20 2.03  
p<0.037 Control girls 20 5.34 1.54 
Control boys 10 6.26 2.09 
ns – not significant 
 
UV testosterone and maternal testosterone were significantly positively correlated in PCOS 
girls (r=0.653, n=9, p<0.028).  
 
 
Discussion 
 
This study provides the first evidence of a hyperandrogenic fetal environment in pregnancies 
where the mother has PCOS. UV testosterone was not only significantly higher in female 
infants of PCOS mothers than of healthy mothers, but was observed to be as high as male 
levels. In our study, unlike that of Maccoby et al. (1979), the difference between control 
boys and control girls did not show statistical significance, possibly due to the sample size. 
 
Post-hoc power calculations comparing UV T in PCOS girls and control populations, 
showed adequate power (0.84).  
 
The finding of raised UV T in these female babies is compatible with the hypothesis of fetal 
programming in PCOS as a result of prenatal androgen excess. The sequelae of prenatal 
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androgen excess are not limited to development of the PCOS phenotype, hypertension and 
diabetes; there also is evidence of altered behavioural development. Exposure to raised 
concentrations of T prenatally has been linked to changes in childhood toy, playmate and 
activity preferences, to social behaviours related to autistic spectrum conditions and to 
sexual orientation and gender identity (Hines, 2004; Knickmeyer and Baron-Cohen, 2006).  
 
Having shown that female fetuses of mothers with PCOS have elevated T concentrations, we 
are planning a follow up study which will address a number of limitations. 
 
The current study used the electrochemilumesence T assay. Although the gold standard 
method is now isotope dilution mass spectrometry, the electrochemilumesence T assay is 
used routinely in clinical practice, as recognised by the 2007 Endocrine Society position 
statement (Rosner et al., 2007).  Nevertheless we are planning to use a mass spectrometry 
assay in our follow up study to eliminate errors from potential cross-reactivity of androgens. 
 
We will modifiy sample sizes as appropriate to the mass spectrometry technique to give 
adequate power. An a priori sample size, based on previous work using this method 
(Maccoby et al., 1979) suggests 13 per group would be required to show a group difference 
(power 0.80). In addition, we will obtain paired arterial and venous umbilical cord blood 
samples in order to compare T levels before and after placental passage in order to 
investigate the source of the hyperandrogenaemia identified in the current study. 
 
For future study, given the well-established influences of prenatal T on human behavioural 
development, our results suggest that studies of behaviour in daughters of women with 
PCOS might prove productive. Finally, in the light of the evidence (Rowan et al., 2008) 
showing the efficacy and apparent safety of metformin treatment in pregnancy it would be of 
interest to explore the effects of this treatment on T levels during pregnancy in women with 
PCOS and their fetuses. To date, the only study (Vanky et al., 2004) of metformin treatment 
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throughout pregnancy did not assess fetal androgen exposure. Interestingly, in women 
receiving metformin, maternal levels of T at 36 weeks gestation were slightly below those in 
the first trimester, as compared to the increase of 0.9nmol/L in the untreated PCOS women. 
 
 
In summary we have shown that female offspring of mothers with PCOS are subject to 
elevated androgen levels compared to babies whose mothers do not have this syndrome.  
There is evidence from human and animal studies that this exposure may have important 
consequences for future health and behaviour.  These findings prompt additional research to 
investigate the mechanism responsible for the hyperandrogenaemia and its consequences for 
health and behaviour, as well as development of an intervention to normalise the prenatal 
environment in PCOS pregnancy. 
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Abstract  
 
Women with Polycystic Ovarian Syndrome (PCOS) have been found to suffer from 
fertility problems and mood dysfunction. To control for any effect of fertility problems, 
the present study compared mood dysfunction in women with PCOS to non-PCOS 
women with fertility problems.  Seventy six women with PCOS and 49 subfertile 
controls reported their anxiety, depression, and aggression levels, and the relationship 
between mood and testosterone (T) was assessed. Controlling for age and BMI using 
MANCOVA, women with PCOS were significantly more neurotic (had difficulty 
coping with stress) than controls, had more anger symptoms, were significantly more 
likely to withhold feelings of anger, and had more quality of life problems related to the 
symptoms of their condition (acne, hirsutism, menstrual problems, and emotions).  In a 
subgroup of 30 women matched on age, BMI and ethnicity, it was found that women 
with PCOS were significantly more anxious and depressed than controls. T was not 
generally correlated with mood states. Conclusion: This is the first study to identify 
problems with neuroticism and withholding anger in women with PCOS. These mood 
problems appear to be mainly attributable to PCOS symptoms, though other factors, 
such as hypoglycaemia, cannot be ruled out.  
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Introduction 
Polycystic ovary syndrome (PCOS) affects 5-10% of women [1] and is characterised by 
elevated testosterone (T), menstrual irregularity, fertility problems, androgen excess, 
acne and hirsutism.  Many studies have found that women with PCOS have greater 
mood dysfunction and psychiatric problems than women who do not have PCOS [2,3]. 
Levels of anxiety and depression are higher in PCOS than healthy women [4,5,6]. Some 
research suggests that aggression [7] and Type A personality [8] is more evident in 
women with PCOS than the norm, but this evidence is not particularly strong.  
Although it has not been measured in a PCOS population before, neuroticism  - a 
character trait that combines features of anxiety, depression, and anger - has been found 
in women with two conditions related to PCOS: hirsutism [9] and fertility problems 
[10]. Eysenck suggests that neuroticism is caused by lability of the autonomic nervous 
system (ANS) which predisposes a person to cope poorly with stressful events [11]. It is 
therefore of interest that women with PCOS show a stronger hypothalamic-pituitary 
adrenal axis (HPA) response to a stressor than healthy women [12,13].  
The results of some studies have shown that concerns about fertility problems 
[14] and miscarriage [15] can be a source of distress in those with PCOS. Other studies 
have not found this link [16,17,18]. To date only one study [19] has compared distress in 
women with PCOS to an infertility control group; it was found that women with PCOS 
were significantly more depressed than the infertility control group, who in turn were 
more depressed than a community control group of women without PCOS or fertility 
problems.  
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Because elevated T appears to be related to the physical symptoms of PCOS, and 
PCOS patients report greater mood disturbance, T could be implicated in causing mood 
disturbance. Nonlinear relationships between testosterone and depression have been 
found in adolescent girls [23] and women with PCOS [24]. However in women with 
PCOS, four studies failed to find a correlation between T levels and depression 
[5,16,20,21]. This is perhaps because correlation is typically assessed with tests based 
on the principles of the general linear model [22] which can only detect linear 
relationships, and studies that are only looking for linear relationships may overlook 
significant nonlinear relationships.  
In summary, the results of previous studies suggest that women with PCOS have 
elevated T, suffer from fertility problems and experience mood dysfunction. It is 
however difficult to confirm a relationship between T and mood dysfunction because of 
the confounding effect of subfertility. The present study was designed to explore the 
association between T and mood dysfunction whilst controlling for the effect of fertility 
problems. This was done by comparing mood dysfunction in women with PCOS to non-
PCOS women with fertility problems, recruited from the same clinics. To control for 
affects of age and BMI, multivariate analysis of covariance (MANCOVA) was used. To 
additionally control for any affects of ethnicity, as subset of the sample were matched. 
We also examined the relationship between T levels and mood dysfunction in these two 
populations using both linear and nonlinear statistical tests. Based on the findings of 
previous research, it was predicted that compared to the control group, women with 
PCOS will score higher on measures of distress (anxiety, depression, neuroticism) and 
aggression, and that T will be correlated with distress and aggression.  
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Methods 
This study was conducted with the approval of the institutional Research Ethics 
Committees of participating clinics. Written, informed consent was given by all 
participants. Participants were identified only by a code to protect confidentiality, 
 
Participants 
All women were examined by an endocrinologist or gynaecologist. 
 
PCOS group 
Eighty-one women with PCOS were recruited from London gynaecology clinics (the 
Royal Free Hospital, University College London Hospital, St Mary’s Hospital, Guy’s 
Hospital, and the Centre for Reproductive and Genetic Health at the Eastman Dental 
Hospital).1 Inclusion criteria: 1/ diagnosis of PCOS by the Rotterdam criteria [25] 
(broadly speaking, women exhibiting any two of the following three symptoms: (a) 
severe menstrual disruption,2 (b) elevated androgens (e.g. T levels above 2.9 nmol/l) or 
clinical signs of such (e.g. acne, hirsutism) (c) multiple ovarian cysts); 2/ aged 18 – 45 
years. Exclusion criteria: 1/ any condition other than PCOS affecting hormones (with 
the exception of hypothyroidism being controlled effectively by medication), for 
example, menopause, congenital adrenal hyperplasia, androgen-secreting tumours, 
Cushing’s syndrome; 2/ being treated with any drugs that affect hormones (other than 
                                                            
1 The sample size was based on the requirement to power between-groups statistical analyses sufficiently 
to detect at least a medium effect size difference (a Cohen’s d of 0.5) with 80% power and alpha set to 
.05. With equal numbers in each group, the sample size required would have been 102. However having 
smaller numbers in the control group meant having larger numbers in the PCOS, and the eventual N for 
the present study (71 versus 43) gives 82.3% power to detect a Cohen’s d of 0.5 with alpha at .05. 
2 This was identified by attending physicians as per the Rotterdam criteria i.e. oligo- and/or anovulation. 
166 
 
thyroid hormone, or drugs used to treat PCOS for example, Metformin or Dianette); 3/ 
history of psychotic illness; 4/ because questionnaires were used, participants who were 
not fluent in English were also excluded.   
 
Control group 
Fifty-four women with fertility issues not related to PCOS were recruited from the same 
London gynaecology clinics as the PCOS participants. Women who would qualify for a 
diagnosis of PCOS according to the Rotterdam criteria were excluded from the control 
group. All other inclusion and exclusion criteria for the PCOS group were also applied 
to the selection of the control group. 
 
Questionnaires   
Hospital Anxiety and Depression Scale (HADS) [26] (14 items). This scale measures 
state anxiety & depression in medical outpatients. Item responses are on a 4-point scale. 
An example of an item from the Anxiety scale is “I feel tense or ‘wound up’: Most of 
the time; A lot of the time; From time to time/ occasionally; Not at all”. Scores of 8-10 
indicate a mild problem; 11-14 moderate; 15-21 indicates a clinical problem.   
 Eysenck Personality Questionnaire (EPQ-R Short) [27] (Eysenck et al, 1985) 
(48 items). This instrument measures three personality traits: Extroversion, Neuroticism, 
Psychoticism and has a social desirability scale. Neuroticism is a measure of 
emotionality, and is measured with questions such as “Are your feelings easily hurt?”   
Aggression Questionnaire [28] (19 items). Measures four aspects of trait 
aggression: Physical Aggression, Verbal Aggression, Anger, and Hostility. Items are 
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measured on a 5-point scale from ‘extremely uncharacteristic of me’ to ‘extremely 
characteristic of me’. An example of a Verbal Aggression item is “When people annoy 
me, I may tell them what I think of them”. 
The State−Trait Anger Expression Inventory (STAXI) [29] (44 items). This 
measures various aspects of current (state) and long term (trait) personal expression of 
anger. The five subscales are State Anger, Trait Anger, Anger In (anger suppression), 
Anger Out (anger expression), and Anger Control. The three latter subscales are 
combined to denote extreme problems in dealing with anger, which is calculated as 
Anger In plus Anger Out, minus Anger Control (plus a constant). 
Framingham Anger Measure [30] (12 items). Four aspects of anger are 
measured: Anger Symptoms (for example, “get tense or worried”), Anger In (for 
example, “keep it to myself”), Anger Out (for example, “take it out on others”) and 
Anger Discuss (for example, “talk to a friend or relative”). Answers are on a 3-point 
scale from ‘very likely’ to ‘not too likely’. 
The Framingham Type A Behaviour Pattern Measure [30] (10 items). This scale 
measures traits such as hostility and competitiveness. Five traits are measured on a 4-
point scale from ‘very well’ to ‘not at all’, and five are measured as either ‘yes’ or ‘no’.  
 
Control measures 
PCOS Quality of Life (QoL) Questionnaire (PCOSQ) [31] (26 items).  The impact of 
emotions, hirsutism, weight, infertility, menstrual problems, and acne on the patient’s 
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QoL are assessed. Answers are on a Likert scale of 1 (‘severe problem’) to 7 (‘no 
problem’), thus the lower the rating, the worse the QoL.  
Socio-economic classification (SEC) was defined by the Office for National 
Statistics’ [32] three-class hierarchy of Managerial & Professional, Intermediate 
Occupations and Routine & Manual jobs.  
Information on the specific diagnosis (PCOS or control) and medication were 
confirmed from hospital records. Smoking / drinking level per week, prescription or 
over−the−counter medicines taken, height and weight were given by the participant in 
the questionnaire. 
 
Hormone assays 
Most of the serum T concentrations (83% of matched pairs and > 90% of the total 
sample) were measured using the Roche Elecsys system 1010/2010 Modular E170, a 
direct electrochemiluminescence (ECLIA) methodology (Roche Diagnostics, 
Indianapolis). The intra-assay coefficients of variation were all less than 4.6%. 
Reference intervals for women between 18 and 40 for this assay are 0.22–2.9 nmol/L. 
The dynamic range for this assay is 0.069 to 52.00 nmol/L. This assay was used in four 
different laboratories in the present study, and the United Kingdom National External 
Quality Assessment Service (UK NEQAS) suggests that the method yields comparable 
results from different laboratories, with coefficients of variation of around 10% [33]. 
Around 10% of T samples were assayed using a competitive CLIA on the Immulite 
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2500 analyser (Diagnostic Products Corporation, Los Angeles, CA). The T levels found 
in samples using the two assay methods did not differ significantly from each other.  
 
 
Procedure 
Patients who met the inclusion criteria were identified by the consultant or other 
attending doctors at the participating clinics.  
Blood Collection  
Blood was taken with a 21-gauge needle by the clinic’s phlebotomist. Serum samples 
were transferred to 10ml gel activator clotting tubes. Samples were centrifuged and then 
frozen until being assayed. 
 
Statistical analyses 
The statistical package SPSS for Windows (Version 16) was used for all statistical 
analyses. In the full dataset, where distributions were non-normal a square root or log10 
transformation was applied. Subsequently all of the distributions in the full dataset 
passed Levene’s tests of homogeneity of variance, apart from QoL acne, hirsutism, 
infertility, and emotion which resisted transformation because only one group’s 
distribution was skewed in each case. Most of the matched distributions passed the 
Kolmogorov-Smirnov test of normality. For normal distributions, matched t-tests were 
used to compare variables, and Pearson’s correlations were used to assess relationships. 
Where a variable was found to be non-normal in either group (PCOS or control), 
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Wilcoxon tests were used to compare the groups, and Spearman’s correlations were 
used for tests of association. The SPSS Curve Estimation function was used to test for 
nonlinear (quadratic and cubic) relationships between T and psychometric variables. 
Demographic variables were assessed by independent t-tests and Fisher’s exact 
tests. In all cases significance thresholds were 2-tailed and p<.05 was required for 
statistical significance. 
  
Results  
QoL for problems related to infertility were similar in each group (Table 1). The two 
largest women in each sample (with BMIs of 42.3 and 50.2) were matched on being 
‘morbidly obese’ (BMI > 40) rather than being of similar BMI.  One woman with 
diabetes in each group were matched to each other. 
The matched data set consisted of Caucasian women only because no non-
Caucasian women in the control group could be matched on age & BMI to non-
Caucasians in the PCOS group. 
Ten of the 81 (12%) of women with PCOS and 11 of the 54 (20%) control group 
were excluded because they did not fill in sections of the questionnaire, or gave 
insufficient data on some subscales for replacement to be possible. The number of 
women who omitted sections did not significantly differ by group (Chi Sq = 1.588, 
df=1, p<.208). Forty five (33%) of the participants did not have T measured.3 For other 
variables in the full dataset an average of 2.54% of data was missing. Little's Missing 
Completely at Random (MCAR) test indicated that the missing data did not show a 
                                                            
3 20% (16) of the 81 women with PCOS and 29% (16) of 54 controls did not have a T measurement. 
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significant pattern (Chi-Square = 376.577, df = 367, p< .354). In the matched groups, an 
average of 3.9% of the data were missing and Little's MCAR test indicated that the 
missing data did not show a significant pattern (Chi-Square = 7.738, df = 230, p< 
1.000). Missing data were replaced with the mean for each participant on the measure 
(subscale or single-domain scale) for which an item was missing, unless the participant 
had omitted 33% or more of data from the measure, in which case their data for the 
measure was deleted from analyses.   
Table I shows descriptive statistics and statistical comparisons for the 
background variables of the PCOS and subfertile control group for the full sample, and 
Table III shows findings for the matched sample. The groups scored similarly for the 
QoL impact of fertility problems, both indicating “some problems” to “moderate 
problems” with fertility. Tables II and IV show the outcomes of comparisons for the 
total sample and matched sample.  
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Table I 
Descriptive statistics (means or medians, and SDs or range) and between groups tests (t-tests, 
Mann-Whitney, or Chi Square) values for the PCOS and subfertile control group. 
Variable PCOS (N=76)d 
 
Controls (N=49)d Test statistic 
Total testosterone (T) nmol/l 2.10 (0.20 – 5.80) 1.10 (0.40 – 4.20) 472*** e 
Age  28.8 (4.81) 35.12 (4.37) -7.38*** f 
BMI 27.87 (7.36) 24.69 (7.08) 3.33*** f 
QoL Weight 3.41 (2.16) 5.02 (1.88) -4.31*** f 
QoL Menstrual 3.5 (1 – 7) 5.3 (2 – 7) 969.5*** e 
QoL Emotions 4.1 (1 – 7) 5 (2 – 7) 1408* e 
QoL Infertility  3.65 (2.06) 3.98 (1.71) -.932 
QoL Acne 4 (1 – 7) 7 (1 – 7) 1076.5*** e
QoL Hirsutism 3.4 (1 – 7) 7 (2 – 7) 557.5*** e 
 
SEC 
Professional 25 (42%) 18 (40%)  
2.87c 
Intermediate occupation 10 (17%) 14 (30%) 
Routine/Manual 24 (41%) 14  (30%) 
 
Ethnic 
Groupa 
White 41 (64%) 33 (72%)  
4.52b 
Black 7 (11%) 1 (2%) 
Indian 5 (8%) 2 (4%) 
Mixed Race 7 (11%) 5 (11%) 
Other 4 (6%) 5 (11%) 
Note. * p < .05. ** p < .01. Significance values are 2-tailed.  
T = Total Testosterone; BMI = Body Mass Index; QoL = Quality of Life; SEC = Socioeconomic 
Classification 
a  Ethnicity was not identified for 12 of the PCOS and 3 of the control participants. 
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b Fisher’s Exact test statistic. 
c Chi Square 
d For total testosterone the sample size was 65 PCOS and 38 controls. 
e Mann-Whitney U test 
f Independent groups t-test 
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Table II  
Comparisons between the PCOS and subfertile control group on the mood measures (anxiety, 
depression, anger) controlling for age and BMI using MANCOVA.   
Variable PCOS (N=76)a Controls (N=49)a F 
Anxiety 9.99 (4.56) 7.57 (4.12) 2.25 
Depressionb  4.88 (1.98) 2.76 (2.04) 1.54 
Neuroticism 7.89 (3.37) 5.61 (3.41) 3.95* 
AQ Physicalb 16.55 (6.98) 14.78 (6.37) 0.01 
AQ Verbal 12.89 (4.57) 11.87 (4.85) 1.64 
AQ Anger 17.05 (5.92) 15.59 (6.89) 
0.01 
AQ Hostilec 18.92 (7.77) 14.98 (6.07) 1.72 
AQ Totalc 16.48 (3.60) 14.36 (4.29) 0.87 
STAXI State Anger 12.50 (5.46) 11.80 (4.55) 0.55 
STAXI Trait Angerb 18.98 (6.01) 18.63 (6.76) 
0.56 
STAXI Trait Temperb 6.40 (1.55) 6.40 (1.51) 1.60 
STAXI Reactivity 9.51 (2.96) 8.65 (2.81) 0.01 
STAXI Anger In 17.55 (4.87) 15.93 (4.98) 2.00 
STAXI Anger Out 15.04 (4.10) 14.98 (4.40) 2.10 
STAXI Anger Control 22.10 (5.67) 22.44 (5.34) 
1.87 
STAXI Extreme 26.49 (10.45) 24.48 (10.30) 0.43 
Fram. Anger Symptoms 2.82 (1.36) 2.02 (1.36) 
2.69* 
Fram. Anger In 1.41 (0.96) 0.84 (0.92) 4.71* 
Fram. Anger Outc 0.65 (0.57) 0.40 (0.48) 
0.29 
Fram. Anger Discuss 1.19 (0.60) 1.28 (0.56) 1.29 
Fram. Type A 0.54 (0.23) 0.51 (0.23) 0.24 
Note. * p < .05. Significance values are 2-tailed. 
AQ = Aggression Questionnaire; STAXI = State-Trait Anger Expression Inventory; Fram. = 
Framingham Anger Measure.  
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a For Framingham measures, n=71 PCOS and 43 controls.  
b log transformed (log 10).  
c square root transformed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
176 
 
Table III 
Descriptive statistics (means and SDs, or medians and ranges) and inferential statistics for the 
PCOS and subfertile control group. 
Variable 
PCOS 
(N=15) a, b 
Subfertile controls 
(N=15) b 
 
Test statistic
T  1.96 (0.76) 1.68 (1.03) 0.84 c 
Age  32.27 (3.22) 34.33 (2.92) - 1.84 c 
BMI 23.10 (19.80 - 42.47) 23.53 (18.67 - 50.15) 107.00 d 
QoL Weight 4.4 (1 – 7) 5.6 (1.2 – 7)  - 0.88 d 
QoL Menstrual 4.18 (1.38) 4.87 (1.30) 1.58 c 
QoL Emotions 4.67 (1.72) 5.54 (0.98) 1.81 c 
QoL Infertility  3.85 (2.08) 3.47 (1.55) 0.511 c 
QoL Acne 6 (1 – 7) 7 (5 - 7) -2.75** d 
QoL Hirsutism 5 (1 – 7) 7 (1 – 7) -1.30 d 
 
SEC 
Professional 9 4  
Intermediate occupation 3 4 3.93 e 
Routine/Manual 2 6  
Note. * p < .01. Significance values are 2-tailed. 
T = Total Testosterone; BMI = Body Mass Index; QoL = Quality of Life; SEC = Socioeconomic 
Classification 
a N=14 in the PCOS group for socially desirable responding 
b N=14 in both groups for SEC 
c matched t-test 
d Wilcoxon  
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e Fisher's Exact Test 
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Table IV  
Comparisons between the matched PCOS and subfertile control group on the mood measures 
(anxiety, depression, anger) using paired t-tests or Wilcoxon tests.  Participants are matched on 
age, BMI, and ethnicity.  
Variable PCOS (N=15) a, b Controls (N=15) a, b Test statistic
Anxiety 9.61 (4.33) 5.67 (3.22) 2.91* c 
Depression  4.00 (1-12) 2.00 (0-7) -2.29* 
Neuroticisma 3.06 (0.82) 2.44 (0.65) 2.91* c 
AQ Physicala 12.5 (9 - 43) 13.00 (9 – 25.4) 0.00 d 
AQ Verbala 12.29 (3.20) 12.14 (3.98) 0.09 c 
AQ Angera 17.14 (6.21) 14.21 (5.10) 1.33 c 
AQ Hostileb 19.0 (8.14) 14.77 (7.46) 1.37 c 
AQ Totalb 15.98 (5.93) 13.35 (4.36) 1.24 c 
STAXI State Anger 10 (10 - 40) 10 (10 - 12) -0.74 d 
STAXI Trait Angerb 17 (13 - 40) 15 (10 - 23) -1.30 d 
STAXI Trait Temperb   6.00 (4 - 16) 6.00 (4 - 9) -1.07 d 
STAXI Reactivitya 8.93 (2.92) 7.64 (2.53) 1.26 c 
STAXI Anger Inb  16.00 (8 - 28) 16.00 (8 - 16) -2.35* d 
STAXI Anger Outa 15.25 (3.89) 15.36 (3.75) -0.06 d 
STAXI Anger Controla 21.79 (5.96) 22.14 (5.96) -0.17 c 
STAXI Extremeb 25.12 (12.63) 19.92 (7.57) 1.11 c 
Fram. Anger Symptomsb 2.64 (1.51) 1.65 (1.09) 2.01 c 
Fram. Anger Inb  1.25 (0 - 3) 0.00 (0 - 2) -2.26* d 
Fram. Anger Outb 1.00 (0 - 1)   0.5 (0 – 1.5) -1.22 d 
Fram. Anger Discussb 1.15 (0.72) 1.39 (0.51) -0.92 c 
Fram. Type Ab 0.37 (0.13 - 0.87) 0.37 (0.13 - 0.87) -0.04 d 
Note. * p < .05. Significance values are 2-tailed. 
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AQ = Aggression Questionnaire; STAXI = State-Trait Anger Expression Inventory; Fram. = 
Framingham. 
a n=14 per group 
b n=13 per group 
c matched t-test 
d Wilcoxon and median (range)  
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QoL for acne, hirsutism, weight, menstrual problems and emotions related to the 
patients’ medical condition were significantly different, so were used as covariates in 
MANCOVA in addition to age & BMI. After controlling for these seven variables using 
MANCOVA, all group differences were reduced to non-significance. 
 
Medication 
Of the 46 women with PCOS whose medication status was identified, 35 (76%) were 
taking PCOS medication (insulin sensitizer or an anti-androgen) as were four of the 36 
controls (11%). In the matched groups, of the 13 women with PCOS whose medication 
use was identified, six were taking medication that can potentially lower T levels (five 
taking metformin and one taking an anti-androgen). In the matched groups, one of the 
control group women was taking insulin and metformin to control diabetes. In 
comparing the women with PCOS on medication and those not on medication, no 
significant effect of medication on T was seen.  
 
Correlations  
In the main dataset there were two significant correlations between T and psychometric 
variables in the PCOS group (QoL hirsutism rs=-.32, n=65, p<.009; QoL menstrual 
problems rs=-.26, n=59, p<.047). There were no significant correlations with T in the 
control group. ANOVA for nonlinear model fit was nonsignificant in most cases, but 
some significant trends were found. In the PCOS group the following trends reached 
significance: QoL hirsutism (linear p<.006; quadratic p<.005; cubic p<.014), QoL 
infertility (cubic p<.031); QoL menstrual (linear p<.03; quadratic p<.041), QoL acne 
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(linear p<.047; cubic p<.042), Framingham Anger Symptoms (quadratic p<.032; cubic 
p<.045), Framingham anger-in (quadratic p<.018; cubic p<.037). In the control group 
the following were significant: AQ hostility (linear p<.047; quadratic p<.018; cubic 
p<.028), STAXI temper trait (cubic p<.047); Framingham anger-out (cubic p<.011).  
 The hypothesis regarding greater distress in the PCOS group had some support, 
so this hypothesis is accepted. More aggression was not seen in the PCOS group, so this 
hypothesis is rejected. There was little evidence of a relationship between T and anxiety, 
depression, or aggression, so this hypothesis is also rejected. 
 
Discussion  
We found that PCOS patients had higher neuroticism and anger-in scores than subfertile 
controls. Both groups had a similar QoL impact of fertility problems, thus the group 
differences are unlikely to be caused by the impact of fertility problems. 
In both the full sample and matched subsample, the PCOS group scored higher 
than the subfertile controls on neuroticism and withholding anger. Neither of these 
variables have been reported as significantly different in previous PCOS research, 
though the neuroticism finding echoes findings of greater anxiety [4], depression [34], 
and anger [7] in previous research. Weiner et al’s [24] finding of a nonlinear 
relationship between T and mood was only weakly supported. 
 When group differences in PCOS symptoms were controlled using MANCOVA, 
the group differences on mood problems became non-significant, suggesting that most 
of the mood problems seen in PCOS are caused by the distressing symptoms of the 
syndrome. However in the matched groups comparison, none of the PCOS symptoms 
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apart from acne were significantly different between the groups, yet neuroticism and 
anger-in remained higher in the PCOS group. In other words, these differences in 
neuroticism and anger-in cannot be explained by fertility problems, age, BMI, most 
PCOS symptoms, or ethnicity, so another factor (or factors) must be responsible. One 
possible explanation is the psychological effects of hypoglycaemia (low blood sugar), a 
condition with a high rate of prevalence in women with PCOS [35]. Experimentally 
induced hypoglycaemia in healthy people can increase anger, anxiety, and low mood 
[36,37], in other words create a pattern of mood disturbance similar to that measured by 
the neuroticism scale. Hypoglycaemia causes autonomic arousal [36,37] and HPA 
activation [38], and because there is evidence of greater HPA activation in women with 
PCOS than controls [12] [13] it is possible that the mood disturbance seen in the present 
study and the HPA abnormalities seen in other PCOS studies are caused by 
hypoglycaemia. Blood sugar levels were not measured in the present study, but future 
studies might investigate the possible role of hypoglycaemia in altering mood in women 
with PCOS. 
The PCOS group scored higher than controls on both measures of anger-in 
(STAXI and Framingham) suggesting that they suppress anger more than the control 
group. Campagne [39] suggests that dealing with stress caused by fertility issues is a 
highly complex task, thus basing treatment solely on expressing emotions might not 
help women with PCOS. Furthermore it is possible that the cause of the anger is simply 
cognitive labelling of HPA activation, as classically described by Schachter & Singer 
[40], and further research is needed to explore the causes of unexpressed anger in 
women with PCOS, and to develop appropriate ways of helping. 
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Although the PCOS group on average scored significantly higher on depression 
in the matched groups comparison, the levels were in the normal range for both groups. 
Previous studies (for example, [7]) found more psychopathology in their PCOS samples 
than the present study.  In the present study women with a history of psychosis were 
excluded, and their exclusion could have lowered a difference in psychopathology 
between the PCOS and subfertile control group. However this will have primarily 
excluded symptoms of psychosis from the present study, and as these were not the focus 
of the present study their exclusion is not of direct relevance. 
There were few linear correlations between T and mood variables for the PCOS 
group and none for the controls. Unlike Weiner et al [24], nonlinear relationships did not 
appear to be noticeably more prominent than linear. The general lack of association 
between T and psychometric measures suggests that T had little activational effect on 
mood in the present sample.  
Log10 transformation of distributions was necessary for some of the variables in 
order to meet the assumption of normality of distribution required for MANCOVA. 
However it is notable that the log transformed variables tended to show a non-
significant difference, even when – in the case of depression – the means and SDs 
indicated a large effect size. For this reason the results from the matched groups, which 
did not require transformation, are probably more important than those of the 
MANCOVA. Some authors suggest that matching is a more efficient method than 
ANCOVA for controlling for the effects of variables because of the fewer assumptions 
required for matching and better statistical power (e.g. [41]). ANCOVA remains 
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appealing to researchers however, because matching can be a difficult process and the 
more variables matched for the more difficult it is to find suitable matches.  
 At 34% the response rate was not high. However the response rate was similar in 
each group, and not dissimilar to response rates in some other questionnaire studies of 
PCOS (e.g. [42]). Many patients declined participation citing time pressure as the 
reason, and 16% of those who participated failed to complete some sections of the 
questionnaire. It could be that the patients who declined participation were different in 
some relevant psychological respect to the patients who participated, but this cannot be 
established because the decliners, inevitably, left no tangible information about their 
psychological state. The issue of response rate should not be given undue weight 
because low response rates don’t necessarily compromise data validity [43].  
The findings of the present study suggest that women with PCOS experience 
more neuroticism and anxiety than women with comparable levels of fertility problems, 
and tend to withhold feelings of anger. Assessment of mood state could be considered as 
part of routine care in PCOS. Care for these women might involve a combination of 
medication (e.g. metformin or an anti-androgen) to treat physical symptoms related to 
PCOS, and the development of a psychological treatment or support programme to help 
with deal with emotional issues. If future studies find that hypoglycaemia is a causal 
factor in mood disturbance in PCOS, a nutritional intervention – the low GI diet [44] – 
might be an appropriate part of a treatment plan because it has the potential to improve 
biochemical and physiological parameters, thus reducing PCOS symptoms and 
improving mood functioning. 
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ABSTRACT. The idea that diet can affect mood and behavior in women with polycystic 
ovary syndrome (PCOS) by altering blood glucose levels has become popular in recent 
years.  This paper describes an online survey (N=462) of 24 women with PCOS, 299 healthy 
control women, 47 women who possibly had undiagnosed PCOS, and 92 men.  The groups 
were compared for symptoms of mood and behavioral symptoms typical of reactive 
(postprandial) hypoglycemia.  The outcome measures were two questionnaires that measure 
states associated with hypoglycemia: the Hypoglycemia Symptom Checklist -7 (HSC-7), 
which measures behavioral symptoms and the Mood Adjective Checklist (MACL), which 
measures emotional states.  Controlling for age and body mass index (BMI) using between-
groups analysis of covariance (ANCOVA), the women with PCOS scored significantly 
higher than the other three groups (p < 0.001) on the outcome measures.  These differences 
remained statistically significant in a subset of twelve women with PCOS compared to 
twelve healthy control women closely matched for age, BMI, and eating behavior.  The 
findings are suggestive of hypoglycemia-related mood and behavioral problems in PCOS.  
Future research should test whether blood glucose levels correlate with these symptoms in 
PCOS, and whether a low glycemic index (‘low-GI’) diet improves the symptoms.  
 
Keywords: polycystic ovary syndrome, eating behavior, mood, hypoglycemia, low-GI diet. 
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Introduction 
 
Polycystic ovary syndrome (PCOS) affects up to 10% of women (Ledger & Clark, 2003).  
As well as the classical symptoms of menstrual irregularity and testosterone excess, women 
with PCOS might report light headedness, trembling or faintness that they may attribute to 
low blood glucose levels (Marsh, Steinbeck, Atkinson, Petocz, & Brand-Miller, 2010).   
Women with PCOS are hyperinsulinemic compared to healthy women of a similar body 
mass index (BMI) (Diamanti-Kandarakis & Papavassiliou, 2006) and it is plausible that 
some of them experience symptoms caused by a sudden fall in blood glucose.  In support of 
the hypoglycemia hypothesis, some PCOS patients say that their supposed hypoglycemia 
symptoms are associated with a craving of sweet food or drinks.  Anecdotally, many treating 
physicians are skeptical that such symptoms are related to hypoglycaemia. 
Reactive (or ‘postprandial’) hypoglycemia (RH) occurs when blood glucose levels 
drop two to five hours after a meal, especially a meal high in carbohydrates.  Reactive 
hypoglycemia is under-researched, but there is evidence to suggest that this condition is 
more common in women with PCOS than in other women.  For example, Sorensen & 
Johansen (2010) found a 12.4% rate of reactive hypoglycemia in women with no reported 
history of plasma glucose dysregulation, and by contrast a study of 64 lean women with 
PCOS found a 50% rate of reactive hypoglycemia (Altuntas, Bilir, Ucak, & Gundogdu, 
2005).  Kasim-Karakas, Cunningham, & Tsodikov (2007) assessed 28 obese women with 
PCOS using a 5-hour oral glucose tolerance test (OGTT) and found a reactive hypoglycemia 
rate of 66%.   
Reactive hypoglycemia (typically mid-afternoon) may contribute to weight gain in 
PCOS (Magnotti & Futterweit, 2007); this could occur because insulin induces the 
production of androgens such as testosterone, that in turn increase visceral fat (Stanley & 
Misra, 2008).  Reactive hypoglycemia has been described as one of the “subtle symptoms” 
of PCOS (Brand-Miller, Farid & Marsh 2004, p.9) and a low glycemic index (GI) diet may 
be a way of controlling this problem. Marsh, Steinbeck, Atkinson, Petocz & Brand-Miller 
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(2010) found that the low-GI diet significantly improved insulin resistance, menstruation 
(probably due to improved insulin sensitivity) and emotional quality of life in moderately 
overweight women with PCOS.Findings from two other recent studies (Galletly et al 2007; 
Herriot, Whitcroft, & Jeanes, 2008) appear to support the efficacy of the low-GI  diet for 
women with PCOS in relation to mood and other symptoms related hypoglycemia.  
Individuals with suspected postprandial hypoglycemia tend to have higher levels of 
psychological distress, including anxiety and depression, than other people (Berlin, 
Grimaldi, Landault, Cesselin, & Puech, 1994).  The mood state typical of hypoglycemia has 
been described as 'tense-tiredness' (Thayer, 1989).  Classic well-controlled studies of the 
effects of experimental induction of hypoglycemia in healthy participants found evidence of 
this ‘tense-tired’ mood state (Gold, MacLeod, Frier, & Deary, 1995; McCrimmon, Frier, & 
Deary, 1999).  More recent research also suggests an effect of hypoglycemia on 
psychological functioning, for example, Bie-Olsen, Pedersen-Bjergaard, Kjaer, Lonsdale, 
Law, and Thorsteinsson (2010) induced hypoglycemia in twenty healthy men and found a 
statistically significant difference between scores before the induction and during induced 
hypoglycemia on the Edinburgh Hypoglycaemia Symptom Score Questionnaire (Hepburn, 
Deary, MacLeod, and Frier, 1994), a scale which includes psychological symptoms typical 
of hypoglycaemia, such as anxiety and tiredness.  Although there is subjective and objective 
evidence of reactive hypoglycemia in women with PCOS, and despite considerable evidence 
of anxiety and depression in PCOS (for example, Himelein & Thatcher, 2006) the possible 
link between reactive hypoglycemia and mood problems in PCOS has received surprisingly 
little scientific attention.  
The present study was designed to test the hypothesis that women with PCOS have 
more symptoms of mood and behavioral disturbance typical of reactive hypoglycemia than 
women who do not have PCOS.  
 
Method 
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Design 
An online questionnaire survey was used to identify PCOS cases and controls. Comparisons 
were made between four groups: women with PCOS, healthy control women, women who 
possibly had undiagnosed PCOS, and men.  From this sample, matches were found between 
women with PCOS and non-PCOS controls on age, self-reported BMI, and eating behavior.  
The main grouping variables were PCOS status and eating behavior. The outcome variables 
were questionnaires measuring symptoms typical of reactive hypoglycemia.  
 
Questionnaires 
Two measures of signs of reactive hypoglycemia were used:  
 The UWIST Mood Adjective Check List (MACL) (Matthews, Jones, & 
Chamberlain, 1990).  This scale assesses happiness, tension, and energy levels using three 8-
item subscales, and changes in scoring on this measure has been found to reflect changes in 
arterialized venous blood glucose levels in studies of experimentally induced hypoglycaemia 
(Gold et al., 1995; McCrimmon et al., 1999).  Similar mood changes are hypothesised to be 
seen in postprandial hypoglycemia because it is hypothesised that low blood glucose causes 
the mood changes regardless of whether hypoglycaemia is naturally occurring or 
experimentally induced.  To increase sensitivity to degrees of mood, the present study 
expanded Matthews et al's checklist from a 'yes/no' format to a 4-point Likert scale prefixed 
with “I generally feel…” and response options of 'never, rarely, sometimes, often' e.g. ‘I feel 
cheerful’. Higher scores indicate positive hedonic tone (happy mood), more tension, and 
more energy.  On each subscale the maximum score is 32, and the minimum is eight.  
The Hypoglycemia Symptom Checklist – 7 items (HSC-7).  This short scale was 
designed for the present study to be a quick test for behavioral symptoms of hypoglycemia.  
The HSC-7 consists of four items related to symptoms of neuroglycopenia and three items 
related to autonomic symptoms of hypoglycemia.  The neuroglycopenia symptoms are: 
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clumsiness, confusion, sudden weakness, and difficulty in speaking.  The autonomic 
symptoms are: unexplained palpitations, sweating, and shivering.  The symptoms are rated 
for frequency of occurrence on a Likert scale from 1 (never) to 4 (often).   
The symptoms listed in the HSC-7 have been variously identified in several sources 
(e.g. Ross, 1975; Deary, Hepburn, MacLeod, & Frier, 1993), which contributes to the face 
validity of the HSC-7.  The HSC-7 also demonstrates good internal reliability; for the 
sample in the present study the Cronbach’s alpha is 0.776.  A principal components analysis 
of the HSC-7 using Varimax rotation with Kaiser normalization indicated sound underlying 
components (Kaiser-Meyer-Olkin index = 0.830), with a good average factor loading 
(0.655).  As mentioned above, the MACL has been validated against biological measures of 
hypoglycemia, and in the present study the HSC-7 subscales show moderate concurrent 
validity with the MACL (mean Pearson’s r = 0.44).   
Eating behavior was assessed by asking participants (a) whether they followed a 
specific kind of diet (e.g. low-GI, calorie controlled, the Atkins diet etc), and (b) to say a few 
words about their eating behavior (e.g. whether they eat healthily, binge eat etc).  Responses 
to these two questions underwent content analysis, and consequently participants were 
classified into one of four categories: healthy eating, unhealthy eating (e.g. “I eat a lot of 
junk food”), binge &/or comfort eating, or ‘other’.  Note that the resulting categories are a 
broad assessment of eating habits, not diagnoses of eating disorders. Those who reported 
binging or comfort eating were combined into one group because both eating behaviors were 
often reported by the same participant, possibly supporting the suggestion by Grucza, 
Przybeck, & Cloninger (2007) that binging and comfort eating share a common underlying 
mood dysregulation.  Eating was categorised as ‘other’ if a participant’s response did not fall 
into any of the three aforementioned categories e.g. “I eat whatever is in the fridge”.  This 
measure relies on conventional content analysis, a well established approach to 
categorization based on qualitative methods (Graneheim & Lundman, 2004). As a qualitative 
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measure it is not amenable to psychometric validation using quantitative methods such as 
Cronbach’s alpha or principal components analysis.   
Demographics, lifestyle (e.g. alcohol consumption), presence of medical conditions 
and medication use were also assessed.  
 
Participants  
Women with PCOS were recruited from the Verity PCOS support group website. Controls 
were recruited from Psychological Research on the Net, a website dedicated to online 
research in a range of topics in psychology.  Responses were anonymous. Because the 
control group website is accessed by the general public, up to 10% of the respondents from 
this source may have had PCOS.  However all potential cases of PCOS – including 
undiagnosed cases - were identifiable because the survey included questions based on the 
diagnostic criteria for PCOS.   
Inclusion to the PCOS group was based upon self-report of (a) having PCOS, and 
(b) having two of the three necessary conditions for PCOS, as defined by the Rotterdam 
criteria (1/ multiple ovarian cysts; 2/ elevated testosterone, or hirsutism or acne; 3/ irregular 
periods).1  Twenty-four women fulfilled these criteria. A further 47 women reported either 
(a) having two of the three diagnostic criteria but did not identify as having PCOS or (b) 
identified as having PCOS but only reported having one of the three diagnostic criteria; 
these cases were categorised as ‘Possible PCOS’.  The female control group consisted of 299 
women who reported one or no symptoms associated with PCOS, and did not identify as 
having PCOS.  
In total, 536 people accessed the questionnaire between March and June 2009.  Of 
                                                 
1 Although not practical for an internet survey, it is undoubtedly preferable to have a confirmable 
diagnosis by a gynaecologist or endocrinologist. However it can be argued that there must be some 
validity in self report of symptoms, whether online or in a clinical interview. Nonetheless in the 
present study, if a participant did not understand a question regarding symptoms they had less 
opportunity to clarify the issue than in an clinical interview. Thus the answers regarding PCOS and 
PCOS symptoms (see Appendix 1) may have less validity than answers confirmable by a clinician or 
from medical records.  
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these, 32 did not go on to fill in the form, leaving an uptake rate of 94%.  A further 42 were 
excluded because they did not give key information e.g. their sex.  This left 462 people (24 
women with PCOS, 299 controls, and 47 ‘Possible PCOS’, and 92 men), a completion rate 
of 86%.  One woman with PCOS was excluded from matching as she did not report her 
weight, but she was included in any total-sample (N=462) analyses that did not require this 
information.  
 
Ethics 
This study was approved by the Department of Psychology Ethics Committee, City 
University, London.  To indicate their consent, participants read an information sheet and 
consent form and ticked a checkbox. 
 
Data analysis 
All variables passed the Kolomogorov-Smirnov test of normality and all ANCOVA models 
passed Levene’s tests of homogeneity of variance, thus comparisons of continuous data were 
performed using parametric tests.  For categorical outcomes, Fisher’s exact test was used 
because expected frequencies were less than five in all cases.  Less than 5% of data was 
missing, and missing data was replaced with the median for each participant’s score on the 
relevant scale or subscale. 
 
Results 
 
The results are presented in two sections.  The first section describes comparisons across the 
four groups, and the second section compares 12 women with PCOS to 12 healthy control 
women matched for age, self-reported BMI, and eating behavior.  
 
Comparisons across the four groups 
The mean (+ SD) ages of the participants were PCOS (31.3 + 7.7), Possible PCOS (26.6 + 
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9.0), healthy control women (24.5 + 9.1), healthy control men (29.1 + 8.0).  The mean BMIs 
were PCOS (29.5 + 6.3), Possible PCOS (19.2 + 3.3), healthy control women (21.1 + 3.6), 
healthy control men (25.7 + 5.2).  
Twenty-two of the women with PCOS and 283 of the healthy control women gave 
information regarding their eating behavior. The different categories of eating behavior were 
represented at significantly different rates in the PCOS group compared to healthy control 
women (Fisher’s Exact = 10.294, p < 0.025, 2-sided).  Of the 22 women with PCOS who 
indicated their eating behavior, 21% reported healthy eating compared to 28% of the control 
women; nobody in the PCOS group reported unhealthy eating compared to 17% of the 
control women, and 58% of the PCOS group reported binge &/or comfort eating compared 
to 32% of control women.  Five of the 22 women with PCOS (23%) and two of the 283 
healthy control women (0.7%) were on a low-GI diet. Three of the five women with PCOS 
on a low-GI diet also binged &/or comfort ate.2  
Of the 462 participants, 52.8% reported that they were not taking any medication, 
13.2% were taking contraception, 5.0% were taking psychiatric medication, 2.2% were 
taking metformin, 10% were taking other medications (mostly vitamins or allergy 
medications), 1.5% were taking more than one type of medication, 10.2% said they were 
taking medication but did not indicate what type, and 5.2% did not state whether they were 
taking medication or not. Regarding medical conditions, of the 462 participants 13.2.0% 
reported a psychological or behavioural issue (mostly depression or anxiety), 4.3% reported 
hypoglycemia, 2.8% reported hypothyroid, 2.8% reported endometriosis, and 1.9% reported 
insulin resistance. The PCOS group’s scores showed more evidence of mood and behavioral 
effects of hypoglycemia than the other three groups (Table 1).   
                                                 
2 The five women with PCOS who were on a low‐GI diet also binged &/or comfort ate. This 
would probably negate any benefits of this diet, thus neutralizing any confounding effect of 
more women in the PCOS group than controls being on a low‐GI diet.  Potential 
confounding effects of higher BMI in the PCOS group were controlled for through the use 
of ANCOVA and matching. 
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Table 1 
Mean (+ Standard Deviation) scores on the three Mood Adjective Checklist subscales 
(MACL) and Hypoglycemia Symptom Checklist – 7 (HSC-7) in the four groups constituting 
the total sample (N=462). 
Outcome measure PCOS 
(n=24) 
Possible 
PCOS (n=47) 
Control 
Women 
(n=299) 
Men 
(n=92) 
Energy 
a
 16.8 + 3.0 19.2 + 3.3 21.1 + 3.6 21.4 + 3.7 
Tension 
a
 20.9 + 5.2 19.2 + 3.3 17.3 + 3.8 17.2 + 3.7 
Hedonic Tone
a
  18.9 + 5.0 22.1 + 4.7 24.3 + 4.3 24.2 + 4.1 
HSC-7 
b
 2.6 + 0.6 2.5 + 0.5 2.1 + 0.6 2.0 + 0.7 
a
 Mood Adjective Checklist (MACL) subscale 
b Hypoglycemia Symptom Checklist – 7 
 
Using ANCOVA to control for any effect of age and BMI, the four groups were 
compared on the psychometric measures.  Significant group differences were found for the 
Mood Adjective Checklist subscales: energy (F (3, 458) = 14.965, p < 0.001), tension (F (3, 
458) = 9.385, p < 0.001), hedonic tone (F (3, 458) = 14.127, p < 0.001).  Significant group 
differences were also found for the Hypoglycemia Symptom Checklist -7 (F (3, 458) = 
10.067, p < 0.001).  The PCOS group had more symptoms typical of reactive hypoglycemia 
than the other groups for each outcome measure.  Least Significant Difference (LSD) 
comparisons of the main effects found that the PCOS and Possible PCOS groups both had 
significantly more symptoms typical of reactive hypoglycemia than the healthy female 
controls on all measures (minimum p < 0.003) and than the healthy men on all measures 
(minimum p < 0.009).  Compared to the Possible PCOS group, the PCOS group had 
significantly lower energy (p < 0.007), more negative hedonic tone (p < 0.003), 
nonsignificantly more tension (p < 0.059) and nonsignificantly more symptoms on the HSC-
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7 (p < 0.352). Healthy control women didn’t score significantly differently to the healthy 
control men on any of the measures (maximum p < 0.143).  
 
Matching 12 healthy control women to 12 women with PCOS 
Twelve healthy control women were matched to 12 women with PCOS on age, BMI and 
eating behavior. Four of the matched pairs reported healthy eating behavior, six pairs binged 
&/or comfort ate, and the eating behavior of two pairs was classified as ‘other’.  Mean (+SD) 
age and BMI were closely matched (PCOS age 31.5 + 8.9; matched controls 30.1 + 9.2 years 
old; PCOS BMI 28.8 + 6.1; matched controls 29.4 + 5.9).  One woman with PCOS and one 
healthy control woman who reported experiencing hypoglycemia were paired; all other 
medical conditions were excluded. Irritable bowel syndrome (IBS) was not excluded 
because IBS may, at least in part, have a psychological aetiology (Choung, Locke, 
Zinsmeister, Schleck, & Talley, 2009).  Fewer than half of the matched participants 
consumed alcohol, and those who did were light drinkers (PCOS = 5.0 + 2.7 units per week, 
and controls = 3.2 + 4.1) compared the average of 9.0 units per week for women in England 
& Wales (Office of National Statistics, 2008). 
The PCOS group reported significantly more symptoms typical of reactive 
hypoglycemia than matched controls on all measures (Table 2).3  
 
                                                 
3 The PCOS group had less energy, more tension, less happiness (hedonic tone) and more 
psychological and behavioural symptoms typical of reactive hypoglycemia. 
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Table 2 
Comparison of the 12 PCOS and 12 healthy matched control women on symptoms typical of 
hypoglycemia. 
 
Outcome measure 
 
Group M SD t  
  
p* 
Energy 
a
 PCOS 16.8 3.4 
-3.883 0.002 
 Control  21.4 2.5 
Tension 
a
 PCOS 19.7 5.8 
2.078 0.031 
 Control  16.3 2.6 
Hedonic Tone 
a
 PCOS 19.2 5.1 
-5.472 0.001 
 Control  26.2 2.6 
HSC-7 
b
 PCOS 2.6 0.6 
2.214 0.025 
 Control  2.0 0.7 
* Probability value is one-tailed 
a
 Mood Adjective Checklist (MACL) subscale 
b Hypoglycemia Symptom Checklist – 7 
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Discussion 
 
Women with PCOS reported significantly more mood and behavioral symptoms 
associated with reactive hypoglycemia than healthy women.  This is the first time that such 
differences have been demonstrated. The differences remained statistically significant after 
controlling for age, BMI and eating behavior.  Before and after matching, the PCOS group 
reported significantly less energy, more tension, less happiness, with more behavioural 
symptoms that may be associated with hypoglycemia. Women with PCOS also demonstrated 
the pattern of 'tense-tiredness' combined with lower mood that has been observed in studies 
of experimentally induced hypoglycaemia (Gold et al., 1995; McCrimmon et al., 1999).    
Based on recent evidence regarding the high rates of hypoglycemia in PCOS and the 
benefits of a low-GI diet, it might be speculated that the type of food eaten may have an 
impact on the symptoms typical of hypoglycemia reported by the women with PCOS in this 
study.  A limitation of the present study is that the number of women in the present sample 
following a low-GI diet was not sufficient to assess its affect on the outcome measures. Also 
the five women with PCOS who were on a low-GI diet also binged &/or comfort ate, which 
might obscure any observable benefit of eating low-GI foods.  A future study should assess 
blood glucose levels and psychological outcomes in women with PCOS on a low-GI diet 
compared to women with PCOS on other diets, controlling for eating behavior.   
One of the strengths of the present study is the novelty of the research focus, the use 
of the internet to maximise the numbers recruited, and the use of a bespoke assessment 
measure of eating habits. However these strengths also have corresponding limitations. For 
example, although the internet can increase the statistical power of analyses because of 
greater numbers, self-report is relied on more heavily than studies recruiting in hospital 
clinics where objective assessments can be made. Thus although some studies have found 
that self-report of height and weight can be reasonably accurate (Goodman et al, 2000; Dahl 
et al., 2010), research ideally should assess these variables objectively where possible. 
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Another limitation is that although the categorisation of eating habits using qualitative 
methods may have the advantage of increasing sensitivity to unique properties of the sample 
in question, future researchers might consider using a validated questionnaire to assess 
eating habits because this will make their findings more easily comparable to studies using 
similar measures. Similarly, the HSC-7 has not yet been validated against a physiological 
measure of hypoglycaemia. In the present study the HSC-7 has proved to have good 
psychometric properties and sensitivity to symptoms seen in hypoglycaemia, but a future 
study might seek to validate the HSC-7 against an objective measure of blood glucose. 
The findings of this study suggest that effectively controlling diet and weight in 
PCOS is not only an important health issue, but also has implications for improving the 
troubling symptoms that may be caused by reactive hypoglycemia.  When women with 
PCOS report hypoglycemia symptoms to their clinicians, these symptoms warrant 
investigation in the form of an extended oral glucose tolerance test.  Readings should be 
taken every 30 minutes over 4 hours; reactive hypoglycemia is diagnosed if there is a sharp 
peak in capillary glucose after an hour followed by a sharp trough, or a trough that goes 
below 54 mg/dl (Marks, 1987).  This test may on occasions be inconclusive because outside 
the laboratory hypoglycemia symptoms appear at higher blood glucose levels (Brun, Fedou, 
& Mercier, 2000).  However where the diagnosis of reactive hypoglycemia is confirmed, a 
low-GI diet is a logical management option.  
In conclusion, this is the first study to demonstrate that women with PCOS have 
significantly more mood and behavioural symptoms that may be associated with reactive 
hypoglycemia than healthy women, and this finding is potentially of clinical importance to 
women with PCOS and the health professionals who help them.   
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Appendix 1. The questionnaire used in the survey. Note that the original questionnaire was 
formatted for online use, and this formatting has been lost in the Word document version 
below. For example, the asterisks below were originally radio buttons in the survey and the 
response scale options boxes are missing. 
Thank you for your interest in this survey. Please take a moment 
to read this information:  
Some people say that certain foods and eating habits effect how 
they feel. The aim of this survey is to see whether certain foods 
or lifestyles are associated with specific mood states that might 
be associated with the metabolism of food,  especially in women 
PCOS (polycystic ovary syndrome) but also other women. 
 
The survey is entirely voluntary, anonymous, and confidential. It 
has been given ethical approval by the Dept of Psychology at City 
University (London) and approved by the research officer for the 
PCOS support group, Verity. All data will be kept safe and secure 
in accordance with the Data Protection Act 1998. There are no 
immediate benefits to you of filling the survey, apart from 
knowing that you are adding to knowledge on the relationship 
between food and wellbeing in PCOS.  
 
If you have any questions about the survey, would like feedback 
on your responses, or wish to withdraw your answers from the 
survey please email John Barry at j.a.barry@city.ac.uk   Note 
that if you would like feedback, please indicate this in the text 
box at the very end of this questionnaire by stating 'I will 
email you for feedback on my answers to the Food and Wellbeing 
Questionnaire. I submitted my form at [state exact time] on 
[state day and date]'.  
* I understand the above information and am happy to take part in 
this survey  
 
This questionnaire is mainly for women, but some men might like 
to participate too. 
Are you male or female?  
* Male  
* Female  
 
 
How old are you?  
 
 
Do you follow any special diet? Please tick any that apply to 
you:  
* Low GI (Glycaemic Index)  
* Vegetarian  
* Vegan  
* Calorie controlled  
* Weightwatchers  
* Detox diet  
* Atkins or low carb diet  
* Mediterranean diet  
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Please say a few words about your eating habits (e.g. eat 
healthily, binge eat, comfort eat, eat unhealthily etc) if not 
covered by the previous question:  
 
 
I feel anxious  
Never  
Rarely  
Sometimes  
Often  
 
I feel contented 
Never  
Rarely  
Sometimes  
Often  
 
I feel jittery 
Never  
Rarely  
Sometimes  
Often  
 
I feel active 
Never  
Rarely  
Sometimes  
Often  
 
I feel energetic 
Never  
Rarely  
Sometimes  
Often  
 
I feel cheerful 
Never  
Rarely  
Sometimes  
Often  
 
I feel satisfied 
Never  
Rarely  
Sometimes  
Often  
 
I feel tense 
Never  
Rarely  
Sometimes  
Often  
 
I feel alert 
Never  
Rarely  
Sometimes  
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Often  
 
I feel happy 
Never  
Rarely  
Sometimes  
Often  
 
I feel nervous 
Never  
Rarely  
Sometimes  
Often  
 
I feel vigorous 
Never  
Rarely  
Sometimes  
Often  
 
I feel dissatisfied 
Never  
Rarely  
Sometimes  
Often  
 
 
I feel calm 
Never  
Rarely  
Sometimes  
Often  
 
I feel unenthusiastic 
Never  
Rarely  
Sometimes  
Often  
 
I feel depressed 
Never  
Rarely  
Sometimes  
Often  
 
I feel restful 
Never  
Rarely  
Sometimes  
Often  
 
I feel sluggish 
Never  
Rarely  
Sometimes  
Often  
 
I feel sad 
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Never  
Rarely  
Sometimes  
Often  
 
I feel relaxed 
Never  
Rarely  
Sometimes  
Often  
 
I feel tired 
Never  
Rarely  
Sometimes  
Often  
 
I feel sorry 
Never  
Rarely  
Sometimes  
Often  
 
I feel composed 
Never  
Rarely  
Sometimes  
Often  
 
I feel passive 
Never  
Rarely  
Sometimes  
Often  
 
I am clumsy 
Never  
Rarely  
Sometimes  
Often  
 
My heart pounds for no obvious reason 
Never  
Rarely  
Sometimes  
Often  
 
I feel sweaty 
Never  
Rarely  
Sometimes  
Often  
 
I feel confused 
Never  
Rarely  
Sometimes  
Often  
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I feel suddenly weak 
Never  
Rarely  
Sometimes  
Often  
 
I have difficulty in speaking 
Never  
Rarely  
Sometimes  
Often  
 
I shiver 
Never  
Rarely  
Sometimes  
Often  
 
Please tick if any of the following apply to you. (Leave blank if 
you are not sure):  
* Diabetes  
* Polycystic ovary syndrome  
* Acne or problems with body/facial hair  
* Irregular periods  
* Overweight  
* Insulin resistance  
* Cysts on ovaries (diagnosed by ultrasound scan)  
* Psychiatric problem (e.g. clinical depression)  
* Eating disorder (e.g. bulimia or anorexia)  
* Low blood sugar (hypoglycaemia)  
* Endometriosis  
* Hypothyroid (underactive thyroid gland)  
 
Please say if you have any other medical condition  
 
How much do you weigh?  
 
How tall are you?  
 
Do you exercise regularly?  
* Yes  
* No  
 
On average, how much alcohol do you consume per week? Please 
answer in units if possible (e.g. one small glass of wine = 1 
unit.  There is an online calculator here 
http://www.bupa.co.uk/health_information/asp/healthy_living/lifes
tyle/alcohol/alctest.asp )  
 
Are you taking any medication at present? 
 
Thank you so much for taking part in this survey! 
 
Is there anything else you would like to add? Please feel free to 
write anything you think might be useful.  
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CHAPTER 7 
General discussion: implications of findings from published papers & programme 
 
Theoretical implications 
PCOS is caused by maternal T during pregnancy 
Any psychological theory proposing activational effects of prenatal T needs first to establish 
that the fetus in a PCOS pregnancy is exposed to elevated T.  One of the most important 
implications arising from the material presented in Chapters 3 and 4 is that not only does it 
appear likely that the female fetus in a PCOS pregnancy is exposed to elevated T (or other 
androgen), but the source of the T is probably maternal. This latter point is suggested by the 
evidence in two ways. Firstly, the PCOS cord T study found that T was higher in the 
umbilical cord vein of female infants of mothers with PCOS than the vein of female infants 
of mothers who didn’t have PCOS. The fact that the T levels were measured in the umbilical 
vein suggests that the T was of maternal/placental origin; this hypothesis is supported by the 
cord T meta-analysis which found evidence that T in the umbilical arteries is of fetal origin. 
Secondly, the PCOS cord T study also found that the T levels in maternal circulation were 
significantly correlated with T levels in the umbilical cord of their female newborns.  This 
correlation did not exist in the male group or female control group. Although these findings 
are not conclusive proof that PCOS is caused by maternal T, both pieces of evidence taken 
together are supportive of the hypotheses that psychological problems in adults with PCOS 
might be traced to elevated prenatal T, and that maternal T is causal in PCOS itself.  
Future studies might replicate Barry et al (2010) using a larger sample, assaying for 
T and other relevant biochemicals using mass spectrometry. The recommendation by Rosner 
et al (2007) of using mass spectrometry when measuring T in women, or T in the umbilical 
cord, raises questions regarding the validity of all previous studies not using mass 
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spectrometry with these populations. It might be reasonable to suggest that previous research 
may have been measuring androgens in general rather than T specifically. If this is true 
however, only studies that sought to make a distinction between the specific effects of T as 
opposed to the specific effects of other androgens may be regarding as being of questionable 
validity. In any case future studies in this field should measure levels of the major 
androgens, as these may have as great an impact on the fetus as T, or more so. This is 
especially true of dihydrotestosterone (DHT) which is bioconverted from T by the enzyme 
5-alpha-reductase. Two recent studies underline the importance of DHT. Carlsen & Vanky 
(2010) studied PCOS pregnancies and found a correlation between maternal and cord levels 
of DHT, but not T. Similarly Anderson et al (2010) found that DHT was nonisignificantly 
higher and E2 significantly lower in the cord blood of daughters of mothers with PCOS, 
suggesting that maternal T has been converted to DHT rather than being transferred directly 
to the fetus as T. In both studies DHT played a more obvious role than T, underlining the 
importance of measuring more than just T in studies of PCOS. 
 
T does not directly cause mood dysfunction 
There were few significant correlations – linear or nonlinear - between T and mood variables 
for the PCOS group, and none for the controls. This suggests that T had little direct effect on 
mood, at least in the women in the sample in Chapter 5. The finding of Weiner et al (2004) 
of a complex relationship between T and mood states is probably an artifact of combining 
two populations with significantly different T levels when there are also opposite patterns of 
correlations between T and mood in each population; the resulting pattern will inevitably 
give the appearance of being nonlinear. However, based on findings from animal research, it 
is possible that prenatal T may programme for the development of insulin resistance and 
type 2 diabetes in later life, and these metabolic issues could cause the hypoglycaemia which 
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may be responsible for the mood problems seen in Chapter 6. Longitudinal studies in 
humans are required to test this hypothesis. 
Future studies of this kind should use mass spectrometry if measuring T or other 
androgens. Also, to test whether mood is related to blood glucose levels, future studies could 
monitor blood glucose levels.  
 
Methodological implications 
The most important methodological issues raised by the present research programme relate 
to the measurement of T in populations where low levels are expected. As stated previously, 
assays should be performed using mass spectrometry. A further issue is to measure cord T 
from the arteries and vein separately, in order to be able to identify the relative contribution 
from maternal and fetal sources. Also the measurement of other hormones – especially DHT 
– is advised. A study that is making these modifications is being conducted by Hardiman, 
Barry et al. and is almost complete.  
Testing for blood sugar problems in PCOS presents methodological challenges. The 
traditional test of hypoglycaemia - an oral glucose tolerance test – might also be passed over 
for more modern methods. A continuous blood glucose monitor (CGM) is a superior method 
and has the advantage of being an unobtrusive way of measuring glucose levels over several 
days, so that the effect of various meals (low GI, high GI) can be assessed. Recruitment for a 
study using CGM and low versus high GI meals is scheduled to begin in July 2011 (by 
Barry, Hardiman et al.). 
 
Clinical implications 
Protect the fetus from maternal T during pregnancy 
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Evidence from the cord T meta-analysis suggests that T in the umbilical vein is of 
maternal/placental origin, and the PCOS cord T study suggests that for females, fetal T is 
correlated with maternal T.  If it is established by further research that maternal T causes 
PCOS, then the modification of maternal T during pregnancy might be considered, 
especially as it would be impractical to try to modify fetal T levels in utero directly. To date 
the only method of reducing T in pregnant women with PCOS has been the use of 
metformin. Metformin is an insulin sensitiser rather than an anti-androgen, and is generally 
prescribed to reduce diabetes in pregnancy rather than specifically to reduce T levels. 
Although this medication will indirectly reduce T levels, any such reduction may take 
several months, as seen in non-pregnant women (Harborne et al., 2003). The slowness of the 
effect of metformin on T is possibly the reason that the evidence to date does not clearly 
show an anti-androgenic effect of metformin in PCOS pregnancies. 
 
Recognise mood problems in PCOS and treat using a low-GI diet or anti-androgen 
The evidence pointing to mood problems in PCOS is clear, as demonstrated by the meta-
analysis of anxiety and depression in PCOS in the present thesis. Clinicians and therapists 
should be aware of this and be sensitive to the fact that women with PCOS may display 
more emotionality than other patients. The origin of these mood problems should be treated 
as potentially multifactorial, and a treatment approach of any appropriate combination of 
medication, counselling and diet should be considered. The meta-analysis examining anxiety 
and depression in PCOS illustrates that improvements in body weight should have at least 
some slight impact on mood. In support of these suggestions, the first test of the low-GI diet 
in women with PCOS, the diet has been found to improve quality of life (QoL) for emotions, 
hirsutism and menstruation, and improved insulin resistance in moderately overweight 
women with PCOS (Marsh, Steinbeck, Atkinson, Petocz & Brand-Miller, 2010).  
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Evaluation  
Despite the strengths of the studies presented in this thesis, there are inevitably limitations.  
The research programme would have been more complete had it used a longitudinal 
design. This is because a longitudinal design has the advantages of (a) eliminating the 
possibility of individual differences across measurement occasions, and (b) allows for the 
use of more statistically powerful within-groups tests. However this was not feasible given 
the time limitations of a PhD programme and it was decided that a series of cross-sectional 
studies was the best that could be achieved. In terms of completeness of the present thesis as 
a representation of the overall research programme, it would have been useful to include all 
of the research undertaken, especially the study of behavioural characteristics of children of 
mothers with PCOS. However the paper based on this study was not accepted for publication 
and its inclusion here could not be justified, given the word limitations.  
A question sometimes raised in regards meta-analyses is whether the conclusions of 
the meta-analysis are the result of publication bias. More than just a moot question of a ‘file 
drawer effect’, meta-analyses are sometimes scrutinised regarding whether an overall large 
effect size is simply an artefact of studies with small sample sizes and null or small effect 
sizes being less likely to be published. Neither of the meta-analyses in this thesis showed 
signs of any serious problems of this kind, as can be seen by the fact that the studies with 
larger sample sizes didn’t tend to have smaller between-groups effect sizes. This can be seen 
by a simple inspection of Table 2 (page 121) in the cord testosterone meta-analysis, which 
shows no relationship between sample size and effect size, and the funnel plots in 
Supplementary Figure I (page 105, with commentary on page 81) for the anxiety and 
depression studies.  
One possible criticism is that the studies in this thesis were natural experiments 
rather than true experiments i.e. none of the participants were randomised into the groups, 
but were assigned to groups by virtue of their PCOS status. On the other hand, in human 
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studies of PCOS a true experimental design is not possible, principally because it is 
unethical to, for example, expose a fetus to elevated T levels and observe subsequent 
developmental phenomena. Thus the studies presented in the present research programme 
might be considered the best that can be done given sensible ethical restrictions. However, 
as a result of the quasi-experimental nature of the research, it is difficult to justify the 
inference of causal relationships between grouping and outcome variables, because factors 
other than group membership have not been reduced to chance levels by the process of 
random allocation.  On the other hand, relevant variables were controlled for by other 
methods, principally matching and ANCOVA, and therefore causal inferences might be 
considered acceptable, given the inevitable experimental limitations when working with 
human participants.   
Some of the key findings of relevance to theories of the etiology of PCOS can be 
questioned on the grounds of being circumstantial or correlational. Thus although the 
evidence for the transmission of maternal T via the umbilical vein is suggested by the 
evidence presented in the cord T meta-analysis, the evidence is indirect. Furthermore, 
although the correlation between maternal and umbilical cord T in the PCOS cord T study is 
suggestive of the maternal transfer of T to the fetus, the evidence is correlational, thus open 
to other interpretations e.g. that T is transferred from the fetus to maternal circulation, or that 
a third variable (e.g. genetic factors) causes both maternal and fetal T levels.  However 
because the evidence from the five published papers represents some of the first attempts to 
identify the biological etiology of PCOS in humans, and as such criticism should not be so 
strong as to negate these early attempts at understanding this complex and multifaceted 
condition. 
The sample size in the PCOS cord T study was small. However it should be noted 
that the only other published study of this kind (Anderson et al, 2010) had fewer observed 
female cord T values than Barry et al (2010). It might also be fair to say that small sample 
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sizes are virtually inevitable given the difficulties of recruiting a specific patient group 
whose delivery times are unknown, and possibly in the early morning hours. Recruiting 
under these circumstances properly requires a team who are on-site 24 hours per day, seven 
days per week. 
The hypothesis that low blood glucose causes mood problems in PCOS is not 
proven in the absence of actual measurement of blood glucose. However the study in 
Chapter 6 is high in originality, and the fact that the findings strongly supported the 
hypothesis after controlling for other variables suggests that the glucose hypothesis is well 
worth further exploration. Another strength is the development of a brief scale for measuring 
behavioural symptoms of hypoglycaemia, the Hypoglycaemia Symptom Checklist – 7 
(HSC-7). This was validated against an existing validated measure of mood symptoms of 
hypoglycaemia (the Mood Adjective Checklist, MACL) and the HSC-7 will be further 
validated against observed blood sugar levels in the forthcoming study by Barry, Hardiman 
et al.  
It could be said that the scope of this thesis was too wide, attempting to take in too 
many aspects of such a complex problem for a single PhD programme. On the other hand 
the breadth of the programme might be considered a positive, especially given the originality 
of many aspects of the research. For example, before 2004 when the present PhD 
programme began there were less than a dozen published papers addressing psychological 
aspects of PCOS. The PCOS cord T paper was almost a first on this subject, second only in 
publication by three months to Anderson et al’s (2010) paper. The PCOS cord T paper has 
been cited three times, two of these by leading international researchers of PCOS etiology 
(Veiga-Lopez et al, 2011; Goodarzi et al, 2011). The PCOS and mood paper is the first to 
conceptualise PCOS mood problems as ‘emotionality’, and the first to identify the tendency 
to withholding anger in women with PCOS. The exploration of psychological factors typical 
of hypoglycaemia in PCOS is a first.  
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Concluding comments 
About 18 000 girls per year are born to mothers with PCOS in the UK (see Appendix 1). The 
prevalence of PCOS means that the costs in terms of health, quality of life, and resources to 
the health services are not inconsiderable. It is the author’s hope that this PhD programme 
contributes to the improvement of quality of life for women with PCOS until such time as a 
cure for this condition is made available.
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Appendix 1 
Estimate of the number of girls born per year in the UK to mothers with PCOS 
The Office of National Statistics (2009) indicates that the total percentage of maternities in 
the UK by women aged 15-44 in 2007 was 6.1%. The number of women in the UK aged 16-
44 is roughly 12.12 million, thus 720 000 births per year. If 5% of these births are from 
mothers with PCOS (based on 10% of women having PCOS, and the miscarriage rate being 
close to half of these pregnancies, according to the Pregnancy Info.Net, 2005) this represents 
36000 PCOS births per year. If half the newborns are girls, this amounts to 18 000 girls born 
to mothers with PCOS per year in UK.  
